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Abstract 
White adipose tissue is not just a storage organ. It is now recognised as an 
endocrine organ. It secretes many substances known as adipokines, which are 
thought to link obesity with type 2 diabetes (T2D). One of the most important 
adipokines is adiponectin. It is a peptide hormone consisting of 244 amino 
acids with molecular weight of 30 KD. It circulates in plasma in high 
concentrations (3-30 µg/ml). Adiponectin polymerises to form many bigger 
forms. Those are low molecular weight (LMW); middle molecular weight 
(MMW) and high molecular weight (HMW). The HMW adiponectin is the active 
form of the hormone.  
The concentrations of most adipokines are increased in obese people. 
Adiponectin is unusual in that its concentration is lower in obese people. 
Consequently its concentration is decreased in some related metabolic 
disorders. Its concentrations decrease in cardiovascular diseases, diabetes, 
dyslipidemia and insulin resistances. It is well known that exercise increases 
insulin sensitivity, also adiponectin was reported to regulate insulin. The 
effect of exercise on the adiponectin concentrations in plasma is 
controversial, but the extent to which the exercise regulates the interstitial 
adiponectin concentrations is not fully examined. The main site of adipokines 
secretion is adipose tissue. Therefore the study of these substances at the 
site of their production has a special interest. Recently, microdialysis 
techniques have been extended to become important in the measurement of 
substances in the extracellular fluid of many tissues such as subcutaneous 
adipose tissue. In particular, it has been used for measurement of adipokines. 
This thesis includes three studies. The first study was aimed at examining the 
effect of one hour of moderate exercise at 50% of maximum oxygen 
consumption v on adiponectin concentration in dialysate samples taken from 
subcutaneous abdominal adipose tissues (SCAAT). 15 healthy young female 
volunteers, age 22.8 ± 3.0 years (mean ± SD) participated in this experiment 
divided into two groups depending on their body mass index (BMI), a lean 
group BMI 22.2 ± 1.6 kg/m2 (mean ± SD) and an overweight group BMI 27.7 ± 
1.9 kg/m2 (mean ± SD). The samples were collected using CMA 66 
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microdialysis catheters with membrane cut off 100 KD. Fitness assessment 
was done for all volunteers about one week before the main trials. The main 
trials were done on two consecutive days, a rest day and an exercise day. 
Each day lasted for 4 to 6 hours. On the first day the microdialysis catheter 
were inserted in abdominal subcutaneous tissue 4 cm lateral to the umbilicus 
on the left side. Dialysate samples were collected every 30 - 45 minutes. On 
the exercise day volunteers exercised for one hour at 50% 2
.
OV max. All 
samples were analysed for adiponectin concentrations using Mercodia ELISA 
technique. 
The principle findings of this study were that CMA 66 microdialysis catheters 
worked effectively for two consecutive days for fluid recovery. Adiponectin 
concentrations were very low and varied, in same volunteer from time to 
time, and between volunteers. However, the statistical analysis showed no 
significant difference in adiponectin concentrations between lean and 
overweight groups. Adiponectin concentrations in the first two samples on 
the first day of the insertion were significantly higher than the first two 
samples on the second day of the insertion. Finally, adiponectin 
concentrations in dialysate samples recovered by 100 KD microdialysis 
catheters were very low. Therefore, the effect of the exercise was not clear. 
The second study aimed to compare the adiponectin concentrations in plasma 
and dialysate samples. Six healthy male volunteers age 32.8 ± 13.1 years and 
BMI 25.9 ± 3.3 kg/m2 (mean ± SD), were recruited for this study. The 
experiment was run for two consecutive days using the same microdialysis 
catheters CMA 66. Dialysate samples were collected as before. 2 ml of blood 
samples were collected using a cannula inserted into the anticubital vein. 
Samples were taken every hour for a period of five hours each day. The 
plasma and dialysate samples were analysed for adiponectin using the 
Mercodia kits. Adiponectin concentrations in plasma samples were 256 and 
1791 times higher than the adiponectin concentrations in dialysate samples. 
The conclusion of the two studies was that the CMA 66 microdialysis catheter 
with cut off 100 KD membranes only recovers a small part of the total 
adiponectin present. 
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Therefore a third study was designed to use plasma samples. The aim of the 
study was to investigate the effect of acute exercise at 50% 2
.
OV max on HMW 
adiponectin, total adiponectin, interleukin  (IL)-6, tumour necrosis factor 
alpha (TNF-α), insulin and glucose concentrations directly after the exercise, 
one hour after and 48 hours. 13 young healthy female volunteers age 24.3 ± 
2.7 years and BMI 21.9 ± 2.2 kg/m2 (mean ± SD) contributed in this study. The 
volunteers were invited for five visits. Their fitness was measured on the first 
visit. Then they came for two main trials rest day and exercise day, which 
they were randomly assigned. The main trails lasted for two hours. Three 
blood samples were collected each day using same cannulated system in the 
second study. The volunteers followed 48 hours after each trial, one blood 
sample were collected each day. The 8 plasma samples were analysed for: 
total adiponectin and insulin concentrations via Mercodia ELISA kits, HMW 
adiponectin, IL-6 and TNF-α concentration via R&D systems and glucose 
concentration using the glucose oxidase colorimetric method.  
The results showed no statistical difference in total or HMW adiponectin, 
TNF-α and glucose concentrations under the effect of moderate exercise at 
50% 2
.
OV max either directly or 48 (p value > 0.05). IL-6 concentrations 
increased about two fold one hour after the exercise above the resting level 
(P value < 0.05). IL-6 concentrations return to the basal level 48 hour latter.  
Insulin concentrations show a decrease one hour after the exercise finished. 
The number of volunteers was small and the change was close to significance. 
A one way ANOVA returned a P value of < 0.05, but a two way ANOVA with 
repeated measures returned a P value of > 0.05.  
In conclusion, the acute exercise at 50% 2
.
OV max changes IL-6 concentrations 
but it has no effect on adiponectin concentrations in dialysate or plasma 
samples. Low adiponectin concentration is related to obesity, insulin 
resistance and T2D. Therefore, increase in adiponectin concentration 
probably lies in weight loss and the exercise may play role, even if it has 
little direct action on adiponectin concentration.  
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Chapter 1 
1 Introduction and literature review 
1.1 Introduction  
Obesity has been the focus of increasing scientific and clinical interest for 
the last 30 years. This concern is justified because of its relationship to 
many serious diseases. The causes of obesity are varied and complex and the 
treatments may be complex too. Many researchers have focussed on 
exercise and diet as possible solutions. Therefore, it is timely to investigate 
the links between obesity, the responses to exercise and the metabolic 
diseases. This offers the hope that factors can be found which might 
improve our understanding. 
Many authors have reported that adipose tissues are not only storage tissues, 
but also secrete a range of substances known as adipocytokines. These 
adipocytokines include leptin, resistin, TNF-α, IL-6, adipsin, visfatin and 
adiponectin. Some of these will be described later in section 1-3. The 
concentration of almost all these adipocytokines increases in obesity. The 
exception is adiponectin, whose concentration decreases in obesity, type 2 
diabetes (T2D) and insulin resistance. This raises a question about why 
adiponectin concentrations decrease in obesity. Since adiponectin exerts 
several protective effects, it is obvious that it is a promising target for 
obesity treatments.  
Adiponectin is a protein which is secreted mainly from the adipocytes. It is 
found in the circulation in a relatively high concentration ranging between 3 
and 30 µg/ml. It is secreted as a monomer with molecular weight of 30 KD. 
These form trimers and hexamers and multimers of high molecular weight 
(HMW). The most common forms found in the plasma are the hexamers and 
HMW. The HMW form has the greatest biological activity.  
Low concentrations of adiponectin have been associated with several 
metabolic diseases, particularly T2D and cardiovascular disease (CVD). One 
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function of adiponectin is to enhance insulin sensitivity and low adiponectin 
concentrations have been suggested to play a role in the development of 
insulin resistance. Administration of adiponectin has been found to reduce 
the glucose concentration in plasma and improve insulin sensitivity. 
Thiazoledinedione is used in the treatment of T2D. Thiazoledinedione 
increases adiponectin concentrations in plasma and that might be related to 
the effect of thiazoledinedione on insulin concentration. In addition, many 
studies have reported a relationship between low concentrations of 
adiponectin and liver fibrosis and cancer.  
It is well known that exercise increases insulin sensitivity. Adiponectin plays 
a role in sensitizing tissues to insulin. Obesity is associated with insulin 
resistance. Thus, what is the link between exercise and insulin sensitivity. 
Since adipocytes secrete adiponectin, is there any role for adiponectin in 
increasing insulin sensitivity in exercise.  
Collection of adiponectin at its site of production is of special interest. 
Microdialysis is a relatively new technique which has been used to collect 
molecules from the extracellular space of many different tissues, including 
adipose tissue. This technique can be used to sample fluid composition 
continuously for up 4 days. Recently, microdialysis has been established for 
monitoring of adipokines and cytokines in the extracellular fluid of 
subcutaneous adipose tissue of human in vivo. 
Obesity, particularly visceral obesity, is more common in females than in 
males. Interestingly, adiponectin concentrations in plasma samples tend to 
be higher in females than males. However, most of the studies on the effect 
of exercise on adipocyte secretions study males. Again this raises questions 
about how similar the responses to exercise are in women and how does the 
increased obesity in women affect the responses.  
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1.2 Obesity 
Obesity is most commonly defined as a Body Mass Index (BMI) of 30 kg/m2 or 
above. It is very big health problem, and it is associated with many diseases 
such as diabetes, coronary heart disease and hyperlipidaemia (Lean, 2000). 
Recently, a national survey based in the USA has shown that the prevalence 
of being overweight or obese among adults remained relatively constant 
between 1960 and 1980. The prevalence began to increase in the mid-1980s 
and it has continued to increase since then (Flegal et al., 1998). It is about 
20% in USA and it is higher in black than the white population (Flegal et al., 
1998). A similar picture is seen in Europe. The prevalence of obesity in 
Britain had increased three times from 1980 to 1997 (Kopelman, 2000).The 
prevalence in the UK in 2002 had increased to 23% and 25% for males and 
females respectively(Department of Health, 2004). 
The picture is similar in Arab populations. This figure was similar to that 
found in Morocco, Tunisia (Mokhtar et al., 2001). One study in Saudi Arabia 
found a prevalence of obesity of 26% in males and 44% in females (Al-Nozha 
et al., 2005). There may be variation with the Arab world because a lower 
percentage of 16% was found among females in United Arab Emirates 
(Sheikh-Ismail et al., 2009). All studies demonstrate that the prevalence of 
obesity is higher among females than males.  
Moreover, this problem extends to include children. Data from the UK 
showed the prevalence of obesity among 15 year old children was 17%, 
(Reilly & Dorosty, 1999). However, this percentage increased in 2004 to 24% 
for males and 26% for females (Reilly, 2006). In the USA Ogden et al, found 
that the prevalence of overweight and obesity among young males 2-19 
years old was 31.9% and 11.3% (Ogden et al., 2008). 
The trend is found among children in Arab countries. Similar results have 
been found in Kuwait (Al-Isa, 2004), Qatar (Bener, 2006) and The United 
Arab Emirates (Malik & Bakir, 2007). In Saudi Arabia the prevalence was 
Chapter 1   
M. Alzwayi  20  
transitional between developing and developed countries, 20.4%, overweight 
and 5.7% obese respectively (El-Mouzan et al, 2010). 
There are regional variations, in Yemen the prevalence was low at 6.2% and 
1.8% for overweight and obesity among schoolchildren respectively (Raja'a & 
Bin Mohanna, 2003). This pattern could reflect economic conditions. 
Furthermore, the prevalence of overweight is similar among girls and boys. 
In contrast, the prevalence of obesity and severe obesity is higher in boys 
than girls (El-Mouzan et al., 2010). The level of education has an impact on 
this problem. It has been found that the obesity rates are lower in more 
educated groups (Pi-Sunyer, 2002). Figure 1-1 shows the prevalence and 
absolute numbers of overweight and obesity in many regions in the world. 
These data are for adults and show the position in 2005. Across the whole 
world, the study suggests that 9.8% of the population are obese with females 
have higher prevalence of obesity than males. This percentage represents 
396 million people. The prevalence of obesity is rising steeply and the 
prediction is that it will >55% in 2030 if the recent trends continue (Kelly et 
al., 2008). The data show considerable regional variations and this probably 
reflects many different causes of obesity. It is unlikely there will be a single 
solution for all cultures.  
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Figure  1-1  
The prevalence (upper) and absolute number (lower) of overweight and obesity in adults in 
different regions for both males and females in 2005. CHN, China; EME, established market 
economies; FSE, former socialist economies; IND, India; LAC, Latin America and the 
Caribbean; MEC, middle eastern crescent; OAI, other Asia and islands; SSA, sub-Saharan 
Africa. Reprinted with permission from (Kelly et al., 2008) 
 
1.2.1 Causes  
Obesity is associated with a heterogeneous group of conditions with several 
causes. The interactions between genetic, ecological and behavioural 
factors are responsible for a progressive rise in body weight. The last two 
factors are probably mostly responsible for the prevalence of obesity, but 
also heredity factors play an important role (Kopelman, 2000). These factors 
will be covered individually. 
1.2.1.1 Genetic factors 
The variation in prevalence of obesity worldwide has led to an impression 
that heredity may play an important role in determining how common 
obesity is in each society. There is considerable evidence to suggest that 
height and weight are heritable traits (Barsh et al., 2000). Overall, data 
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from twin and adoption studies give a consistent finding showing that 
genetic factors contribute between 40% and 70% of the variation in BMI 
(Maes et al., 1997). Other studies of the causes of obesity estimate the 
percentage contribution of genetic factors from 30% to 40% and 
environmental factors between 60% and 70% (Pi-Sunyer, 2002). Several 
heritable factors are likely to be responsible and are likely to work through 
various possible mechanisms, such as energy intake and energy expenditure 
(Farooqi & ORahilly, 2007). It is also important to consider the interaction 
between genetic and environmental factors such as availability and 
nutritional content of food. For instance, in some cases the expression of 
genotype needs certain adverse environmental conditions (Stunkard, 1988). 
1.2.1.2 Environmental factors  
Obesity develops when energy intake is more than energy expenditure. 
Nowadays, lifestyle in developed countries is associated with the availability 
of convenient, cheap food with a high energy content and increasingly with 
sedentary life style requiring less physical activity (Hill & Peters, 1998). The 
low level of exercise or physical activity is directly linked to obesity. In 
Finland, a decline in physical activity at work and in transport during the 
past 10 years has been accompanied by a significant increase in leisure time 
(Kopelman, 2000). It has been demonstrated that decrease in energy 
expenditure results in an increase weight seven times (Ferro-Luzzi & 
Martino, 1996).  
These trends may be more extreme for women than for men. Almost all 
studies show that females are more obese than males (El Ati et al., 2012; 
Flegal et al., 2010; Kelly et al., 2008). This effect is clearly seen in some 
Arab countries. The reduction in the level of activity by women might be 
very large because there is an increasing trend to employ housemaids and 
there is a culture which makes it difficult for women to exercise (Alsaif et 
al., 2002).  
In the case of children, the introduction of electronic devices, such as 
computers, televisions and electronic games, allow children spend much 
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time in sedentary activities. This might contribute to the high prevalence of 
obesity in children (Kautiainen et al., 2005). Several studies have shown a 
positive relation between time spent watching television and the incidence 
of obesity in children (Kautiainen et al., 2005; Lioret et al., 2007). In 
contrast, Kautiainen found that being overweight was not related to time 
spent playing computer games (Kautiainen et al., 2005).  
1.2.2 Fat distribution 
As described above in section 1.2, obesity is a problem almost everywhere in 
the world. The form of body shape associated with obesity depends on the 
degree and site of the fat accumulation. The regional distribution of fat may 
be extreme in some ethnic groups, like Hottentot women, where the fat is 
accumulated in their buttocks (Ersek et al., 1994).  The accumulation of 
adipose tissue in humans takes place over an extended time period. Body fat 
is a very specific tissue that stores metabolic energy in the form of 
triglycerides and releases them when the other tissues in the body need 
energy (Cinti, 2007). It is mainly found either superficially in subcutaneous 
stores or more deeply in visceral stores. In lean male adults, adipose tissue 
constitutes about 8 to 18% of body weight, while for females it is about 14 to 
28%. This percentage greatly increase in case of obesity and could reach 60 
to 70% of body weight (Cinti, 2007). 
The adipose tissue pool has at least two functionally different types of fat: 
white and brown adipose tissue. In general, accumulation of white adipose 
tissue is associated with increased risk of diseases, while the brown adipose 
tissue reduces the risk of obesity  and is associated with a protective action 
(Chalfant et al., 2012). 
1.2.2.1 White adipose tissue 
White adipose tissue (WAT) is the primary site for the fat storage. It also 
secretes hormones and releases cytokines (Ronti et al., 2006). About 30 % of 
circulating IL-6 comes from WAT mainly from visceral adipose tissue (Fried 
et al., 1998). 
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WAT shows clear differences between genders. Women have lesser amounts 
of intra-abdominal white adipose tissue and more subcutaneous white 
adipose tissue (SAT). In women SAT is found more in the thigh and hip 
regions than men (Gesta et al., 2007). Heredity can also have a big influence 
on fat mass and fat distribution (Montague & O'Rahilly, 2000). In addition, 
Saxena et al found that the ethnic group to which children belonged was 
more important than their social class in determining their chances of being 
overweight or obese (Saxena et al., 2004). They found that British Afro-
Caribbean and Pakistani girls and Indian and Pakistani boys have a 
significantly increased risk of being overweight or obese than the general 
population (Saxena et al., 2004). 
Obesity occurs as a result of WAT accumulation. It is most dangerous if it is in 
the visceral area because of its correlation with metabolic risk factors like 
high blood pressure, dyslipidemia, insulin resistance and T2D (Briatore et al., 
2008) and cardiovascular disease (Fox et al., 2007). The risk is lower if this 
accumulation is subcutaneous around the gluto-femoral region or in the lower 
part of the abdomen (Arner, 1998; Haffner et al., 1991; Lakka et al., 2002). 
Not only this but also extra fat could be stored in other fat deposits around 
and within other tissues and organs such as heart, blood vessels and kidney, 
which is known as “ectopic fat storage”. This accumulation of fat around such 
organs could impair their functions (Montani et al., 2004). The fat 
immediately adjacent to blood vessels may be one key factor predisposing to 
complications in obesity. The mobilisation of free fatty acids from visceral 
adipose tissue is more rapid than from SAT due to the higher lipolytic activity 
in visceral adipocytes. This variation involves the function of different 
andrenergic adrenoceptor subtypes and the function of insulin receptors 
(Arner, 1998). 
Adiponectin influences many cellular processes in the heart and vascular 
endothelial cells and these processes are mediated by adenosine mono 
phosphate kinase (AMPK) activation. In endothelial cells the signalling of 
AMPK is required for the adiponectin proangiogenic effects (Ouchi et al., 
2004; Shibata et al., 2004) and reduction of myocardial infarct size in a 
mouse model of heart ischemia (Shibata et al., 2005). 
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1.2.2.2 Brown adipose tissue 
Brown adipose tissue is mainly found in infants and young children (Cannon 
& Nedergaard, 2004). In new born infants it is important for thermo-genesis 
and it affects whole body metabolism. It may also alter insulin sensitivity 
(Almind et al., 2007). However, there is a continuing debate about the 
presence of brown adipose tissue normally in adults (Garruti & Ricquier, 
1992). Significant masses of brown adipose tissue have been found in adult 
males and females using 18F-fluorodeoxyglucose (18F-FDG) positron-emission 
tomographic and computed tomographic (PET-CT) scans (Cypess et al., 
2009). Brown adipose tissue has been found to be active in adults exposed to 
cold conditions or subjected to hyper-adrenergic stimulation in 
pheochromocytoma (Nedergaard et al., 2007). The distribution of brown 
adipose tissue is similar in male and females, however; the accumulation 
and activity of brown adipose tissue are more in females than males (Cypess 
et al., 2009).  
1.2.3 Problems 
Many physiological and psychological problems are associated with obesity. 
These include diabetes, cardiovascular diseases, hypertension, cancers, 
joint trauma, increased mortality, low self esteem and depression (Ashton 
et al., 2001; Wadden et al., 2006). 
1.2.3.1 Insulin Resistance and Hyper-insulinaemia 
Insulin is an important hormone in metabolic regulation. It is synthesised by 
the β cells of the pancreas. It stimulates glucose up take in many organs, 
especially muscle, liver and adipose tissue. Insulin also inhibits lipolysis in 
adipose tissue (Ruan & Lodish, 2003). Insulin resistance can be inherited or 
it can be acquired as a consequence of obesity (Pi-Sunyer, 2002). One of the 
proposed mechanisms of insulin resistance which is induced by lipid is the 
impairment of insulin action either through stimulation of protein kinase C 
(PKC) activity or directly (Hegarty et al., 2003). Kahn et al. showed that 
insulin resistance is directly proportional to BMI in non-diabetic individuals 
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(Kahn et al., 1993). Furthermore, in normal and overweight females the 
main determinant of insulin resistance is visceral obesity. This is a stronger 
influence than total body fat content, limb or trunk fat (Carey et al., 1996). 
Peripheral obesity may even protect against the development of insulin 
resistance (Lewis et al., 2002).  
There are two theories proposed to explain how visceral obesity induces 
insulin resistance. Firstly, the expansion of adipose tissue ultimately 
saturates its storage capacity and therefore limits its ability to accumulate 
more fat. Consequently, the excess fat will accumulate in other organs such 
as the liver, pancreas and muscles. The accumulation of fat on these organs 
can induce insulin resistance. Secondly, the extra accumulation of fat in 
adipose tissue is able to alter its ability to secret adipokines such as 
adiponectin, leptin, resistin, IL-6 and TNF-α. These adipokines regulate 
insulin sensitivity in adipose tissue and other organs (Fantuzzi, 2005).  
One of the most important pathogenic features of T2D is insulin resistance 
(De Leo et al., 2003). Therefore, insulin resistance should be managed to 
treat these metabolic disorders. The most effective treatments for insulin 
resistance are weight loss and exercise (Greenfield & Campbell, 2004). 
Pharmaceutical approaches are also used. Metaformin and thiazolidinediones 
can have a very effective role in treatment of insulin resistance (Greenfield 
& Campbell, 2004). The mode of action of metaformin is through the 
reduction of hepatic glucose production (Inzucchi et al., 1998). It also 
decreases the systemic concentration of triglyceride and free fatty acids 
(Bailey & Turner, 1996). While the precise mechanism of thiazolidinediones 
action is not clear, part of its action is thought to be through effects on 
body fat (Gurnell et al., 2003) 
1.2.3.2 Type 2 Diabetes and obesity 
T2D is also known as non insulin dependent diabetes or diabetes mellitus 
(NIDDM). It develops in two ways: as a result of insulin resistance where 
there is a failure of the body to respond to insulin, or by a decrease in the 
ability of the pancreas to secret an adequate amount of insulin (Banting et 
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al., 1922; Garvey et al., 1985). This form of diabetes is usually associated 
with obesity. It is now very common (Mokdad et al., 2003).  
Many studies have found a close link between diabetes and obesity (Colditz 
et al., 1995; Ford et al., 1997; Wannammethee & Shaper, 1999). The 
development of diabetes increases gradually with increasing BMI for males 
and females. Colditz et al. found that the risk of diabetes in adult females 
increases two fold if body weight increases by 7 kg. The risk of developing 
diabetes is four times greater if their BMI is more than 23 kg/m2 than it is if 
the BMI less than 22 Kg/m2 (Colditz et al., 1995). Koh-Banerjee et al. 
determined that the risk of developing diabetes increases by 7.3% for every 
kilogram weight gained (Koh-Banerjee et al., 2004). They also found a close 
relation between fat distribution and the risk of T2D. Abdominal obesity 
might be stronger predictor of risk of diabetes than BMI alone (Hartz et al., 
1983; Koh-Banerjee et al., 2004; Ohlson et al., 1985). The bigger size of the 
abdominal adipocytes might be related with metabolic disturbance. In 
addition, the abdominal adipocytes are more responsive to insulin than the 
femoral adipocytes (Smith et al., 1979).  
1.2.4 Possible Solutions to the problem of obesity 
The National Weight Control Registry has pointed out that diet and exercise 
are the bases in the treatment of obesity (Wang et al., 2002). Furthermore, 
it has been demonstrated that exercise is an important component of 
control of weight and that a higher duration and intensity of exercise may 
improve long term weight loss. Weight loss also has beneficial effects which 
reduce the health risks (Jakicic & Otto, 2005). In short, adipose tissue, in 
addition to being specialized organ for fat storage, can be considered as the 
largest endocrine gland because it synthesises and secrets a range of 
hormones known as adipokines many of which affect insulin sensitivity.  
1.3 Adipose tissues as an endocrine organ 
WAT is not only a storage organ but also complex endocrine organ. It 
secretes free fatty acids, cytokines and a range of hormones known as 
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adipokines. They are peptides or small proteins secreted by adipocytes into 
the systemic circulation and they have autocrine, paracrine and endocrine 
actions (Antuna-Puente et al., 2008; Bastard et al., 2006; Hill et al., 2009)  
Many biological functions in many organs, including the brain, liver, adipose 
tissue, skeletal muscles, reproductive system and blood vessels are related 
to adipokines (Hill et al., 2009). These adipokines include: leptin, 
adiponectin, resistin, visfatin, adipsin, IL-6 and TNF- α (Antuna-Puente et 
al., 2008). For instance, adipokines play a vital role in the regulation of 
glucose and lipid metabolism because they enhance insulin sensitivity (Fisher 
et al., 2005; Oh et al., 2007; Scherer et al., 1995). Adipokines affect lipid 
intake and energy expenditure (Ahima & Flier, 2000). They have an anti 
atherogenic and anti inflammatory action (Fisher et al., 2005; Oh et al., 
2007; Scherer et al., 1995). Eventually, the over production of these 
adipokines is linked with some pathological conditions relating to lipid 
metabolism, insulin sensitivity and CVD (Hill et al., 2009).  
Adipose tissue is responsible for changes in the physiological and functional 
role of these adipokines in the body. However, these adipokines are also 
present in other parts of the body such as the immune system, reproductive 
system, brain, liver and skeletal muscle (Hill et al., 2009). The secretion of 
adipokines show signs of regional variation, where the release and 
expression of IL-6 and IL-8 are more expressed and released by visceral 
adipose tissue than subcutaneous adipose tissue (Fried et al., 1998). While 
adiponectin and leptin are more expressed and released by subcutaneous 
adipose tissue than visceral adipose tissue (Lihn et al., 2004).  
1.3.1 Leptin  
Leptin is one of the best known adipokines. It is a 16 KD protein made up of 
146 amino acids and it is encoded by the ob gene (Zhang et al., 1994). It was 
named leptin from Greek word meaning ‘thin’ (Ahima & Flier, 2000). There 
is a direct relationship between leptin concentration and obesity; leptin 
concentrations are higher in obese people than in lean people (Minokoshi & 
Kim, 2002). While this adipokine is thought to be mainly expressed by white 
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adipose tissue, recent research has showed that it is also expressed in many 
other sites including the hypothalamus (Morash et al., 1999), the pituitary 
gland (Jin et al., 2000) and skeletal muscle (Wang et al., 1998).  
Leptin has several actions. It enhances insulin sensitivity by decreasing the 
fat concentration in skeletal muscle, liver and pancreatic beta cells (Ronti 
et al., 2006). Another important action, it influences the control of food 
intake and energy expenditure by the central nervous system (Ahima & Flier, 
2000). There is strong evidence to show that the main action for leptin is to 
act as a ‘starvation signal’. In addition its concentrations in plasma and 
adipose tissues are dependent on the amount of the energy stored. The 
concentration of leptin increases in case of over feeding and decrease in 
fasting. Consequently; it is higher in obese individuals and lower in lean 
individuals (Ahima & Flier, 2000). Leptin concentrations increase in response 
to hyperinsulinaemia, glucocorticoids, acute infections and proinflammatory 
cytokines. On the other hand, leptin concentrations are decreased in 
response to the stimulation of thyroid hormone, growth hormone and 
thiazolidinediones (Ahima & Flier, 2000). 
1.3.2 Resistin 
Resistin is another important hormone of this group. It is also known as 
“Adipose tissue-specific Secretary Factor” (ADSF) (Kim et al., 2001) and as 
“found in inflammatory zone” FIZZ (Holcomb et al., 2000). Resistin is a 
peptide hormone of 12.5 KD. It is composed of 114 amino acids and is 
encoded by a gene known as retn. This gene is found on chromosome 19 in 
humans and on chromosome 8 in mice. It is belonging to group of proteins 
rich with cysteine named “resistin – like molecules” (RELMs) (Rajala et al., 
2003).  
Resistin is found to induce insulin resistance in mice (Rajala et al., 2003). Its 
production in adipose tissue is suppressed by thiazoladinedione treatment. It 
is believed that resistin could be the link between obesity and insulin 
resistance (Steppan et al., 2001). Resistin is similar to all adipokines, except 
adiponectin, in its relationship to obesity. It has a direct relationship with 
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obesity (Rajala et al., 2003). The greater part of the study of resistin actions 
has been done in mice. The physiological role of resistin in humans is not 
clear (Savage et al., 2001). 
1.3.3 Tumour Necrosis Factor α (TNF-α) 
TNF–α was the first molecular link between obesity and insulin resistance to 
be identified (Moller, 2000). TNF-α is a pro-inflammatory cytokine, secreted 
mainly by lymphocytes, macrophages. Adipocytes in humans produce small 
amounts of this hormone (Hotamisligil et al., 1993). It is 26 KD protein with 
157 amino acids, composed of three identical subunits (Hotamisligil et al., 
1993). 
TNF-α mRNA shows a relationship with BMI, percentage of body fat and 
hyper-insulinaemia. Its concentration decreases during weight loss and after 
improvement of insulin sensitivity (Guerre-Millo, 2004). Insulin signalling is 
inhibited by TNF–α and this might be the mechanism of insulin resistance in 
obesity (Fried et al., 1998). In addition, adiponectin secretion from 
adipocytes is inhibited by TNF–α (Garg, 2004). In contrast, Ofei et al. 
demonstrated that glucose concentration and insulin sensitivity were not 
altered by the infusion of antibodies raised against TNF–α (Ofei et al., 1996). 
The role of TNF–α and IL-6 in the regulation of adiponectin secretion has been 
studied by many researchers. Maeda et al. confirmed the inhibitor role of 
TNF-α on adiponectin production and gene expression (Maeda et al., 2001). In 
humans, TNF-α has been shown to decrease adiponectin gene expression and 
adiponectin secretion from adipose tissue (Lihn et al., 2003b). The same 
result has been found in pre-adipocytes (Kappes & Loffler, 2000). These and 
other data from in vivo studies in humans and rodents show a negative 
relation between TNF-α and adiponectin (Lihn et al., 2003b). As a result, 
TNF–α might play an important role in the path-physiology of insulin 
resistance (Hotamisligil et al., 1993). 
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1.3.4  Interleukin – 6 (IL-6) 
IL-6 is a cytokine with many forms, ranging from 22 to 27 KD. It is secreted 
by many cells including: fibroblasts, endothelial cells and monocytes. 
Adipose tissues secrete significant amounts of IL-6, about 10% of IL-6 is 
secreted from adipocytes themselves (Fried et al., 1998). As with other 
adipocytokines, the IL-6 concentrations increase in obesity, particularly 
visceral obesity. The expression of IL-6 mRNA is higher in visceral adipose 
tissue than subcutaneous adipose tissue (Fried et al., 1998). IL-6 secretion is 
related to BMI and fat mass (Vozarova et al., 2001). There is a low 
concentration of IL-6 mRNA in resting muscle but IL-6 is secreted by skeletal 
muscle in response to exercise (Plomgaard et al., 2005). 
IL-6 has many functions. One of the most important is the stimulation of C 
reactive protein (CRP) production in the liver (Ridker, 2003). Moreover, IL-6 
is an important link between obesity, inflammation and coronary heart 
disease (Yudkin et al., 2000). Other studies have suggested that IL-6 might 
play a role in insulin resistance (Bastard et al., 2002). In addition, IL-6 
inhibits adiponectin secretion and decreases the signals of insulin receptors 
(Kershaw & Flier, 2004). 
IL-6 is one of the cytokines which increases in obesity and this might be 
responsible for the high level of acute-phase proteins, such as CRP, in obese 
subjects  (Fantuzzi, 2005 ). 
1.3.5 Adiponectin 
Adiponectin is one of the main adipokines. It has several names: “adipocyte 
complement-related protein of 30 KD” (Acrp30) (Scherer et al., 1995), 
“Adipose most abundant gene transcript 1” (apM1) (Maeda et al., 1996),  
“gelatine binding protein -28” (GBP28) (Nakano et al., 1996) or adipo Q (Hu 
et al., 1996). These five names were given by the five different research 
groups who worked on the early stage of its detection. Scherer was the first 
to identify adiponectin as a protein synthesized in adipose tissue and 
secreted from mouse adipocyte cells from the 3T3-L1 line. At about the 
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same time, Nakano et al. discovered a similar protein with a molecular 
weight of 28 KD. Maeda et al. isolated the specific gene in adipose tissue 
from humans and called it apM1. A polypeptide of 247 amino acids was 
found by Hu et al. working on adipose tissue using cDNA and mRNA 
techniques (Hu et al., 1996) 
Adiponectin is secreted mainly by adipocytes; however, it can be expressed 
by osteoblasts (Berner et al., 2004), skeletal muscle (Krause et al., 2008) 
cardiomyocytes (Pineiro et al., 2005) and epithelial cells in salivary glands 
(Nishida et al., 2007). It circulates in plasma in relatively high 
concentrations of about 3- 30 µg/ml (Arita et al., 1999; Scherer et al., 
1995). It accounts for about 0.01% of the total plasma proteins in normal 
persons (Antuna-Puente et al., 2008; Whitehead et al., 2006). Thus the 
concentration of adiponectin is far higher than the concentration of any 
other hormone in the blood of lean individuals (Hu et al., 1996; Maeda et 
al., 1996; Nakano et al., 1996).  
This concentration of adiponectin in plasma is three times higher than the 
concentration of leptin, which is typically measured as nanograms per 
millilitre, and about six times the concentration of IL-6, which is typically 
measured as picogram per millilitre. One question arises at this point: why is 
the concentration of adiponectin so much higher than other hormones 
secreted by adipose tissue? One might speculate that it reflects its 
important role. Alternatively, it might exert its action through very low 
efficiency receptors (Sun et al., 2009). 
1.3.5.1 Structure  
Adiponectin is similar in structure to complement protein C1q and tumour 
necrosis factor α Figure 1-2. It consists of four domains including amino 
terminal region, a variable region, a globular domain near the c terminus, 
and a collagen-like domain (Scherer et al., 1995). Total adiponectin acts to 
reduce glucose production in the liver (Combs et al., 2001). In contrast, the 
globular form of adiponectin plays an important role in stimulation of fatty 
acid oxidation in liver and skeletal muscle (Yamauchi et al., 2003a). 
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Therefore, the way in which the different forms of adiponectin work and 
their site of the action might be different (Wang et al., 2002). 
1.3.5.2 Forms 
There are many isoforms of adiponectin found in human blood and each may 
have different effects (Hill et al., 2009). These forms are illustrated in 
figure 1-3. The principal forms are:  low molecular weight probably a trimer 
(Mangge et al., 2009), the albumin binding trimer (Alb-LMW), middle 
molecular weight or hexamer (MMW) and a high molecular weight form,  
which probably consists of large multimers (Hada et al., 2007; Hill et al., 
2009). 
These forms have been identified by a range of different techniques such as 
gel filtration chromatography, velocity sedimentation centrifugation and 
reducing polyacrylamide gel electrophoresis (Oh et al., 2007) 
 
Figure  1-2  
Adiponectin structure and it is similarity with TNF-α (Shapiro & Scherer, 1998) 
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Figure  1-3 
Multimeric forms of adiponectin. (Oh et al., 2007) 
 
The concentrations of many adipokines are significantly different in plasma 
and interstitial fluid. The concentration of adiponectin and leptin in 
interstitial fluid is lower than in plasma (Nielsen et al., 2009). This is 
surprising because the main site for adiponectin secretion is adipose tissue. 
There are two possible explanations for this. Firstly, adiponectin may be 
transported actively from the secretion site to plasma. Secondly, 
adiponectin in plasma found in two forms, a free form and a bound form 
which binds strongly to a transporter protein. The low concentration of the 
free form may be in equilibrium with interstitial fluid. Furthermore; the 
distribution of adipose tissue around the body is clinically important. 
Accumulation of fat in abdominal regions is more dangerous than elsewhere 
since insulin resistance is related to the accumulation of abdominal adipose 
tissue. In contrast, lower –body fat mass is related positively to insulin 
sensitivity (Buemann et al., 2005). Cnop et al. showed that, there is a 
positive relation between adiponectin concentrations and insulin sensitivity. 
This supports the concept that there is a link between adiponectin and 
insulin action. However, the concentration of adiponectin is negatively 
related to the distribution of body fat and the size of the body. Further 
there is a strong correlation between adiponectin concentration and the 
Globular      
domain 
+ + = 
Collagenous 
domain 
Monomer 
Trimer 
+ = ―S  S― 
 S― ―S    ―S     S― + 
Hexamer 
= 
HMW multimers 
Chapter 1   
M. Alzwayi  35  
concentration of HDL cholesterol and the size of LDL particle. Another 
finding in this study is that the relation between adiponectin and obesity is 
similar in both sexes (Cnop et al., 2003). 
Adiponectin does not circulate as monomer, but it forms multimeric 
structures through disulphide bonds that link the collagenous domains 
(Trujillo & Scherer, 2005). This is illustrated in figure 1-3. 
The monomeric form of adiponectin is found only in adipose tissue but not in 
the peripheral circulation (Giannessi et al., 2007). Ebinuma et al. reported 
that 50% of the total adiponectin was in the HMW form and 25% in each of 
the MMW and LMW forms (Ebinuma et al., 2006). Beltowski et al. Found 
slightly different proportions: HMW were 40%, MMW 35% and LMW 25% of the 
total adiponectin in human serum (Beltowski et al., 2008).  
The trimer is the basic form of circulating adiponectin (Wang et al., 2006). 
These trimers range between 75-90 KD and can join together to form low 
molecular weight hexamers between 180 – 190 KD (Mangge et al., 2009) and 
high molecular weight forms, with molecular weight of more than 420 KD 
(Navaneethan et al., 2010). The LMW and HMW are more easily detectable 
in blood than the trimer. This is probably because the trimer has a the 
shorter half life (Pajvani et al., 2003b). The HMW form is only formed in 
eukaryotic cells, but the maximum form found in the prokaryotic cells are 
the trimer and hexamer (Richards et al., 2006). 
Many authors report that HMW adiponectin is the most active form and its 
concentration is changed significantly with some diseases (Fisher et al., 
2005; Hara et al., 2006; Hill et al., 2009; Tsao et al., 2003). For example, 
low concentrations of HMW are found in patients with T2D (Hill et al., 2009). 
In addition, the effect of insulin resistance on adiponectin secretion is 
mainly because of the down regulation of HMW multimers (Basu et al., 
2007). Furthermore, the proportion of HMW is higher in women than men 
(Pajvani et al., 2003a). HMW adiponectin is a better predictor of insulin 
resistance, metabolic syndrome (Fisher et al., 2005; Hara et al., 2006) and 
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coronary artery disease (Von et al., 2008). Little data has been published 
about the physiological role of the multimeric forms of adiponectin. 
1.3.5.3 Secretion 
The production of adiponectin by adipocytes is a multistep process. This 
process of production can be regulated at the level of gene expression, 
secretion and the formation of the isoforms of the adiponectin (Guerre-
Millo, 2008). The molecular mechanisms of adiponectin secretion are 
unknown (Motoshima et al., 2002; Qiang et al., 2007; Guerre-Millo, 2008). 
Adiponectin is synthesized as a single polypeptide of 30 KD and before its 
secretion it is assembled to form HMW in the endoplasmic reticulum (Qiang 
et al., 2007). Adiponectin has been shown to be secreted from human 
visceral adipose tissue in vitro, and its mRNA appears to be negatively 
regulated by glucocorticoids and positively by insulin (Halleux et al., 2001). 
Hajri et al suggested the requirement of insulin sensitivity for adiponectin 
secretion (Hajri et al., 2011). Other studies have demonstrated that 
adiponectin expression and secretion from adipose tissue are regulated by 
insulin, TNF- α and IL-6 (Fasshauer et al., 2002; Fasshauer et al., 2003). 
Further more, endothelin-1, which is an important vasoconstrictor, has a 
role in the stimulation of adiponectin secretion from the 3T3-L1 adipocytes. 
However its mechanism of action on adiponectin secretion is unknown 
(Clarke et al., 2003). 
Motoshima et al demonstrated that the adiponectin secretion was not 
different between the omental and subcutaneous adipose tissue; however 
the stimulation of the secretion was different. Adiponectin is secreted more 
from omental adipose cells than subcutaneous cells under the effect of 
insulin. The basal adiponectin secretion from omental adipose tissue was 
negatively correlated to BMI, while there was no correlation between the 
secretion from subcutaneous adipose tissue and BMI (Motoshima et al., 
2002). 
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1.3.5.4 Regulation 
Adiponectin has a relatively long half life of 2.5-6 hours in human plasma 
(Hoffstedt et al., 2004). Its concentration shows some diurnal variation in 
human subjects as it is higher in the late morning and lower at night (Gavrila 
et al., 2003). “Ultradian pulsatility’’ has been observed in circulating 
adiponectin levels (Gavrila et al., 2003). It is remarkable that transcription, 
translation and post translation levels of adiponectin may take part in its 
regulation. Moreover, variations in the renal and hepatic clearance of 
adiponectin provides another mechanism for  regulation of its concentration 
(Tietge et al., 2004). 
Adiponectin is known to be regulated by other adipocytokines such as TNF-α 
and IL-6. The expression and secretion of adiponectin from human pre-
adipocyte is decreased by TNF-α (Kappes & Loffler, 2000). Weight loss has a 
direct effect on adiponectin concentration. However, weight loss induced by 
calorie restricted diet does not affect adiponectin concentrations (Garaulet 
et al., 2004; Xydakis et al., 2004).  
1.3.5.5 Distribution 
Adiponectin concentrations vary. It is higher in plasma than in the 
interstitial fluid of subcutaneous adipose tissue in both lean and overweight 
males (Hojbjerre et al., 2007). Its gene expression is higher in subcutaneous 
adipose tissue than visceral adipose tissue (Lihn et al., 2004), but there is no 
difference between the concentrations in interstitial fluid collected from 
the gluteal and abdominal subcutaneous adipose tissue (Nielsen et al., 2009) 
Adiponectin concentrations are also affected by factors such as gender, age 
and ethnicity (Hill et al., 2009). Women have higher adiponectin 
concentrations than men (Cnop et al., 2003; Gilardini et al., 2006). This is 
probably due to the difference in fat distribution, since women have larger 
subcutaneous fat deposits and the inhibitory effects of androgens on 
adiponectin secretion in men (Cnop et al., 2003). Nishizawa et al 
demonstrated that the secretion of adiponectin was suppressed by 
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testosterone and dihydrotestosterone (5α-DHT) in 3T3-L1 adipocytes. This 
adiponectin concentration in plasma of mice treated with androgens was 
also reduced (Nishizawa et al., 2002). There is no clear view of the effect of 
oestrogens. It has been suggested that the oestrogens could have a 
stimulatory effect on the production of adiponectin (Sieminska et al., 2005). 
However one investigation found negative effects of oestrogens on 
adiponectin concentrations (Combs et al., 2003).  
Adiponectin concentration is affected by age and it is higher in older people 
than young people. This finding may be related to changes in testosterone 
and oestrogens concentrations with increasing age, possibly removing the 
inhibitory effect (Nishizawa et al., 2002). Another possible reason is the 
reduction of adiponectin clearance in older people (Cnop et al. 2003). 
Adiponectin concentrations are affected by the ethnicity. Its concentration 
is lower in Indo-Asians and Black African people than Caucasians people 
(Steffes et al., 2004). 
1.3.5.6 Actions 
The metabolic effects of adiponectin are similar to those that happen by the 
activation of the 5`-AMP-activated kinase in liver and muscles. Therefore; 
the adiponectin action could be through the stimulation of AMPK (Kola et 
al., 2006). The main target tissues for adiponectin action are skeletal 
muscles and liver (Guerre-Millo, 2008). In skeletal muscle adiponectin 
regulates lipid metabolism via the activation of AMPK. It stimulates the fatty 
acid oxidation in mice (Fruebis et al., 2001). Adiponectin stimulates the 
synthesis of protein and inhibit it is degradation. Therefore a hypothesis 
arose for the role of adiponectin in the skeletal muscle growth (Yamauchi et 
al., 2001). 
In the liver, adiponectin increases fatty acid oxidation and inhibits fatty acid 
synthesis through the stimulation of AMPK (Yamauchi et al., 2001). 
Furthermore adiponectin increases insulin sensitivity in hepatocytes, 
consequently the glucose production decreases (Berg et al., 2001). Low 
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adiponectin concentrations have been found in association to liver disease. 
Low serum adiponectin concentrations were found in patients suffering from 
chronic hepatitis (Durante-Mangoni et al.,2006). Another finding of 
decreased adiponectin concentrations was related with the fatty liver 
disease in rodents (Neumeier et al., 2006). 
1.3.5.7 Functions 
Adiponectin has many physiological functions including: actions on glucose 
and lipid metabolism, producing an insulin sensitizing action (Stefan & 
Stumvoll, 2002), appetite regulation, an anti-inflammatory action (Weyer et 
al., 2001),  regulating cardiac function, angiogenesis, vascular remoulding, 
regulation of blood pressure, blood coagulation and immunity (Hill et al., 
2009). Adiponectin has been suggested to play a role in the maintaining 
healthy body weight (Hill et al., 2009).  
This catalogue of adiponectin actions became easier to understand with the 
discovery of  family of adiponectin receptors (Yamauchi et al., 2003a). 
Adiponectin 1 receptors (AdipoR1) are expressed in skeletal muscle and  
adiponectin 2 receptors (AdipoR2) are expressed in liver (Nishida et al., 
2007). In addition  T – cadherin receptors on endothelial cells expressed in 
the cardiovascular system, nervous system and muscles, bind hexametric 
and HMW adiponectin (Hug et al., 2004). These receptors are also expressed 
in other tissues such as brain (Yamauchi et al., 2003a), pancreatic cells 
(Kharroubi et al., 2003), also in the macrophages and atherosclerotic lesions 
(Chinetti et al., 2004). 
AdipoR1 receptors have a high affinity for globular adiponectin and a low 
affinity for full length adiponectin (Kharroubi et al., 2003). AdipoR1 
receptors mediate adenosine mono phosphate kinase (AMPK) activation 
which increases glucose uptake and fatty acid oxidation in skeletal muscle 
(Kharroubi et al., 2003). AdipoR2 receptors have an intermediate affinity for 
both globular and full length adiponectin. This seems to be mainly 
responsible for mediating the effects of the full length adiponectin in the 
liver, through the activation of AMPK (Yamauchi et al., 2003a). However; 
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AdipoR1 and AdipoR2 have not yet been detected in the human plasma 
(Garaulet et al., 2004). The T-cadherin receptor on vascular endothelial and 
smooth muscles is known to relate to atherosclerosis (Takeuchi et al., 2007, 
Tilg & Moschen, 2006).  
Adiponectin infusion into the liver increases the effects of insulin. It reduces 
the expression of gluconeogenic enzymes and suppresses glucose production 
(Combs et al., 2001). 
Adiponectin has an anti-inflammatory action. It enhances the effect of anti 
inflammatory cytokines like interleukin 1 and interleukin 10 (Wolf et al, 
2004). Adiponectin also suppresses the production of IL-6 and TNF-α in 
lipopolysaccharide activated human macrophages (Wulster-Radcliffe et al., 
2004). Adiponectin has a protective effect against arteriosclerosis, most 
likely because it suppresses macrophage production of pro inflammatory 
cytokines (Wolf et al., 2004; Wulster-Radcliffe et al., 2004). It also inhibits 
monocyte adhesion to aortic endothelial cells and suppresses the 
transformation of macrophages to foam cells (Ouchi et al., 2001). Vascular 
anomalies were found in adiponectin deficient mice. These are the result of 
increased proliferation of vascular smooth muscle cells in response to 
external arterial injury (Matsuda et al., 2002). Conversely, adiponectin 
administration to apolipoprotein-E deficient mice reduced the size of the 
atherosclerotic lesions (Yamauchi et al., 2003b). More recently, studies in 
adiponectin deficient mice have revealed new roles for adiponectin: 
protecting the heart against ischemia reperfusion injury and acting as an 
endogenous antithrombotic factor (Kato et al., 2006).   
1.3.5.8 Clinical importance of adiponectin 
A decrease in adiponectin concentrations in plasma is related to many 
aspects of the metabolic syndrome, like insulin resistance, dislipidemia with 
low concentrations of high density lipoprotein (HDL) cholesterol (Hulthe et 
al., 2003). A low concentration of adiponectin in plasma is related to several 
other conditions. These include increased risk of T2D and CVD (Sattar et al., 
2006). In addition, there is evidence to suggest a relation between low 
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adiponectin concentrations and development of liver fibrosis which might 
also raise the risk of malignancies (Kelesidis et al., 2006). 
In the case of CVD and insulin resistance, patients have low total 
adiponectin concentrations and the adiponectin is mainly found in low 
concentration of its HMW form (Lara-Castro et al., 2006). Adiponectin gene 
mutations have consistently been associated with T2D. These conditions are 
associated with impaired formation of HMW adiponectin hexamers. This 
finding suggest that the HMW adiponectin is the active form of the hormone 
(Waki et al., 2003). Thus, it is clinically important to identify a means of 
restoring normal adiponectin levels, in particular, the HMW form (Guerre-
Millo, 2008). It is interesting to note that even moderate weight loss 
increases adiponectin concentration in plasma by increasing the 
concentration of the HMW form (Bobbert et al., 2005). 
1.3.5.9 Adiponectin and obesity 
Adiponectin is different from the other adipokines in that its concentration 
is inversely proportional to the fat level in the body (Weyer et al., 2001). 
Positive correlations have been found between the concentrations of 
adiponectin and HDL- cholesterol. In contrast, it is negatively correlated 
with triglycerides, low density lipoprotein (LDL) - cholesterol (Cnop et al. 
2003). The expression of the adiponectin gene in adipose tissue and its 
plasma concentration are decreased in cases of lipodystrophy and HIV- 
associated lipodystrophy, where there is a redistribution of fat with 
associated metabolic abnormalities such as insulin resistance (Lihn et al., 
2003b)  
These papers show that the insulin resistance associated with obesity might 
be a result of reduction in adiponectin concentrations (Lihn et al., 2005). 
Yamauchi et al. demonstrated that high insulin and glucose concentrations 
in mice with lipodystrophy and insulin resistance have been ameliorated 
with the infusion of recombinant adiponectin or adiponectin combined with 
leptin. This finding indicates that a decrease in the concentration of some 
adipokines like adiponectin and leptin might lead to some extent to insulin 
Chapter 1   
M. Alzwayi  42  
resistance in lipodystrophic mice (Yamauchi et al., 2001). Maeda et al. 
recognized that over nutrition leads to reduced concentrations of 
adiponectin and this is in turn related to development of insulin resistance 
and diabetes (Maeda et al., 2002). Other findings by Xu et al. Show that the 
fat content of the liver is reduced by an infusion of adiponectin. One 
possible explanation of this is that adiponectin reduces the synthesis of fatty 
acids and increases fatty acid oxidation in the liver (Xu et al., 2003).  
Studies of humans who display low adiponectin concentrations indicate that 
adiponectin plays a role in the development of insulin resistance (Hotta et 
al., 2000). Obesity, T2D and coronary heart disease reduce adiponectin 
concentrations (Arita et al., 1999). Accordingly, the concentration of 
adiponectin mRNA in adipose tissue from lean people is higher than that in 
obese ones (Lihn et al., 2004). A close relation exists between adiponectin 
concentration and different indicators of insulin resistance in subjects of 
normal weight. Intra-abdominal fat has a stronger effect on determining 
insulin sensitivity than does subcutaneous fat (Cnop et al., 2003). In 
contrast, the adipocyte derived hormone concentration is mainly 
determined by the subcutaneous fat (Havel, 2000). Not only this, but also a 
low level of adiponectin mRNA has been found in the tissues of a group of 
people who have first degree relatives who are diabetic (Lihn et al., 2003a). 
Gene expression of adiponectin is negatively correlated with insulin 
sensitivity (Lihn et al., 2005). Adiponectin has insulin sensitizing, anti 
inflammatory and anti atherogenic properties (Hotta et al., 2000; Yamauchi 
et al., 2003b). The concentration of adiponectin in the interstitial fluid of 
adipose tissue is more affected by acute hyperinsulinaemia than the 
concentration of adiponectin in blood. Hyperinsulinaemia reduces interstitial 
adiponectin concentrations by ~ 40%, while the decline in the plasma 
concentration is only ~ 15%. Moreover, the loss of adiponectin caused by 
acute hyperinsulinaemia may be different in lean and obese subjects. This 
could be regulated primarily at a post-transcription level (Murdolo et al., 
2009).  
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1.3.5.10 The effect of exercise on adiponectin 
Extensive studies have been done on the mechanism of the effect of 
exercise on insulin sensitivity. There is no single cause of T2D. It is unlikely 
that there will be only one mechanism linking exercise and insulin 
sensitivity. 
As mentioned before, adiponectin concentrations decrease in cases of 
obesity, T2D and coronary heart disease (Arita et al., 1999). In humans, 
treatment for insulin resistance with thiazolidinediones has positive effects 
on adiponectin concentrations (Yang et al., 2002). Furthermore, adiponectin 
concentrations are  enhanced by weight loss, which also improves insulin 
sensitivity (Yang et al., 2001). 
The effect of exercise training on adiponectin concentrations in blood is 
controversial; some studies conclude that adiponectin concentrations are 
not affected by chronic exercise. Yatagai et al. found that a programme of 
exercise training in healthy men, lasting for one and half months, enhanced 
insulin sensitivity without reducing body weight or increasing plasma 
adiponectin concentrations (Yatagai et al., 2003). This was in agreement 
with other studies (Hojbjerre et al., 2007; Hulver et al., 2002; Jurimae et 
al., 2006; Nassis et al., 2005). Punyadeera et al. found that there was no 
effect of prolonged, moderate intensity exercise on plasma adiponectin 
levels in healthy lean males (Punyadeera et al., 2005).  
In contrast, other studies have found big increases in adiponectin 
concentrations after exercise training for two and half months. One study 
tested young and middle aged healthy females, found increases in 
adiponectin concentrations was accompanied by a reduction in body mass 
index in the older group but not in the younger group (Lim et al., 2008). 
Similar increases in adiponectin concentrations were found after short bouts 
of exercise by overweight males. This exercise programme did not change 
their BMI (Kriketos et al., 2004). The effect of exercise on adiponectin 
concentrations in interstitial fluid was investigated by Hojbjerre et al. and 
they found that acute exercise increased the adiponectin concentrations in 
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interstitial fluid of subcutaneous adipose tissue in lean and over weight 
males (Hojbjerre et al., 2007). Previous data suggests that the effect of the 
exercise might be similar in males and females. It seems that weight loss is 
an essential factor to increase adiponectin concentrations. 
1.4 Exercise  
The conversion of the chemical energy to mechanical energy is the main 
factor that affects the ability of the human to exercise. This chemical 
energy is obtained from adenosine tri phosphate (ATP). The intra muscular 
store of ATP is small and can be consumed very quickly during the 
contraction. So other sources are available to provide ATP for the 
contractile muscles such as creatin phosphate (PCr), break down of muscle 
glycogen to lactate and oxidative metabolism of carbohydrate and lipid. Fat 
metabolism can provide enough ATP to maintain exercise up to 75% of 
maximal oxygen consumption ( 2OV& max) depending on the aerobic exercise of 
the individual. While carbohydrate can provide ATP up to 100% of 2OV& max in 
trained or untrained individuals (Hargreaves & Spriet, 2006) 
The aerobic system has the ability to produce ATP at a moderate to high 
rate for several hours. However there are some limitations. At the onset of 
the exercise the aerobic exercise takes a limited time to reach the required 
rate of ATP production. The ATP production is less than the requirement of 
the muscle during the intense exercise. These limitations are filled with the 
anaerobic system (Hargreaves & Spriet, 2006). 
At low intensity exercise (35% 2OV& max) a low rate of ATP is used. The 
aerobic metabolism provides most of the ATP needed and there is little need 
for the PCr breakdown or lactate production. As the exercise intensity 
increases (65% 2OV& max) both aerobic and anaerobic pathways are activated 
to a bigger extent. A large proportion of the required energy is supplied by 
fat, and muscle glycogenolysis increases. With an increase in exercise 
intensity (90% 2OV& max) the need for ATP production increases above that 
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which can be provided by aerobic metabolism so the anaerobic pathway 
continues to supply the energy (Howlett et al., 1998; Romijn et al., 1993). 
1.4.1 Maximal oxygen consumption 
The lungs and cardiovascular system supply oxygen and remove carbon 
dioxide from the working muscles. Under steady-state conditions the 
measurement of oxygen consumption per unit time ( 2OV& ) and carbon 
dioxide production per unit time ( 2COV& ) by mouth correspond to oxygen 
utilization and carbon dioxide production in the cell (Milani et al., 2006).  
“Cardiovascular fitness reflects the maximal amount of oxygen consumed 
during each minute of near-maximal exercise. Values for maximal oxygen 
consumption ( 2OV& max) are generally expressed in millilitres of oxygen per 
kilogram of body mass per minute (ml/kg/min). 2OV& max can be determined 
by a variety of exercise tests that activate the body’s large muscles provided 
exercise intensity and duration maximize aerobic energy transfer. The usual 
exercise modes include treadmill running, or walking, bench stepping and 
stationary cycling” (McArdle et al., 2007). 
2OV& max is affected by several factors include: age, gender, genes, mode of 
exercise and body mass. 2OV& max decrease gradually with age. It is about 27% 
lower at age 55 than at 20 years old (McArdle et al., 2007). It is higher in 
males than females. This difference between genders is mostly related to 
body composition and haemoglobin concentrations (McArdle et al., 2007). 
The effect of the mode of the exercise on the 2OV& max is mostly related to 
the amount of the muscle mass activated (McArdle et al., 2007). 
1.4.2 Respiratory exchange ratio (RER) 
The RER corresponds to the exchange of the metabolic gases in the tissues 
and it is relatively dependent on the main energy source used for the 
cellular metabolism, carbohydrate and fat. Thus it is defined as the ratio of 
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carbon dioxide production ( 2COV& ) to oxygen consumption per unit time 
( 2OV& ) (Astrand et al., 2003). 
                            (RER = 2COV& / 2OV& ). 
The percentage of participation of carbohydrates and fat in energy 
metabolism depends primarily on two main factors: the type of the exercise 
and the state of physical training (Astrand et al., 2003). 
1. Type of exercise: Carbohydrates and fat contribute equally in the 
supply of the energy at rest and during light or moderate exercise. As the 
exercise progresses and its duration extends, the contribution of fat to the 
energy supply increases. Therefore, the contribution of carbohydrate in 
prolonged exercise is minor. In contrast, the contribution of carbohydrate in 
energy supply for the high intensity exercise is greater than the fat 
contribution (Astrand et al., 2003).  
The initial training status of volunteers and the intensity and duration of 
exercise all affect the substrate metabolism. The most important source of 
energy in high exercise intensity is glycogen in muscles and liver. In the case 
of moderate to intense exercise muscles metabolise complete intramuscular 
triglycerides more effectively. When exercise lasts for more than one hour, 
the glycogen stored in the muscle is run down, and accordingly the 
contribution of plasma substrates to total energy increases. Plasma glucose 
concentration remains constant during moderate exercise since the increase 
of hepatic glucose production is in proportion to the increased muscle 
glucose uptake (Eriksson & Lindgarde, 1991). The production of glucose in 
the liver consists of glycogenolysis and gluconeogenesis from precursors like 
lactate, pyruvate, glycerol and amino acids. At the beginning of the exercise 
about 75 % of the glucose production comes from glycogenolysis in the liver. 
Later, glycogenolysis will reduce, due to the depletion in glycogen stores, 
and gluconeogenesis will contribute in the glucose production up to 50 % of 
the total. Never the less, this compensation is not enough to balance all 
glucose requirements. For that reason, the blood glucose will reduce after 
90 minutes of exercise (Felig et al., 1982).  
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2. Training state: oxygen uptake is essential for fat metabolism. 
Therefore, the use of fat as a source of energy supply is depending on the 
work rate that provides maximal oxygen uptake (Costill et al., 1979; Rahkila 
et al., 1980).  
1.5 Exercise and insulin sensitivity 
Insulin is a peptide hormone with many important effects on different types 
of cells (Rosen, 1989; Greenspan & Gardner, 2004). It principally has 
anabolic effects on hepatocytes, myocytes and adipocytes (Greenspan & 
Gardner, 2004). Insulin stimulates cell growth and differentiation and 
promotes the storage of substrates in fat, liver and muscle by stimulating 
lipogenesis and lipid storage, and glycogen and protein breakdown (Saltiel & 
Kahn, 2001). Thus, hyperglycaemia and hyperlipidaemia occur as a result of 
insulin resistance. Where as a lack of insulin gives rise to protein wasting, 
ketoacidosis and if not corrected eventually, death. Insulin is essential to all 
intermediary metabolic processes and its most important action is to 
promote glucose homoeostasis (Greenspan & Gardner, 2004; Saltiel & Kahn, 
2001).  
Insulin resistance is usually defined as a decrease of insulin-mediated 
glucose clearance in the tissues sensitive to insulin and an increase 
production of glucose in the liver. Peripheral insulin resistance, or decreased 
insulin sensitivity, is a low ability to use glucose in target tissues, most 
importantly skeletal muscle. In adipose tissue the most important 
characteristic of insulin resistance is an increase in lipid storage (Fritsche et 
al., 2008).  
Insulin resistance is the most important feature of the metabolic syndrome, 
T2D and CVD (Bloomgarden, 2007). On the other hand, insulin resistance is 
not always pathological, but it might be found in some normal conditions 
like pregnancy and puberty (Wallace & Matthews, 2002). 
Exercise plays a very vital role in the protection against diseases such as T2D 
and atherosclerosis (Blair et al., 2001). Evidence has been provided by many 
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epidemiological studies about the inverse relation between the physical 
activity and the incidence of the T2D (Eriksson & Lindgarde, 1991; Manson et 
al., 1991) 
1.6 Microdialysis 
Microdialysis is a relatively new sampling technique used initially for the 
collection of neurotransmitters in vivo (Church & Justice, 1987; Ramaiya et 
al., 1997; Zetterstrom et al., 1984; Ungerstedt & Hallstrom, 1987). It is a 
well known technique for the collection of water soluble molecules with a 
low molecular weight (Ao & Stenken, 2006). As a result of its success in the 
collection of the small molecules, it has been interesting to extend its use to 
more tissues and bigger molecular weight molecules. Particularly it has been 
shown that the concentration of adipokines in the plasma might not reflect 
their concentrations at the site of their secretion (Dostalova et al., 2009; 
Mohamed-Ali et al., 1997)  
The site for secretion of adipokines is adipose tissue. Therefore the study of 
these hormones at the site of their production has a special interest. 
Microdialysis technique has been used to study secretion by human adipose 
tissue. It was developed originally to study brain function (Ungerstedt & 
Pycock, 1974). Recently, microdialysis techniques have been extended to 
become an important in the measurement of substances in the extracellular 
fluid of many tissues such as subcutaneous adipose tissue, liver and muscles 
(Romijn et al., 1993). In particular, it has been used for measurement of 
adipokines (Ungerstedt 1991). 
1.6.1 Principle of microdialysis 
The principle of microdialysis is based on the movement of substances by 
diffusion down their concentration gradients, through a dialysis membrane 
which separates two different compartments; the interstitial fluid and the 
fluid perfusing the catheter (Chaurasia, 1999). The perfusion fluid is 
transported to the outlet tube and recovered so that it can be analysed 
figure 1-4. 
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Figure  1-4  
Figure shows the principle of the microdialysis (Luppa et al., 2011) 
 
The molecular weight cut off of the microdialysis membranes range between 
5 and 100 KD. Therefore the small molecules can pass easily, while the large 
molecules are rejected or diffuse very slowly through these pores (Ao & 
Stenken, 2006). To collect samples from particular tissues by using 
microdialysis, the catheter is inserted into the tissue and a perfusion fluid 
enters at specific flow rate (0.2 – 5 µl/min). At typical perfusion rates, non 
equilibrium conditions develope between the substance in the dialysate and 
its concentration in the extra cellular fluid. The ratio between the fractions 
recovered to the real concentration is known as relative recovery 
(Chaurasia, 1999). In contrast, the absolute recovery is the amount of the 
substance collected from the catheter in specific time. At low perfusion 
rates less substance is removed and that increases the reliability of the 
physiological experiment (Wages et al., 1986). 
The recovery of adipokines is dependent on many factors including: the 
properties of the substances, the microdialysis membrane, the perfusate, 
the tissue (Clausen et al., 2009), perfusion rate and the length of 
microdialysis tube (Plock & Kloft, 2005). The utilization of a short catheter 
with fast perfusion rate decreases the diffusion of substances into the 
dialysate (Clausen et al., 2009).  
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The microdialysis system contains a pump, catheters or probes and micro-
vials. The pump is designed to pump the perfusion fluid at adjustable flow 
rates ranging from 0.1 to 5 µl/min. It is a battery driven pump which works 
automatically over periods up to 16 hours. It is easy to handle and portable 
due to its lightweight. The catheters contain thin dialysis tubes of different 
lengths, shapes and materials according to the tissue being studied. The 
semi-permeable membranes typically form the last 30mm at the tip of the 
concentric catheters or a similar length in the middle portion linear 
catheters figure 2-4. The perfusion fluid is returned to micro-vials for 
collection (Tegeder et al., 1999). Each micro vial contains a volume of 200 
µl and it takes about 3 hours to be filled at a flow rate of 1 µl/min appendix 
6. 
1.6.2 Relative recovery (RR) 
Relative recovery (RR) means the ratio between the concentrations of the 
substance in the dialysate to the concentration in periprobe fluid. The 
relative recovery is depending on many factors (Plock & Kloft, 2005 ): 
1- Diffusion coefficient: 
The RR can differ according to the diffusion coefficient (D) of different 
molecules. The diffusion process of the molecule is directly related to the 
temperature and inversely to the on the size of the molecule. Consequently 
it is preferable for the microdialysis experiment to be carried out at a 
constant body temperature (Kendrick, 1989; Young & Bradford, 1986). 
2- Weight cut-off and membrane area: 
The substances can pass through the membrane if their molar mass is lower 
than the cut-off of the membrane (Plock & Kloft, 2005). In addition, the RR  
is also affected by the length and the area of the membrane, it increases 
with increase in the length of the membrane (Tossman & Ungerstedt, 1986). 
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3- Concentration gradient and the composition of perfusate: 
The concentration gradient is an essential factor for the diffusion. The 
concentration changes during the diffusion process so the composition of the 
perfusate is an important factor in RR (Plock & Kloft, 2005). Osmotic agents 
are used to improve the RR for macromolecules and to prevent fluid loss in 
the case of high molecular weight cut-off of up to 100 KDa (Trickler & Miller, 
2003). 
4- Flow rate: 
The flow rate is another important factor affecting the RR. There is an 
inverse relationship; the best RR recovery can be achieved with a low flow 
rate. However, this has a negative impact on the volume of the sample and 
later on the analysis of these samples. It will consequently take a longer 
time to obtain enough samples (Chaurasia, 1999). 
5- Matrix tortuosity 
The nature of the sample matrix is another factor affecting the RR (Bungay 
et al., 1990; Stahle et al., 1991). For the substance to diffuse across the 
dialysis membrane, it must first diffuse across the surrounding tissue. This 
tissues contains barriers that could interfere with free diffusion and 
therefore affect the RR (Chaurasia, 1999) 
1.6.3 Performance 
Microdialysis can be used to collect samples of the interstitial fluid or deliver 
samples into this fluid (Plock & Kloft, 2005). Primarily the microdialysis 
catheters were manufactured to collect small molecules such as 
neurotransmitters, glucose, glycerol, and lactate (Ungerstedt & Hallstrom, 
1987). The molecular weights for glucose, glycerol and lactate lie between 90 
to 180 Da. These small hydrophilic substances diffuse freely.  
Recently, the recovery of large molecules became possible by microdialysis 
with the introduction of polycarbonate dialysis membranes (Plock & Kloft, 
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2005). The cut off of these membranes is about 300 KD reflecting a 
maximum pore size of about 0.3 µm. This type of microdialysis catheter has 
been used in human and animal experiments to recover adipokines (Winter 
et al., 2002), serum proteins, neuropeptides, cytokines and growth factors 
(Clough, 2005 ). In addition, microdialysis catheters made from another 
plastic, polyethersulphone have become commercially available. These have 
molecular cut offs between 6 to 100 KD. These catheters are well tolerated 
by tissues and can be used to collect samples from subcutaneous adipose 
tissue for four days (Clausen et al., 2009). 
It is clearly attractive to measure adipokine concentrations in adipose 
tissues over several days. This could allow direct comparison of 
concentrations at the same site in response to changes of activity or diet. It 
is also possible that the performance of catheters may change, either to 
improve as local trauma after insertion passes off or to reduce if the 
permeability characteristics are compromised. This longer term performance 
of the catheters was assessed over 4 days by Clausen et al (Clausen et al., 
2009). Changes day by day in concentrations of the adipokines were 
observed. Adiponectin concentrations were higher on first day after catheter 
insertion and then reduced by about 33%. In contrast, the concentrations of 
other adipokines like: IL-1B, IL-8 and TNF- α increased. This could be due to 
the difference in the roles of these adipokines in local inflammation 
responses (Clausen et al., 2009). In practice, 1-2 hours was recommended 
for tissue equilibration to minimise the effect of inflammatory responses on 
study results (Clausen et al., 2009; Hojbjerre et al., 2007). Rapid changes in 
the concentration of cytokines and adipokines can occur immediately after 
the implantation of the microdialysis probe. These changes slow after a few 
hours. 
1.6.4 Advantages and disadvantages of microdialysis 
As a method of sampling of adipokines, microdialysis has many advantages. 
One of the most important features is the possibility of collecting substances 
at their site of secretion or action (Clausen et al., 2009; Plock & Kloft, 
2005). Furthermore, by using microdialysis catheters with an appropriate cut 
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off, samples can be obtained that do not require time consuming 
preparation. The samples are ready for a direct measurement (Waga, 2000). 
The catheters can stay in place for many days and this allows continuous 
monitoring and collection of sufficient quantities of samples (Buerger et al., 
2003). Serial samples can be taken from one subject which aids 
experimental design and ultimately means that smaller numbers of subjects 
need to be recruited (Horal et al., 1995).  
Nevertheless, there are some negative features associated with 
microdialysis. There may be tissue trauma at the time of implantation of 
microdialysis catheter and this could affect local lymphatic filtration for up 
to six hours (Hildingsson et al., 1996). Even though the insertion technique is 
modestly invasive, acute tissue responses to the insertion are obvious as 
local reddening in skin (Ault et al., 1994) . Bacterial infection could result 
from inadequate sterilisation (Stenken et al., 2010). This will be particularly 
serious when catheters are inserted into the CNS. However, the use of this 
technique continues to expand and that suggests that inflammatory 
problems must be relatively minor. Lastly, the cost of the commercial 
microdialysis catheters is significant. Each microdialysis catheter currently 
costs about 100 pounds excluding accessories such as syringes, micro vials 
and the perfusion fluids. This might matter less in a clinical project but cost 
is a significant factor in laboratory studies. Catheters with particular 
permeability characteristics have been made by individual experimenters 
(Clausen et al., 2009; Hojbjerre et al., 2007; Nielsen et al., 2009). This is 
beyond the technical competence of almost all researchers and then adds 
the need for careful sterilisation after manufacture.  
1.7 Technique for measurements 
1.7.1 ELISA technique 
The ability to measure the concentrations of cytokines and other 
inflammatory mediators with high specificity and sensitivity is very 
important in this project. Enzyme linked immuno-sorbant assays (ELISA) are 
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the most common technique used in clinical laboratories and they are the 
best validated method (Leng et al., 2008) 
ELISA techniques have been used in research since 1970s to replace older 
radioactive isotope labelling techniques which had high risks of 
contamination (Butler et al., 1978). The ELISA technique relies on 
comparative antibody/antigen interactions, where the target protein 
concentration is subsequently determined from a standard curve prepared 
from a sequence of standards offered with the kit. Two different ELISA 
techniques are available: sandwich and competitive. The most popular one 
is sandwich technique. The principle of this method depends on two 
monoclonal antibodies. One is fixed on the wall of the micro titration well in 
the first step. The second one is in the conjugate solution labelled with a 
peroxidase enzyme. It is delivered in the second step. A washing step 
removes remaining unbound labelled antibodies.  
In this case, the complex formed between labelled antibody and the 
adiponectin is fixed in the wall and reacted with 3,3 ,5,5 –
tetramethylbenzidine (TMB). The density of the colour generated is directly 
related to the concentration of the antigen or adiponectin in the sample. At 
the end of the incubation 0.5 M sulphuric acid (H2SO4) is added to stop the 
reaction and give the colour of the end point to be read by the 
spectrophotometer figure (1-5). 
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Figure  1-5  
ELISA sandwich technique (Leng et al., 2008) 
 
1.8 Conclusion and Aims 
It is clear from the literature review above that obesity is a major problem 
everywhere in the world. It is strongly linked to many serious chronic 
diseases such as T2D, CVD and insulin resistance. Curiously, whilst women 
form the majority of most populations there have been fewer studies of 
these diseases in women than in men even though the prevalence of obesity 
is higher among females.  
Adipose tissues are very vital endocrine tissues. They synthesise many 
substances such as adipokines and cytokines that play a considerable role in 
determining insulin sensitivity. It is well known that exercise increases 
insulin sensitivity. However; it is not clear if this effect of exercise on insulin 
sensitivity is related to the effect of the exercise on adipokines, particularly 
adiponectin. Further; most of the studies on the effect of exercise on 
adipokines were in males. Detection of these adipokines at their site of 
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secretion has special interest. Microdialysis is a relatively new technique for 
collecting interstitial fluids which contain substances such as adipokines.  
The hypothesis to be tested in this project is that exercise increases 
adiponectin concentrations. Therefore; the overarching theme of the studies 
in this thesis was to investigate the effect of acute exercise on adiponectin 
concentrations in dialysate and plasma samples in healthy young women. 
This thesis reports three studies. The aims of the first study were:  
• to evaluate the feasibility of using microdialysis catheters  
• to investigate any differences in adiponectin concentrations in lean and 
overweight females.  
• to study the effect of a single bout of exercise on adiponectin 
concentrations.  
The second study aimed to compare the adiponectin concentration in plasma 
samples and dialysate samples collected by 100 KD microdialysis catheters.  
The third study aimed to investigate the effect of acute exercise on total 
adiponectin concentrations and HMW adiponectin concentration in plasma 
samples.  
Chapter 2   
M. Alzwayi  57  
Chapter 2 
2 General Methods 
All experiments and analysis of samples described in this thesis took place in 
the West Medical Building, School of Life Science, University of Glasgow, 
between October 2010 to October 2012.  
2.1 Ethical review process and approval 
All experiments were reviewed and approved by the College Ethics 
Committee for Non-Clinical Research Projects. It took a long time to gain 
approval. The initial application was made on 27/1/2010 and the first 
response from the committee was on 23/2/2010, but the final approval was 
not given until 17/5/2010. The application forms are shown in Appendix 1. 
No significant changes were made by the committee. This delayed the start 
of the experimental work by about four months. 
Each volunteer was given an information sheet and the chance to discuss 
their participation before they agreed to take part. They were asked to sign 
two copies of a consent form. One was kept by the volunteer and the other 
kept by the researcher. The information sheets and the consent form are 
shown in Appendix 2 and Appendix 3. 
All volunteers were informed that they could stop the experiment at any 
time.  
2.2 Subjects 
Only young healthy women were recruited for the experiments described in 
chapters 3 and 5. Participants were recruited from students of University of 
Glasgow. They were recruited by email contact, or via their class moodle 
site, or posters displayed around the main campus. Lastly, personal contacts 
were made directly to friends and fellow students.  
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Information sheets were given to each subject. These included details of the 
experiment protocol and any related discomfort or risk. The information 
sheets are shown in Appendix 2. In addition, face to face explanations of 
technical matters were given. Volunteers were invited to ask questions and 
told they were free to stop at any point.  
Twenty five female volunteers were identified and recruited, but only 15 
volunteers completed the first study as described in chapter 3. Their mean 
age was 22.8 ± 3.0. Their range of ages was between 20 – 30 years. Their 
anthropometric data is shown in table 3-1 on page 78 of chapter 3. The 
volunteers were assigned to two groups (lean and overweight) on the basis 
of their BMI.  
The second study recruited six healthy male volunteers. Their mean age was 
32.8± 13.1 years (mean ± SD). Their range of ages was between 22 – 58 
years.  
Lastly for the third study, thirteen female volunteers were recruited for the 
experiments described in chapter 5. None of these volunteers took part in 
the experiments described in Chapter 3. Their mean age was 24.3 ± 2.7 
years. Their range of ages was between 21-30 years. 
2.3 Inclusion and exclusion criteria 
The inclusion criteria for participation in the first and third experiment 
were: 
 Healthy young women between 20 to 30 years old,                         
 No current prescription medication,                                              
 Body mass index between 19 and 29.9 kg/m2. 
The exclusion criteria were: 
 Illness,                                                                                            
 Pregnancy,                                                                                     
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 First relative diabetic,                                                                    
 Obesity (defined as BMI ≥ 30 kg/m2,                                     
 Participation in vigorous regular exercise.                                        
The inclusion criteria for male volunteers in the second study were: healthy 
and non obese.   
For the last study in this thesis, the volunteers were healthy females, aged 
between 18 to 30 years. They had a sedentary life style and they had no 
regular exercise programme. They had normal body weight with a BMI < 25 
kg/m2. The volunteers refrained from exercise during the period of the 
experiment.  
2.4 General plan of the experiment 
Volunteers came to the lab for familiarisation. They were shown the 
equipment and its use was explained. The dates and times for the 
experiments were arranged. 
On the first visit, volunteers signed the consent form and completed the 
questionnaire shown in appendix 3. Volunteers wore sport clothes. Their 
weight and height were taken. Their fitness level was assessed as described 
in section 2.5.6. 
Order of the rest and exercise days were randomly arranged. Coin was used 
for randomisations.  
The volunteers were asked to come to the lab in fasted state at 8 am on the 
days of their tests. They had fasted overnight. The subjects had refrained 
from vigorous physical exercise at least 24 hours before the experiment. 
They were allowed and encouraged to drink water during the tests 
particularly on exercise day.  
The details of the catheter insertion are given in section 2.6.3. At the end of 
recoding on day 1, the pump was disconnected and the sample tube was 
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covered with a sterile dressing to allow the free movement of the subject. 
The volunteers were asked to keep the catheter inserted overnight. No 
infections or redness were recorded. All catheters worked very well next day 
Volunteers in the third study followed a similar protocol, but with out 
catheter insertion. Only blood samples were collected.  
2.5 Base line investigations 
2.5.1 Weight 
Weight for all volunteers was measured using digital balance weighing to 
0.1kg. The zero adjustment was set each day. The volunteers wore 
lightweight clothing and were barefoot. They were weighed with both feet 
flat on the balance and their arms relaxed in a lateral position. 
2.5.2 Height  
Their height was measured using fixed stadiometer. The volunteers were 
barefoot and stood with their back positioned against scale. They stood with 
their neck and head in a normal position and the arms relaxed in lateral 
position.  
2.5.3 Body mass index 
Body mass index (BMI) was calculated as the ratio between weight in 
kilograms and height in metres, squared.  
BMI = Weight (kg)/ Height squared (m2) 
2.5.4 Measurements of the percentage of body fat: 
The percentage of body fat was measured by using a Bodystat 1500 
Bioelectrical Impedance Analyser (Bodystat, Douglas. Isle of Man). The 
device is illustrated in figure 2-1. The volunteer removed their shoes and 
rested on bed for 5 minutes. 
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Four electrode pads were attached to the hands and feet of the volunteers. 
These are shown in figure 2-2. The Bodystat 1500 was switched on and 
details of their gender, age, height, weight and activity level were entered 
using the three keypads. Once the test had been performed a complete body 
composition analysis was displayed on the screen within few seconds. This 
included percentage body fat; lean body mass, total body water, metabolic 
rates, BMI and impedance are also displayed on the screen.  
 
Figure  2-1 Bodystat 1500 
 
    
Figure  2-2  
Body stat 1500 in use. These photographs show the points of attachment of the electrode 
pads to the foot and hand of a volunteer. 
 
2.5.5  Measurement of the abdominal skin fold thickness 
All measurements of abdominal skin fold thickness were performed by the 
same researcher using the same Harpenden skin fold calliper 
(http://www.harpendencalipers.co.uk). The abdominal skin fold was 
measured for the volunteers while they were standing. The site of 
Chapter 2   
M. Alzwayi  62  
measurement was marked four centimetres from the midpoint of the 
umbilicus on the right side. The skin was pulled between thumb and index 
finger of the researcher’s right hand. The fold was held by the calliper in 
perpendicular position for about two seconds. The measurement was done 
three times and the mean was calculated.  
2.5.6 Measurement of maximal oxygen consumption using a 
sub-maximal test ( 2. OV max) 
A sub-maximal 2
.
OV max test was performed by all subjects using standard 
Douglas bag techniques whilst volunteers walked on a treadmill (Woodway 
Ergo ES2, Germany).  
Each volunteer wore a head set to support a mouth piece and valve. The 
expired gas was collected in a Douglas bag for periods of 2 minutes. The 
volunteer’s heart rate was measured with a Polar Heart Rate Monitor.  
The test started by the volunteer standing at rest for 3 minutes. An expired 
gas sample was taken during this period. The treadmill was switched on and 
the speed was increased, starting at 2.7 km/h and rising up to about 8 
km/h. The speed was increased in stages lasting three minutes until subject 
reached 80 to 90% of her maximum heart rate. The precise speed depended 
on the age and heart rate of the subject. During this process five or six 
expired gas samples were taken. The maximum heart rate (MHR) was 
predicted using the equation, MHR = 220-age. 
The oxygen and carbon dioxide fraction in the gas samples were measured 
using a Servomex 1440 gas analyser (Servomex Limited, Crowborough, 
England). This was calibrated each day using gases of known concentration 
(Appendix 4). The volume of the gas inside the Douglas bag was measured 
with a Harvard Dry Gas meter (Harvard Apparatus Ltd, Kent England). The 
gas temperature was measured concurrently with a digital thermometer and 
corrections were made for temperature and barometric pressure. These 
measurements allowed the oxygen consumption to be calculated using the 
equations listed below and more details are shown in appendix 5. 
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SWVP = (1.1001 x t) – 4.19                                                                      
SWVP is saturated water vapour pressure in mm Hg at ambient temperature  
V
.
ESTPD = V
.
EATPS x (BP – SWVP)/760 x 273/ (273 + t) 
BP is barometric pressure in mm Hg 
t is ambient temperature in degrees Celsius 
ATPS is ambient temperature and pressure, saturated with water vapour. 
 
FIN2% = 100 - FIO2% - FICO2% 
FEN2% = 100 - FEO2% - FECO2% 
FIN2% is the percentage of nitrogen in atmospheric air. 
FEN2% is the percentage of nitrogen in expired air. 
FIO2% is the percentage of oxygen in atmospheric air, assumed to be 20.93%.  
FICO2% is the percentage of carbon dioxide in atmospheric air, assumed to 
be 0.03%. 
FEO2% is the measured percentage of oxygen in expired air. 
FECO2% is the measured percentage of carbon dioxide in expired air. 
 
V
.
I = V
.
E x FEN2%/FIN2% 
V
.
I is the inspired air volume per minute 
V
.
E is the measured expired air volume per minute  
 
V
.
O2 = V
.
I x FIO2%/100 - V
.
E x FEO2%/100 
V
.
CO2 = V
.
E x FECO2%/100 - V
.
I x FICO2%/100 
V
.
O2 Oxygen uptake (l/min) 
V
.
CO2 Carbon dioxide production (l/min) 
 
V
.
O2 (ml/kg/min) = V
.
O2 (l/min) / weight (kg) 
V
.
CO2 (ml/kg/min) = V
.
CO2 (l/min) / weight (kg) 
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A graph was plotted of oxygen consumption and heart rate for each 
volunteer. A specimen is shown in figure 2.3. The volunteers predicted 
2
.
OV max was calculated by extrapolation to expected maximum heart rate. 
The walking speed associated with 50 % 2
.
OV max was estimated and that was 
used in future exercise periods. 
 
y = 2.7113x + 79.056
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Figure  2-3  
A graph showing specimen data for one volunteer. It shows the oxygen consumption in 
ml/kg/min and the heart rate in beats /minutes during sub maximal exercise. In this case, six 
samples were taken and a linear trend line was added. This was extrapolated up to predicted 
maximum heart rate (220 – age). It was a good fit to the data, R2 = 0.9896.  
The volunteer exercised up to about 85% of her maximum heart rate. The estimated 
2
.
OV max 
was 42 ml/kg/min and the 50% of 
2
.
OV max was 21 ml/kg/min. Therefore the heart rate on her 
exercise day was around 135 b/min. 
 
For each volunteer the range of walking speeds were 2.5, 4, 5.5, 6.8 & 8 
km/hour, with measurement of heart rate and V
.
O2. The speed for one hour 
walk was chosen by picking the speed which delivered the target heart rate. 
For example this volunteer walks at a speed of about 5.5 km/hr to get a 
heart rate about 135 b/min. 
V
.
O2 (ml/kg/min) 
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2.6 Sampling of the interstitial fluid 
Microdialysis is a technique used to collect samples of interstitial fluid. It 
has been used to study fluid from many tissues such as brain, liver, muscles 
and subcutaneous tissues. All the equipment used was purchased from CMA 
Company (CMA Microdialysis AB, Solna, Sweden).  
2.6.1 Microdialysis catheter 
Linear catheters with a 30 mm length of semi permeable membranes were 
used (CMA 66, Solna, Sweden) appendix 6. The catheter consists of a thin 
dialysis tube (polyurethane, outer diameter (OD) 0.4 mm connected to semi-
permeable membrane (polyarylethersulphone, OD 0.5 mm) at two ends. 
Details of its introduction are given in section 1.6.1. Briefly, this membrane 
inserted into the tissue using introducer needle 21 G, which was removed 
soon after the microdialysis membrane has been inserted into the tissue. 
One end of the catheter was connected to an infusion portable pump CMA 
107, whose rate can be controlled between 0.5–5 µl/min. The dimensions of 
this pump are 90 x 50 x 20 mm, with weight of 70 g including battery. This 
pump is shown in figure 2-6 and Appendix 6-B. In these experiments the flow 
rate was set to 1 µl/min. Thus was a compromise choice set to deliver a 
sufficient volume of fluid for analysis and to allow reasonable equilibration 
with tissue fluids. Fluid returned from the catheter is finally collected in a 
microvial. The component parts of this system are illustrated below in figure 
2-4. 
The CMA 66 catheter has a large pore diameter and allows molecules up to 
100 KD to diffuse.  
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Figure  2-4   
CMA 66 high cut off linear catheter. A- 0.4 mm outer diameter dialysis tube. B-  0.5 mm OD 
semi-permeable membrane. C- 1 mm OD inlet tube. D- Pump connection side. E- 21 G 
introducer needle 50 mm length.  
 
2.6.2 The perfusion fluid T1 
CMA T1 Perfusion Fluid was used. This is a sterile isotonic fluid developed 
for microdialysis in peripheral tissues. It is packed in glass ampoules of 5 ml. 
Each ampoule lasted for a single experiment. The T1 fluid contains 147 
mmol/l Na+, 4 mmol/l K+, 2.3 mol/l Ca2+ & 156 mmol/l Cl- .  
The relatively large pore size of the CMA 66 membrane has a problem in that 
it allows a net loss of perfusate into the interstitial space. The T1 solution 
balances the crystalloid composition of interstitial fluid but does not balance 
the colloid osmotic forces. Consequently, Dextran 60 was added at 30 g/l to 
the perfusate fluid in all experiments (Dextran 60 EP, Pharmacosmos, 
Denmark). This follows the advice of the catheter manufacturer and Rosdahl 
et al. (Rosdahl et al., 2000). With this balance achieved, it was always 
possible to recover fluid from the catheters. In this experiment the volume 
of the recovered fluid was approximately equal to that expected on the 
basis of the pumping rate and the time of collection.  
The experiments lasted up to 6 hours. The subjects were encouraged to 
drink at least 100 ml/hour water to maintain normal hydration. 
 E 
 A 
 B 
 D 
 C 
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2.6.3 CMA microdialysis catheter insertion  
The site of the insertion was marked 4 cm lateral to the umbilicus on the 
left side. The area of skin around the insertion was cleaned using Alcotip 
Swabs containing 70% Isopropyl Alcohol. In addition, a local anaesthetic 
EMLA cream was applied 5 to 10 minutes before insertion, each gram of the 
cream containing 25 mg of lidocaine and 25 mg of prilocaine (EMLA 5%, 
AstraZeneca UK Ltd., 600 Capability Green, Luton, UK).  
The insertion of the catheter was carried out using an introducer needle. 
This needle was removed once the membrane was fixed inside the 
abdominal fat pad. The first insertions used a 21 G needle. This caused 
problems with damage to the delicate microdialysis membranes. A damaged 
membrane is shown in figure 2-5. A larger diameter 18 G needle was used 
for all subsequent experiments. The change was made at the manufacturer’s 
suggestion after rupture of many catheters. The link below shows details of 
similar insertion procedure (http://www.youtube.com/watch?v=U7ZDhx7tS2A)  
 
Figure  2-5   
Example of broken microdialysis catheter membrane. A- Intact lengths of semi- permeable 
membrane. B- Exposed inner tube at the site of membrane tear.  
 
 A 
B 
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Figure  2-6  
Microdialysis catheter insertion. Redness at the site of the insertion disappeared after few 
minutes. 
 
The insertion sites for the inlet and outlet tubes were covered using 
Tegaderm film (3M, Health Care, USA). The CMA 107 pump was connected to 
one side of the catheter with special syringe containing the perfusion fluid. 
Lastly, the micro vial was connected at the exit end for dialysate collection 
every 30 to 60 minutes figure 2-6 & 2-7.  
 
Figure  2-7  
This figure shows the microdialysis equipment in use.  At the top of the picture, the CMA 107 
pump lies on the volunteer’s abdomen. In use it is stored in the volunteer’s pocket. The pump 
is connected to the microdialysis catheter by a polycarbonate luerlock-connector and a fine 
polyurethane inlet tube. The tubing is inserted through the skin using aseptic technique, and 
the site of insertion is covered with a sterile Tegaderm dressing. The dialysate leaving the 
catheter is collected in a micro vial seen in the lower part of the picture. 
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All volunteers finished the experiment. Nobody stopped their participation 
during the catheter insertion procedure. The insertion and removal of the 
catheters were done under antiseptic conditions. No catheters were 
removed during experiment because of infection, soreness or discomfort. 
Removal of catheters was always clean and no parts were retained. After 
catheter removal, the sites of inlet and outlet punctures were cleaned, 
checked and covered with a plaster.  
2.7 Blood samples  
Venous blood samples were collected from a cannula inserted into a vein in 
the forearm. 20 G VenflonTM Pro Safety cannulae were used. The needle was 
removed and replaced by three way valve connecter with a 10 cm 
connecting tube (BD ConnectaTM, Sweden). This connection was kept fixed in 
place via IV peripheral line dressing with transparent membrane (EASI-V, 
Unomedical, UK). The blood samples were collected in 2 ml tubes containing 
potassium ethylene di-amine tetra acetic acid (K3EDTA) (BD Vacutainer 
systems, Plymouth, UK) for subsequent measurement of adiponectin, insulin, 
HMW adiponectin, IL-6 and TNF-α. An additional 2 ml of blood was collected 
in fluoride oxalate tubes (BD Vacutainer systems, Plymouth, UK) for glucose 
measurements. These anticoagulants were chosen according to the 
recommendation of the kits. After each collection the cannula was flushed 
by non-heparinised saline solution (0.9% NaCl, BD PosiFlushTM SP Syringe) to 
prevent blood clotting and to maintain patency. When single blood samples 
were required, a butter-fly needle (BD Vacutainer® Safty-lokTM, 21G, 0.8 x 
19 mm x 178 mm) was used to take blood from an antecubital or forearm 
vein.  
Blood samples destined for adiponectin, insulin and glucose measurement 
were immediately centrifuged at 1400 g at 4oC for 10 minutes (Universal 
320R centrifuge, Germany). Those samples intended for HMWA, IL-6 and 
TNF-α analysis were centrifuged at 1000 g at 4 oC for 15 minutes (Sorvall, 
legend RT plus centrifuge, Germany). Plasma was then pipetted into 
Eppendorf tubes. Each sample was separated into two 0.5 ml Eppendorf 
tubes and stored at −80 oC up until subsequent analysis. The storage time 
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was a maximum one month, except for plasma glucose samples which were 
stored for about six months due to a technical problem. 
2.8 Sample analysis 
2.8.1 Principle for ELISA technique  
All ELISA procedures depend on a sandwich technique, in which two 
antigenic determinants are directed against two monoclonal antibodies. One 
was fixed on the wall of the micro titration well in the first step and the 
other is found in the conjugate solution labelled with a peroxidase enzyme 
in a second step. The washing process removes remaining unbound labelled 
antibodies. The complex formed between labelled antibody and the 
adiponectin fixed in the wall reacts with 3,3,5,5 –tetramethylbenzidine 
(TMB). The density of the colour directly relates to the concentration of the 
antigen or adiponectin in the sample. At the end of the incubation 0.5 M 
sulphuric acid (H2SO4) was added to stop the reaction and give the colour of 
the end point to be read by a spectrophotometer.  
2.8.2 Measurement of adiponectin concentrations 
The adiponectin concentration in dialysate samples and blood samples was 
measured using Mercodia Adiponectin ELISA kits (Mercodia AB, 
Sylveniusgatan, Uppsala, Sweden, 10-1193-01). 
2.8.2.1 Preparation of the solutions and dilution of the samples: 
The dialysate samples were taken from the freezer and left to thaw at room 
temperature. This took 20-30 minutes. In addition, the reagent kits were 
kept at room temperature. All the solutions were prepared as described in 
the instructions supplied with the kit. Details are given in appendix 7. 
Mercodia kits were used to measure the adiponectin concentrations in 
plasma. The concentrations were typically 3-30 µg/ml. Details are given in 
section 1.3.5. The adiponectin concentrations in interstitial fluid were much 
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lower than that in plasma. The dilution factors were reduced to 1:11 to keep 
the adiponectin within the working range of the kits.  
The instructions of the kit provide dilution factor of 101 (1:101) for plasma 
samples. It was expected that the concentration in dialysate would be less 
than in plasma. Therefore, this factor was reduced to 1:11 (20 µl of the 
sample with 200 µl of the sample buffer), for the first two sets of samples. 
In subsequent experiments the dilution factor was reduced again to 1:3 (20 
µl samples + 40 µl of sample buffer) for the rest of the samples, and 1:2 (30 
µl sample + 30 µl sample buffer) for the second study. 
However; the dilution factor for the control and the plasma samples in the 
second and third studies was kept as mentioned in the instructions of the 
kit. All samples from one individual were constantly run in the same set. 
2.8.2.2 Test procedure and concentrations 
The procedure followed was exactly as specified in the instructions in each 
kit Appendix 7. Control samples from the manufactures were tested with 
each run (Mercodia Obesity Control A and C Human, Sweden). All standards, 
controls and samples were run in duplicate. After the dilution of the samples 
and the controls; the plate was labelled to identify the location of every 
sample.  
25 µl of each sample were added into an appropriate well using a variable 
micropipette (Fimpipette, Thermo Lab System). 100 µl of assay buffer were 
added to all wells. This plate was incubated for 1 hour on a plate shaker 
(VELP Sientifica Vortex mixer) at 500 rpm. Thereafter, the plate was washed 
with a solution provided with the kit six times automatically using a Dynex 
MRW plate washer. Then, 100 µl of prepared conjugate solution was added 
to all wells and incubated again on the shaker for another one hour. Next, 
the washing step was repeated. Later 200 µl of substrate TMB was added to 
each cell on the plate and incubated at room temperature for fifteen 
minutes. Finally, 50 µl of stop solution was added. The endpoint was read at 
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450 nm by a Spectra Max M2 spectrophotometer (Spectra Max M2, 
California,USA). 
Softmax Pro 5.4 software was used to calculate the standard curve to 
measure the concentration for adiponectin hormone. A specimen curve is 
shown in figures 2-8.  
The results of control samples showed the reliability and consistency of the 
assays. The inter assay coefficients of variation for obesity controls was 
1.7%, while the intra assay coefficient of variation was 2.6%. 
 
Figure  2-8  
This figure shows an example of a standard logarithmic curve used for measurement of 
adiponectin concentration in the samples. It is obtained from the Spectra Max M2 
spectrophotometer and Softmax Pro 5.4 software. Linearity R2 0.999.   
 
2.8.3 Measurements of insulin concentration 
Similar ELISA techniques and Mercodia Insulin ELISA kits (Mercodia reference 
10-1113-01) were used to measure the concentration of insulin in plasma 
samples. Again low and high control samples were tested with each run 
(Mercodia Diabetes Antigen Control (low & high) Human, 10-1164-01, 
Sweden) 
 Adiponectin conc (ng/ml)
1 10 100 1000
0.01
0.1
1
10
StandardCurve
Log-Log Fit: Log(y) = A + B * Log(x): A B R^2
Std (Standards: Conc vs MeanValue) -1.9 0.949 0.999
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2.8.3.1 Test procedure and concentrations 
The procedure was similar to that described above in section 2.8.2.2. The 
inter and intra assay coefficients of variation for diabetes control was 2.7% 
and 4.6% respectively.  
2.8.4 Measurement of HMW adiponectin, IL-6 and TNF-α 
These hormones were measured using similar ELISA techniques. The analysis 
kits were bought from R & D Systems (QC01-1, R&D Systems Europe Ltd. 
Abingdon Science Park, UK). The procedures for the measurement of these 
three hormones were done according to the manufacturer’s instructions. 
Control samples were tested with each run. Details are given in appendix 8. 
2.8.4.1 Concentrations 
The concentrations of HMWA, IL-6 and TNF-α were measured using the 
Spectra Max M2 spectrophotometer and Softmax Pro 5.4 software. The inter 
assay coefficients of variation for HMWA, IL-6 and TNF-α were 3.5%, 4.7% 
and 2.5% respectively. The intra assay coefficients of variation were 3.9%, 
2.4% and 3.7% respectively. 
2.9 Glucose measurement 
The concentrations of glucose in the samples were measured using 
commercially available glucose oxidase reagents supplied by BQ Kits (Valley 
Centre Dr., San Diego, CA.) appendix 9. 
2.9.1 Principle 
β-D- Glucose + H2O + O2   H2O2 + D-Gluconic Acid 
H2O2 + 4-Aminoantipyrine + p-HBS                  Immunoquinone + H2O 
Immunoquinone is a red dye, whose concentration is directly proportional to 
the concentration of the glucose in the sample. The colour intensity was 
Glucose Oxidase 
Peroxidase 
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measured by a Spectra Max M2 spectrophotometer using Softmax Pro 5.4 
software. 
2.9.2 Procedure 
The instructions supplied with the kit were followed as described in 
appendix 9. Control samples were tested with each run (Horiba ABX, 
Montpellier Cedex, France). The inter assay coefficient of variation for the 
controls was 4.8%, while the intra assay coefficient of variation was 3.7%. 
2.9.3 Concentrations 
The concentrations of all samples were measured manually according the 
equation:  
 
To convert the results into SI units (mmol/l), the results were multiplied by 
ten and divided by 180. 
 
2.10  Statistical analysis 
Statistical software (Minitab 16) was used for data analysis. Descriptive 
statistics for all variables were expressed as mean ± SD of the mean. All 
variables were tested for normality using Ryan- Joiner test.  
ANOVAs with a two way repeated measures were applied for normally 
distributed data. Non parametric statistics were applied for not normally 
distributed data. Statistical significance was accepted at the 5% level (P < 
0.05). 
Standard absorbance  
X 
Sample absorbance  
Concentration of Standard (mg/dl) 
mg/dl X 
10 
180 
= mmol/l 
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Chapter 3 
3 Adiponectin concentrations in dialysate 
samples 
3.1 Introduction 
In recent years, more attention has been given to adipose tissue as an 
endocrine organ, rather than only as a storage site for fat (Kershaw & Flier, 
2004; Scherer, 2006). Subcutaneous adipose tissues produce many 
substances that play a vital role as paracrine/endocrine regulators for many 
metabolic, inflammatory and immune processes. These substances include 
adiponectin, leptin and resistin and cytokines such as IL-6 (Kershaw & Flier, 
2004).  
Low plasma adiponectin concentrations are associated with obesity in 
humans, diabetes (Weyer et al., 2001) insulin resistance (Hotta et al., 2000) 
and cardiovascular diseases (Sattar et al., 2006). Goodpaster et al. 
demonstrated that a 15.1±1.2 kg of weight loss in an exercise program for 
about 4 months in human subjects improved insulin sensitivity and 
prevented insulin resistance (Goodpaster et al., 1999).  
The effect of exercise on adiponectin concentration in plasma has been 
studied by many researchers. Conflicting results have been reported in the 
last 10 years. Some of these differences can be attributed to different 
exercise protocols. Some studies found no effect of acute moderate 
intensity exercise on plasma adiponectin concentration (Hojbjerre et al., 
2007; Numao et al., 2008; Numao et al., 2011). Others report that even 
chronic aerobic exercise has no effect on adiponectin concentrations 
(Boudou et al., 2003; Hara et al., 2005; Hulver et al., 2002; Marcell et al., 
2005; Nassis et al., 2005; Yatagai et al., 2003; Punyadeera et al., 2005; 
Ferguson et al., 2004). On the other hand, a significant increase in 
adiponectin concentration has been found under the effect of chronic 
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exercise in some other studies (Bluher et al., 2006; Kriketos et al., 2004; 
Ring-Dimitriou et al., 2006)  
Almost all those studies were on plasma adiponectin concentrations. Only 
one study was on the effect of the exercise on interstitial adiponectin 
concentrations in lean and over weight men. They use BMI to decide who 
was overweight. The samples were collected by 950 KD microdialysis 
catheters. A Significant increase in adiponectin concentrations was found 
after one hour of exercise at 55% of maximum oxygen uptake (Hojbjerre et 
al., 2007). Although obesity is a big problem for both sexes in almost all 
cultures (Flegal et al., 2010; Katzmarzyk, 2002; Stamatakis et al., 2010) it is 
surprising that most of these studies used male volunteers.  
BMI is not tightly linked to fitness. Problems are known with persons who 
have unusual characteristics, for example those who are very short in 
stature or who are very muscular. There are other problems in dealing with 
women during pregnancy. None of the persons studied in this chapter are of 
short stature, well muscular or pregnant. Consequently, BMI was chosen 
following the practice of Hojbjerre 2007. 
The original site for secretion of adiponectin is adipose tissue. However, the 
concentration of adiponectin in adipocytes is lower than the concentration in 
plasma. It is about 20% lower than the adiponectin concentration in plasma 
(Hojbjerre et al., 2007). This might be because the dominant form in 
adipocytes is the trimers and LMW (Bodles et al., 2006) and these probably 
have a relatively short half-life (Pajvani et al., 2003b). In contrast the major 
forms found in plasma are the hexamers and HMW (Nakano et al., 1996) and 
these probably have a longer half-life. The study of these hormones at the 
site of their production is of special interest. Concentrations in blood may not 
reflect local concentrations near the site of production. This could be due to 
dilution by plasma or the action of enzymes or binding to proteins. The 
concentration of the substance in plasma samples might change over time 
due to enzyme action or binding. In contrast, micro-dialysate samples do not 
contain enzymes or plasma proteins since these are too large to pass the 
membrane. Thus they are ‘cleaner’ samples which do not need any special 
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preservatives or processing. The microdialysis technique is a sampling method 
developed about 25 years ago by Ungerstedt. It collects fluids directly from 
the extracellular spaces and it has been used to study a range of tissues 
including adipose tissue. It has a variety of advantages and disadvantages. 
These were reviewed in chapter 1 section 1.6.4.  
In a recent paper Clough demonstrated that the use of microdialysis for 
monitoring of large molecules has been very limited to date mainly due to 
some methodological challenges (Clough, 2005). In this project this issue 
revolves round the collection of large molecules through a semi-permeable 
membrane. Even with these technical problems, the microdialysis technique 
has been applied to monitor adipokines and cytokines in the extracellular 
fluid of subcutaneous tissue.  
The principle of microdialysis is based on the movement of the substance 
according to their concentration across the semi-permeable membrane, 
which separate two different compartments, and this known as passive 
diffusion. The microdialysis catheter is connected on one side to the CMA 
pump; perfusion fluid is pumped into the catheter at 1ul/min, and the other 
end of the catheter is connected to a micro-vial for collection of the 
sample.  
3.2 Aim 
This study aimed to investigate: 
1- The feasibility of using microdialysis techniques in abdominal fat pads in 
lean and overweight young women. 
2- If the concentration of adiponectin in adipose tissue is different over two 
days. 
3- If the concentration of adiponectin in adipose tissue is different in lean 
and overweight women. 
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4- If the concentration of adiponectin in adipose tissue is affected by a 
short bout of exercise. 
3.3 Material and Methods 
Volunteers were screened and enrolled for this study as described in chapter 
2 section 2.2, following the inclusion and exclusion criteria in chapter 2 
section 2.3. 
3.3.1 Subjects 
The initial contact with potential volunteers was made through personal 
contact, posters displayed on campus and messages on the University 
website. The women who responded were all students; except for one 
member of administrative staff; mostly young and mostly of European origin. 
Table 3-1 shows the volunteer characteristics. A- Lean group. B- Overweight 
group. 
25 potential volunteers were identified, and 15 subjects completed the 
whole experiment. The reasons given by the 10 who did not continue were: 
2 completed their studies and moved from Glasgow, 3 stopped after the 
initial anthropometry and fitness tests; 1 had a high resting heart rate, 2 did 
not meet the inclusion criteria. In addition two volunteers started the 
catheter insertion phase of the experiments but their catheters did not 
function correctly. They decided to withdraw from the experiment rather 
than have a second insertion.  
The differentiation of the two groups in this experiment depends on the BMI 
because it is widely used and this also follows Hojbjerre protocol. 
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A- Lean Group 
 
Subjects 
Age 
(Years) 
Weight 
(kg) 
Height 
(m) 
BMI 
(kg/m2) 
Fat 
(%) 
Abdominal 
Skin fold 
(mm) 
2
.
OV max 
(ml/kg/min) 
Lean 1 21 56.0 1.62 21.3 24.1 21.5 22.0 
Lean 2 27 55.1 1.59 21.8 29.8 25.0 36.0 
Lean 3 23 48.9 1.59 19.3 35.7 20.0 32.0 
Lean 4 24 59.0 1.63 22.2 36.3 21.0 29.0 
Lean 5 22 54.7 1.59 21.6 32.9 22.0 38.0 
Lean 6 28 67.1 1.68 23.8 30.6 26.0 38.0 
Lean 7 20 70.4 1.74 23.3 28.6 19.0 55.0 
Lean 8 23 62.0 1.59 24.5 33.2 25.0 35.0 
Mean  
± 
SD 
23.5 
± 
2.8 
59.2 
± 
7.1 
1.63 
± 
0.05 
22.2 
± 
1.6 
31.4 
± 
4.0 
22.4 
± 
2.6 
35.6 
± 
9.5 
 
B- Overweight Group 
 
Subjects 
 
Age 
(Years) 
Weight 
(kg) 
Height 
(m) 
BMI 
(kg/m2) 
Fat 
(%) 
Abdominal 
Skin fold 
(mm) 
2
.
OV max 
(ml/kg/min) 
Overweight 1 22.0 67.8 1.64 25.2 35.0 30.0 32.0 
Overweight 2 21.0 80.2 1.67 28.8 46.1 41.0 33.0 
Overweight 3 22.0 70.6 1.63 26.6 35.0 28.0 35.0 
Overweight 4 20.0 77.0 1.61 29.7 43.0 50.0 29.0 
Overweight 5 20.0 73.5 1.69 25.7 36.5 29.0 40.0 
Overweight 6 29.0 72.2 1.56 29.7 46.4 39.0 24.0 
Overweight 7 20.0 67.7 1.54 28.5 43.9 31.0 30.0 
Mean  
± 
SD 
22.0 
± 
3.2 
72.7 
± 
4.6 
1.62 
± 
0.06 
27.7 
± 
1.9 
40.8 
± 
5.2 
35.4 
± 
8.2 
31.9 
± 
5.0 
Table  3-1  
The general characteristics for all volunteers: A- Lean group. B- Overweight group. The 
highlighted subject in each group was not included in the statistical analysis because of error 
at the time of sample analysis. 
 
3.3.2 The design of the experiment and sample collection 
All volunteers attended the laboratory for three days within a period of two 
weeks. The first day was given over to information sheets, gaining consent, 
anthropometric measurements and fitness assessment. Volunteers returned 
within 1 week for two consecutive days. Subjects arrived at 8 am having 
fasted overnight, i.e. for at least 10 hours. On the first day the microdialysis 
catheter was inserted, see Chapter 2 section 2.6.3 for details. After 90 
minutes for recovery the volunteer rested for the rest of their visit or 
Chapter 3   
M. Alzwayi  80  
followed a rest, exercise, rest protocol, figure 3-1. The sequence of rest or 
exercise was randomised. The volunteer returned the next day to complete 
the other sequence.   
The insertion of the microdialysis catheters could damage the tissues at the 
side of the insertion. To minimise any effect on the results 1.5 hours was 
allowed from the insertion to the start of the fluid collection. An 
equilibration period of 1-2 hours was applied in previous studies (Hojbjerre 
et al., 2007; Simonsen et al., 2008). On the rest day, the subjects rested 
quietly in the laboratory for about 4 hours. On the exercise day the 
volunteers rested for 1 hour, exercised for 1 hour at 50% of their 2
.
OV max and 
rested again for 2 hours.  
 
Figure  3-1  
Schematic diagram to show the sequence of events during the experiment. In this case the 
events follow the protocol for the first day, i.e. with catheter insertion and subsequent 
exercise. In some cases, the volunteers would have rested for the whole session after 
catheter insertion. On their second experimental day, the first activity is to check that the 
catheter is still functioning, this took 5-10 minutes, and there was no delay of 1.5 hours to 
allow for recovery. 
 
3.3.2.1 Sample collection 
Dialysate samples were collected in 250 µl micro vials. The catheter was 
perfused by a microdialysis pump. The flow rate of the pump was kept at 1 
µl/min. This flow rate followed the protocol of previous studies. They found 
Sub maximal 
2
.
OV max 
measurement 
-7 days 
◊ ○ 
0 1.5 
hours 
   30      60       90      120    150    180     210      240 min 
Micro trauma 
release   
Exercise 
◊      Fat percentage measurements. 
○      Abdominal skin folds thickness measurements. 
        CMA microdialysis catheter insertion.  
        107 CMA pump disconnected and CMA catheter removed (on the second day). 
    Dialysate sample collection. 
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the best relative recovery for adiponectin was at 1 µl/min (Dostalova et al., 
2009; Hojbjerre et al., 2007). Thus, in the initial experiments samples were 
taken every 30 minutes, so the volume in each vial was 30 ± 2 µl. This small 
volume was troublesome in dilutions and so in later experiments the time of 
the collection was increased to 45 minutes (giving 45 µl). 
3.3.2.2 Sample storage  
The samples were kept in plastic bags, in a freezer at -80 oC up to the time 
for analysis (New Brunswick Scientific, U725-86). The maximum period of 
storage was one month. This followed the same protocol as previous studies 
(Clausen et al., 2009; Dostalova et al., 2009; Hojbjerre et al., 2007; Nielsen 
et al., 2009). 
3.3.2.3 Sample analysis 
The dialysate samples were analysed for adiponectin concentration using 
Mercodia ELISA kits as mentioned before (chapter 2). Each kit has one plate 
with 96 wells. Samples of two volunteers were tested each run. Each sample 
was processed in duplicate with a series of standards and controls. Storage 
of the samples in the freezer allowed the maximum economy and efficient 
use of reagents in running the tests. Figure 2-8 on page 72 shows a typical 
standard curve for this analysis. The lowest calibration standard supplied by 
Mercodia is 5 ng/ml. The adiponectin concentrations of some samples were 
below this value. These values must be treated with some caution, though 
the extrapolation appears linear down to detection limit of 1 ng/ml. These 
low values, below 5 ng/ml were included in the analysis. 
3.3.2.4 Statistical analysis 
Data for 13 subjects were analysed using statistical software (Minitab 16). 
Descriptive statistics were calculated for all parameters. Data were 
presented as mean ± SD. Normality test was applied for all parameters using 
Ryan Joiner normality tests. Two sample t-tests were used to compare the 
means of the anthropometric data. Nonparametric statistic was applied for 
not normally distributed data. Mann-Whitney tests were used to compare 
the first two samples on the resting day between lean and overweight 
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groups. Kruskal-Wallis test were used to compare changes across the two 
groups and to compare changes across the two trials. 
3.4 Results  
3.4.1 Comparison of two experimental groups  
The anthropometric data for the lean and overweight groups is presented in 
table 3-1. The recruitment to the two groups was not exactly balanced in 
numbers because of the withdrawals described earlier.  
It was difficult to recruit volunteers. After the initial contact was 
established, some withdrew citing reasons such as: dislike of needles, dislike 
of exercise tests, and pressure of time. These problems were greater for the 
overweight group. The introduction of payments to volunteers helped with 
recruitment and retention.  
However, as shown by the data in figure 3-2 there are no significant 
differences in age or height when tested with a two sample t-test (p values 
> 0.05). Figures 3-3 and 3-4 show that there were clear differences in body 
weight, BMI, fat percentage and skin fold thickness (p values <0.05). 
Interestingly the two groups were similar in fitness as shown by the 
measurements predicted maximum oxygen consumption (p value = 0.35) 
figure 3-2 C.  
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Figure  3-2  
These bar charts show the means and standard deviations of the data for -age (A), height (B) 
and 
2
.
OV max (C) for volunteers in the lean and overweight groups. It is easy to see that the 
two groups are well matched for these characteristics. 
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Figure  3-3  
These bar charts show the means and standard deviations of the data for body weight (A) and 
BMI (B) for volunteers in the lean and overweight groups. It is obvious that there are 
differences in both of these characteristics. These are statistically significant (P values < 0.05)  
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Figure  3-4  
These bar charts show the means and standard deviations of the data for fat percentage (A) 
and abdominal skin fold (B) for volunteers in the lean and overweight groups. It is clear that 
there are differences in both of these characteristics. These are statistically significant (P 
values <0.05)  
 
3.4.2 Microdialysis catheter functioning  
Overall, the microdialysis catheters functioned well over the period of the 
study. They were well tolerated by the volunteers and after their insertion, 
they were barely noticed by almost all subjects, although some reddening 
skin was observed near the entry and exit points figure 2-6 of chapter 2. No 
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pain or irritation was reported by any subject. No catheters were removed 
during the experiments because of problems.  
In the initial set of experiments an introducing needle was used as 
recommended by the manufacturer. This caused problems during insertion 
and of the first eight catheters, four were broken during insertion. The 
diameter of the introducing needle was nearly the same as the outside 
diameter of the microdialysis membrane. The insertion process probably 
rubbed the microdialysis membrane and it broke. An example is shown in 
figure 2-5 of chapter 2.  
The manufacturers were consulted and they recommended a change from a 
21G to a larger bore 18G needle. The link below shows an application of the 
insertion method using similar CMA catheters and large bore needle 
http://www.youtube.com/watch?v=U7ZDhx7tS2A. Subsequently, all the insertions 
with the larger introducing needle were successful and no catheter was 
broken at the time of insertion.  
3.4.2.1 Recovery of the fluid 
After insertion, a period of 90 minutes elapsed before samples were taken. 
During this time perfusion fluid passed through the catheter but the fluid 
collected was discarded. The recovery of the fluid was successful in all 
cases. However, the volume of the fluid recovered was very small (30 – 45 
µl). This could cause problems with the subsequent analysis. Reading of 
some samples was below the lower concentration of the standards (5 
ng/ml). These samples were included in statistical analysis, which might 
have a negative effect on the normal distribution of the data.  Additionally; 
several samples had a pale red colour. These samples were very clear but 
the colour was still obvious. These samples were analysed but the readings 
were high compared with the uncoloured samples. The three samples which 
can be identified as statistical outliers are plotted separately in figure 3-5 A. 
Four other samples attracted attention because of their colour but these 
were not identified as statistically different from the uncoloured samples. 
However, these 4 samples were also excluded on the grounds that the colour 
might affect the optical density of the sample in the ELISA analysis. It is 
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clear from the figure 3-5A that adiponectin concentrations in the uncoloured 
samples collected on the first day of the insertion lies in range between 1 
and 100 ng/ml. Figure 3-5B shows the box plots of the data re-plotted with 
the high concentrations from the coloured samples deleted. Figure 3-6 
shows the data for the individuals plotted separately.  It is easy to see that 
the adiponectin concentrations were stable in most cases over the period of 
the collection. In some cases the concentrations fall progressively. In few 
cases the values rise and fall.  
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Figure  3-5  
The figures show box plots to show the means, medians, quartile ranges and ranges of the 
adiponectin concentrations in microdialysate samples taken on the day of insertion of the 
catheter. The upper panel shows all data including the coloured samples described in section 
3.4.2.1. The starred values clearly lie outside the expected ranges. The lower panel shows the 
data re-plotted after removal of the seven coloured samples.  
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Figure  3-6  
The scatter plots show the adiponectin concentrations for each volunteer on their first day of 
the insertion. Adiponectin concentrations are stable over the period of the collection in many 
volunteers e.g. lean 5 and overweight 6. Some show a decline e.g. overweight 1and 3. Some 
show rises and falls e.g. lean 2 and 3.  The data plotted omits the very high values identified 
in 3-5A. Some have missed data either because their value under the detection limit e.g. lean 
1 or have high values due to the coloured samples. 
 
3.4.3 Adiponectin concentrations 
The distribution of adiponectin concentrations was investigated by 
conducting a Ryan Joiner test. The samples after deletion of the coloured 
samples were plotted and are shown below in figure 3-7A. It is clear from 
the plot and the p value <0.01 that these numbers are not normally 
distributed.  
Chapter 3   
M. Alzwayi  90  
A 
150100500-50-100
99.9
99
95
90
80
70
60
50
40
30
20
10
5
1
0.1
Adiponectin concentration.
P
e
rc
e
n
t
Mean 28.62
StDev 34.12
N 85
RJ 0.874
P-Value <0.010
 
Figure  3-7  
Examples of Ryan Joiner plots of the adiponectin concentrations measured on rest day. The 
figure shows that the data were not normally distributed.   
 
3.4.3.1 Difference between day one and day two of the insertion 
One aim of the experiment was to investigate how stable the catheters were 
over several days. The means of adiponectin concentrations, for the first 
pair of samples from all volunteers on day 1 and day 2 were calculated. This 
avoids the effects of exercise later in the collection period. The pairs of 
means are plotted in figure 3-8. The figure shows that most often there is a 
lower mean value on the second day. Two volunteers had a higher value on 
the second day. Interestingly, these volunteers showed low values on the 
first day. A paired t-test showed that the mean concentration was 
significantly higher on day 1. The mean values on first and second days were 
26.0 ± 15.9 ng/ml and 7.6 ± 5.1 ng/ml (mean ±SD) respectively, P value < 
0.05. 
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Figure  3-8  
The interaction plot shows the mean of adiponectin concentrations of the first two samples for 
each volunteer on day 1 and day 2. Data for thirteen volunteers is shown. In two cases, only 
one mean is available. Most of the concentrations were higher on first day than the second 
day. Two samples show lower concentration of adiponectin on first day. 
 
3.4.3.2 Difference in adiponectin concentrations in lean and overweight 
volunteers on their rest day 
The third aim of this experiment was to investigate the difference in 
adiponectin concentration between lean and overweight volunteers. As it 
was mentioned before, rest and exercise days were run in random order for 
all volunteers. So the rest day could be the first day or the second day of 
the insertion.  
The mean of the first two samples on the rest day were examined for both 
groups. Nonparametric Mann-Whitney test showed no significant difference. 
The median values were 13.4 ng/ml and 11.0 ng/ml for lean and overweight 
groups respectively. The mean values were 30.7 ± 15.9 ng/ml and 23.8 ± 
14.9 ng/ml (mean ± SD) for lean and overweight groups respectively, (P 
value > 0.05) figure 3-9. 
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Figure  3-9  
Box plots show the mean of adiponectin concentrations of the first two samples for lean and 
over weight volunteers on their rest day. It is clear from the mean of the first day values; the 
two groups were not different. (*) is outlier concentration. 
 
This analysis was extended to compare the adiponectin concentrations over 
the whole period of the rest day i.e. as the fasting continued for another 6 
hours. Adiponectin concentrations for each volunteer on their rest day are 
illustrated in figures 3-10A. There were no significant differences in the 
mean concentrations in the two groups over the whole fasting period figure 
3-10B. The mean values were 28.7 ± 5.1 ng/ml, for lean volunteers and 28.5 
± 5.4 ng/ml (mean ± SD) for overweight volunteers. The differences were 
tested using nonparametric Kruskal-Wallis test. It showed no significant 
difference between lean and overweight group (P value >0.05). The median 
was 13.5 ng/ml for lean group and 10.6 ng/ml for overweight group.  
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Figure  3-10  
A- Scatter plots show the adiponectin concentrations for each volunteer (lean and overweight) 
over the period of rest. Most of the volunteers show stable adiponectin concentration over 
time. Two lean volunteers show fluctuations in adiponectin concentrations. Three overweight 
volunteers show a progressive drop in adiponectin concentrations. B- A box plot shows the 
adiponectin concentrations for lean and overweight volunteers during the rest day. The mean 
values for the lean volunteers were more stable but overall the mean values for lean and 
overweight volunteers were not significantly different. (P value >0.05) 
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3.4.3.3 The effect of exercise on adiponectin concentrations 
The last aim of this series of experiments was investigating the effect of the 
short bout of exercise at 50% 2
.
OV max on adiponectin concentrations. Both 
groups exercised by walking for one hour on a treadmill. The randomisation 
process ensured that this was done of the first day by some volunteers and 
on the second day by others. The data shown above illustrates clearly that 
the adiponectin concentrations are stable during periods of rest. 
Figure 3-11A shows the adiponectin concentration for each lean volunteer 
during the exercise day. The period of the exercise started after the second 
sample. It is clear that there is no obvious effect of the exercise on the 
adiponectin concentrations. The sampling period for three volunteers lasted 
for longer time because the collection time for each sample was changed 
from 30 to 45 min.  
Figure 3-11B shows the mean adiponectin concentrations in lean volunteers 
at points during their exercise day. Visual inspection shows that the mean 
adiponectin concentrations fall progressively after sample 3, midway 
through the exercise period. However, these changes were not statistically 
significant. A non parametric Kruskal-Wallis test showed no significant 
difference (p value >0.05). 
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Figure  3-11  
A- Scatter plots show the adiponectin concentrations for each volunteer over the period of the 
exercise. Four volunteers showed fluctuation in adiponectin concentration and three volunteers 
were stable over the whole period. B-The figure shows box plots to show the means, medians, 
quartile ranges and ranges of the adiponectin concentrations from lean volunteers on their 
exercise day. The trends show slight increase after the first half hour of exercise and then a 
decrease.  
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Figure 3 -12A shows the data for each volunteer in the lean group on their 
rest and exercise days. The exercise period started after the second sample. 
It is clear that almost all volunteers show no change in adiponectin 
concentrations during or after the exercise. One volunteer, who has the 
highest adiponectin concentration on rest day, shows a continuing decline.  
Figure 3 -12B shows the data for the lean volunteers on their rest and 
exercise days. Again by eye an apparent difference appears to develop after 
exercise, but a non parametric Kruskal-Wallis test showed no significant 
difference (p value >0.05). The median values were 13.5 ng/ml and 11.2 
ng/ml for rest and exercise days. The mean values for all samples on the 
two days were 28.7 ± 5.1 ng/ml and 19.76 ± 1.9 ng/ml on resting and 
exercise days respectively. 
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Figure  3-12  
A- Scatter plots show the adiponectin concentrations for each volunteer in the lean group on 
rest and exercise days. B- Box plots show adiponectin concentration in lean subjects on rest 
and exercise day. Nonparametric Kruskal-Wallis test showed no significant change (p value 
>0.05). 
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Figure 3-13A shows the adiponectin concentration for five overweight 
volunteers over the period of the exercise day. The exercise period started 
after the second sample. It is clear that there is no obvious effect of the 
exercise on the adiponectin concentrations. One volunteer shows unusually 
high adiponectin concentration in comparison with the rest of the group. 
Four volunteers show low and stable adiponectin concentrations. 
Figure 3-13B shows the adiponectin concentrations in the overweight 
volunteers on their exercise day. As with the lean volunteers’ data in figure 
3-11B, the mean adiponectin concentrations appears to fall progressively 
after exercise. Again, these changes were not statistically significant. 
Kruskal-Wallis test showed no significant difference in adiponectin 
concentration over time (p value >0.05). 
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Figure  3-13   
A- Scatter plots for five over weight volunteers on their exercise day. Data from the overweight 
3 volunteer not available. Almost all volunteers show stable adiponectin concentration. B- The 
box plots to show the adiponectin concentrations from overweight volunteers on exercise day. 
Almost all samples were stable all over the time.  
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Figure 3 -14A shows the data for the each volunteer in the overweight group 
on their rest and exercise days. The exercise period started after the second 
sample. It is clear that almost all volunteers show no change in adiponectin 
concentrations during or after the exercise. The three volunteers, who have 
the highest adiponectin concentration on rest day, show a continuing 
decline. One volunteer shows similar pattern on exercise day.  
Nonparametric Kruskal-Wallis test showed no significant difference for 
adiponectin concentrations in overweight volunteers between resting and 
exercise days (p value >0.05) figure 3-14B. The median values were 10.6 
ng/ml and 7.4 ng/ml for rest and exercise days. The mean values on the two 
days were 28.5 ± 5.4 ng/ml and 20.1 ± 4.0 ng/ml on resting and exercise day 
respectively. 
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Figure  3-14  
A- Scatter plot shows the adiponectin concentrations for each volunteer in the overweight 
group on rest and exercise days. Data are not available for overweight 3 volunteer on 
exercise day. B-The figure shows box plots for adiponectin concentration on rest and exercise 
day for overweight volunteers. It is clear from the figure that there is no significant difference 
between rest and exercise days for over weight volunteers (p value>0.05)  
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3.5 Discussion 
The present study demonstrates the possibility of using microdialysis 
catheters in SAT in both lean and overweight women. All the insertions were 
successful with out any infections or problems. It was very successful in 
terms of fluid recovery, after the initial problems of insertions were 
resolved. Furthermore, it was an easy technique to use because no 
processing or preservatives were needed to maintain the samples. All the 
catheters functioned satisfactorily over the two day period. This was in 
agreement with one previous study where large pore microdialysis catheters 
were inserted in SAT of ten men for periods of 4 days. All their catheters 
functioned fully for two days, 90 % worked on the third day and 30 % on the 
fourth day (Clausen et al., 2009).  
The main difficulty with the microdialysis technique was the small volume of 
the samples collected. As mentioned in section 3.3.2.1, the volume of each 
sample collected was 30 µl for the first nine volunteers. This volume was 
collected because the best recovery of adiponectin was at 1 µl/min 
(Dostalova et al., 2009; Hojbjerre et al., 2007) and the time of the 
collection was 30 minutes. The period of collection was increased to 45 
minutes. The larger volume collected allowed less dilution of the sample 
before the ELISA analysis. This improved the ELISA performance, but it also 
increased the time spent by volunteers in the lab by two hours each day. 
This did not cause any problems. 
The CMA 107 pump had higher available flow rates of 2 and 5 µl/min. These 
were not used because of the lower recovery rate of adiponectin at those 
flow rates. Dostalova found that the relative recovery of adiponectin at 2 
µl/min was 8.5 ±1.9 %, and at 5 µl/min was 0.7 ± 0.3 % (Dostalova et al., 
2009). 
This study was an attempt to apply the microdialysis technique to study 
adiponectin concentrations at the site of its secretion in adipose tissue. The 
catheter chosen was a commercial product with a pore size of 100 KD. This 
catheter was chosen because the molecular weight of the adiponectin 
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hormone as a monomer is 30 KD. The catheter worked successfully in terms 
of fluid recovery but the concentration of adiponectin in the samples was 
very low and for some samples below the detection limit of the ELISA kit 
(section 3.4.2.1). This could be because adiponectin occurs in several forms. 
The monomer form, 30 KD, is secreted from the adipose tissue. It 
polymerises to form a low molecular weight trimer of 90 KD (Mangge et al., 
2009), medium molecular hexamer at 180 KD (MMW) and an even larger 
polymer ranging between 240 to 400 KD (Navaneethan et al., 2010). 
Therefore, 100 KD microdialysis catheters probably collected the monomer 
but not significant quantities of the larger forms that constitute the greater 
part of adiponectin in a sample (Hada et al., 2007; Hill et al., 2009; Pajvani 
et al., 2003b). On the other hand, some samples with a pale red colour had 
high Adiponectin concentration in the ELISA tests. This was mentioned in 
section 3.4.2.1 and figure 3-5A. The obvious colour on those samples might 
be result of entry of haemoglobin molecules into the microdialysis catheter. 
It is possible that some localised bleeding at the entry site was followed by 
localised haemolysis leading to a localised concentration of haemoglobin. Its 
MW is 67 KD and so it is possible that it entered the dialysate. This colour 
could interfere with the ELISA analysis and explain the high colorimetric 
reading. It is unlikely for this colour to be due to bursting of the dialysis 
membrane.  
As a result, low concentrations of the monomer form of adiponectin were 
found. On the other hand; this could confirm the finding that the 
adiponectin monomer is found only in adipose tissue but not in the 
peripheral circulation, where only the other forms were detected (Giannessi 
et al., 2007). Ebinuma et al. demonstrated that the 50% of the total 
adiponectin are HMW, and 25% are MMW and LMW (Ebinuma et al., 2006). 
Whereas Beltowski et al. projected that the percentage of HMW were 40%, 
MMW 35% and LMW 25% of the total adiponectin in human serum (Beltowski 
et al., 2008).  
These finding was in agreement with Dostalova who use the concentric 
microdialysis catheter with same cut-off (100 KD) to measure adiponectin in 
subcutaneous adipose tissue. She demonstrated a significant variation in 
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adiponectin concentration in subcutaneous adipose tissue during a full day 
study period with low concentration (data not shown) (Dostalova et al., 
2009). Clausen et al. used a similar microdialysis catheter (CMA 71) with 
same cut-off to study SAT. He also found low adiponectin concentrations. 
This made subsequent Luminex analysis not possible (Clausen et al., 2009). 
The data shown in section 3.4.3.1, figure 3-8 shows a significant difference 
in adiponectin concentrations in microdialysate on the first and second day 
after insertion. Similar results were found by Clausen et al. (Clausen et al., 
2009). They observed a change in adipokines concentrations in the early 
samples taken immediately after the insertion. This decline continued more 
slowly during the following day. Both of these sets of observations suggest 
that the insertion of microdialysis catheter should be done one day prior the 
actual study starting. This is based on the observations in this study that the 
catheters were well tolerated by volunteers and that no significant infection 
problems were encountered.  
The lower concentrations of adiponectin on day 2 could have several 
potential causes. For example, insertion of the catheter could cause local 
tissue trauma and this could affect the secretion of adiponectin, even 
though 1.5 hours elapsed between the insertion and the first samples being 
taken to allow for tissue recovery. This delay was proposed by (Dostalova et 
al., 2009). A local inflammatory response for the catheter was observed by 
Murdolo et al. They found that the insertion of the microdialysis catheters 
increased the concentration of inflammatory cytokines such as IL-6 and IL-8 
in lean and obese individuals (Murdolo et al., 2008). An alternative 
possibility is that psychological stress in the volunteers was greater on the 
first day.  
The data in section 3.4.3.2 shows that the mean adiponectin concentration 
was not different in lean and overweight volunteers. This might be because 
the volunteers were moderately overweight, with a mean BMI of 27.7 ± 1.9 
kg/m2, rather than obese. As described in chapter 2, there were problems in 
recruiting overweight volunteers. The author suspects it might have been 
even more difficult to recruit obese volunteers. This could have been 
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worthwhile but additional problems with their health status might have been 
encountered. Hojbjerre et.al., using microdialysis techniques in male 
volunteers, also found no significant difference in adiponectin concentration 
between lean and overweight. In that study the mean BMI of the overweight 
group was 28 kg/m2 (Hojbjerre et al., 2007). However, other studies 
measuring plasma adiponectin concentrations have found a strong negative 
correlation with BMI in males and females volunteers (Arita et al., 1999; 
Weyer et al., 2001). This will be discussed in chapter 6.  
Lastly, the data from this experiment showed no significant effect of one 
hour of exercise at 50% 2
.
OV max on adiponectin concentrations which were 
stable on both resting and exercise days. This might have two possible 
causes: poor recovery of heavier isoforms of adiponectin or the intensity and 
duration of exercise might have been too low.  
Low concentrations of adiponectin were found in the recovered interstitial 
fluid (see section 3.4.3.3). These are likely to be principally the monomeric 
and trimer forms, with MWs of 30 and 90 KD respectively. The cut off of the 
microdialysis catheter was 100 KD. These might not represent the actual 
effect of the exercise on total adiponectin. Only one study has been 
published on the effect of exercise on dialysate adiponectin concentrations. 
Positive results were found and exercise increased adiponectin 
concentrations. That study used a particularly leaky type of catheter with a 
950 KD pore (Hojbjerre et al., 2007). This catheter is not commercially 
available.  
Using this 950 KD catheter, Hojbjerre et al. found that the concentration of 
the interstitial adiponectin increases significantly in healthy men after acute 
bouts of exercise at 55% of their 2
.
OV max. The study reported in this thesis 
exercised women at 50% of 2
.
OV max. It is unlikely that the difference 
between 50% and 55% was responsible for the lack of effect in women 
volunteers.  
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The study by Hojbjerre et al.(2007) also found that the concentration of 
interstitial adiponectin in subcutaneous abdominal adipose tissue was 20% of 
the plasma adiponectin concentration. The same research group have also 
shown that concentration of adiponectin recovered by the 950 KD catheters 
can be up to 25 fold higher in plasma than in abdominal subcutaneous tissue 
(Nielsen et al., 2009).  
In conclusion, the commercially available microdialysis system performed 
well. However, the CMA 66 catheters with a 100 KD cut off used in this study 
was poor at recovering the larger molecular weight forms of adiponectin. 
This makes the interpretation of the results difficult especially in case of the 
effect of the exercise on adiponectin.  
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Chapter 4 
4 Adiponectin concentrations in plasma and 
dialysate samples 
4.1 Introduction 
The data reported in chapter 3 showed that the recovery of adiponectin using 
100 KD microdialysis catheters was very low. This confirmed data published 
by other authors (Dostalova et al., 2009; Clausen et al., 2009). Other authors 
have shown big differences in adiponectin concentration in plasma and 
microdialysate recovered from SAT. These studies used the specialised 
catheters with a 950 KD cut off (Hojbjerre et al., 2007; Nielsen et al., 2009).  
Therefore, the purpose of the small study described in this chapter was to 
compare adiponectin concentrations in the plasma and in dialysate samples. 
In this study the CMA 66 microdialysis catheter with a 100 KD cut off was 
used. 100 KD microdialysis catheters were the largest size commercially 
available 
4.2  Aim 
The aim of this study was to investigate the differences in adiponectin 
concentrations in the plasma and in dialysate samples.  
4.3 Material and Methods 
4.3.1 Subjects 
Six male volunteers were recruited for this study from University of 
Glasgow. It was easier to recruit male volunteers and this avoided retesting 
females who had already participated in the earlier experiments. This 
satisfied local ethics committee regulations.  
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The inclusion criteria were similar to the previous study, the volunteers 
were healthy males. Consent forms were signed by all volunteers.  
The anthropometric data for the volunteers is given below.  
No 
 
Age 
(Years) 
Weight 
(kg) 
Height 
(m) 
BMI 
(kg/m2) 
1 29 82 1.72 27.7 
2 35 75 1.70 26.0 
3 58 98 1.82 29.6 
4 28 91 1.88 25.7 
5 25 84 1.77 26.8 
6 22 64 1.79 19.9 
Mean  
 ± 
SD 
32.8 
± 
13.1 
82.3 
± 
11.9 
1.78 
± 
0.06 
25.9 
± 
3.3 
Table  4-1  
The general anthropometric characteristics for the volunteers.  
 
4.3.2 Design of the experiment: 
The experimental design was similar except that no exercise was required. 
Volunteers were invited to attend the lab on two days. They fasted 
overnight on one day and the other day they ate normally. The sequence 
was randomised. 
On the first day, volunteers arrived at 8 am in the morning and a CMA 66 
microdialysis catheter was inserted 4 cm lateral to the umbilicus, on left 
side. This positioned the catheter in their abdominal subcutaneous tissue. 
The pump was connected and perfusion started. After one hour collection of 
microdialysate began, an intravenous cannula was inserted and collection of 
blood sample began. Five blood samples and five dialysate samples were 
collected. The dialysate was collected every hour and the blood samples 
were taken at hourly intervals.  
At the end of day 1 the intravenous cannula was removed and the 
microdialysis catheter covered with a sterile dressing. On the following day 
the catheter was checked for infections or other problems. The pump was 
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reconnected and dialysate collection restarted. A new intravenous cannula 
was inserted. The sample collection protocol was repeated as on the first 
day. 
The microdialysate samples were stored directly at -80oC for subsequent 
analysis. The blood samples were centrifuged at 3000 rpm for 10 min at 4oC. 
The plasma was separated into three Eppendorf tubes and stored at -80oC. 
The maximum storage time in this series of experiment was two weeks.  
4.3.3 Samples analysis 
Adiponectin concentrations for all samples were measured using the ELISA 
technique described in Chapter 2.  
4.4 Results  
4.4.1 Plasma adiponectin concentration 
The adiponectin concentrations in first samples of plasma on day one and 
day two are plotted in figure 4-1. The adiponectin concentrations for these 
early samples in the five volunteers were within the normal range for 
healthy adults i.e. 2,000-30,000 ng/ml (Arita et al., 1999). There is no 
obvious difference in concentration between the two days. The mean values 
were 5,887 ± 1634 ng/ml and 5,925 ± 1574 ng/ml (mean ± SD) for first and 
second days, respectively. A paired t-test showed no significant difference 
between the means (P value >0.05). One must interpret these cautiously 
because of the small numbers.  
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Figure  4-1  
Graph shows the first samples of plasma adiponectin concentrations for five volunteers, on 
first and second day. One volunteer had only one day. It is clear that there is no difference 
between the first samples on two days for all. 
 
Figure 4-2 A shows the adiponectin concentrations in each of the subsequent 
samples taken from the volunteers. It appears by visual inspection that the 
concentrations are very stable over the five hours of sampling. These are re-
plotted as box plots in figure 4-2 B.  
Given that this was a short series of experiments, there are relatively few 
data points to include in a statistical analysis. Even though their distribution 
was not normal (Ryan Joiner p<0.05) an ANOVA with repeated measures was 
conducted. This showed no significant differences with time or trial, fasted, 
or not fasted. 
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Figure  4-2  
A- Scatter plot showing the plasma adiponectin concentrations for all volunteers on two days. 
Data for each volunteer is plotted separately. B- The box plot shows the mean values for fast 
and non fasting days. Again it is clear that there is little difference between the two days. Two 
volunteers did only the first day of the collection. It is clear that there is a small difference 
between first and second days of the collection. 
  
 
 
 
 
Time (hour) 
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4.4.2 Dialysate adiponectin concentration  
Four of the catheters worked for the whole duration of the experiment. Two 
volunteers completed only the first day because their catheter stopped 
working. The samples from one volunteer had adiponectin concentrations 
below the detection limit of the ELISA kit. Thus, data is available for five 
subjects on their first day and three on second day of the collection. 
Dialysate adiponectin concentrations were similar to that in previous studies 
reported in chapter 3. The graph below shows data for dialysate adiponectin 
concentration in three volunteers on their first and second day. Two 
volunteers showed no difference in adiponectin concentration. One 
volunteer showed a big decrease on second day.  
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Figure  4-3  
Graph shows the first samples of dialysate adiponectin concentrations for five volunteers, on 
their first and second days. Data for two volunteers are not available for day two. No obvious 
pattern for the samples. One had a sharp decrease and two had similar concentrations on 
both days. 
 
Figure 4-4 shows the adiponectin concentrations in each of the subsequent 
samples taken from the volunteers. It shows one volunteer with higher 
adiponectin concentrations on first day. His data is very similar to the other 
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volunteers on the second day. The other volunteers show stable adiponectin 
concentrations.  
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Figure  4-4   
Scatter plot showing the raw data for adiponectin concentrations in dialysate for three 
volunteers on two days. Each volunteer has data plotted for two days by same symbols and 
same connect line. Two subjects completed only one day. 
 
The data were re plotted as box plots in figure 4.5. The high adiponectin 
concentrations for the fourth subject on day one were omitted. It is clear 
from the box plot that the adiponectin concentrations are similar on both 
days. No further statistical analysis was attempted because of the small 
volume of data.  
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Figure  4-5  
Box plot for adiponectin concentrations on first and second days.  
 
Table 4-2 contains the mean adiponectin concentrations for plasma and 
dialysate samples in all volunteers. It is obvious that there is a very 
substantial difference between plasma and dialysate adiponectin. The 
differences are so large that no formal statistical analysis was attempted.  
 
 
 
 
 
 
 
 
 
 
 
 
Table  4-2  
Table shows the substantial difference between mean adiponectin concentrations in plasma 
and dialysate for all volunteers. 
 
Volunteers 
Mean plasma 
adiponectin 
concentrations 
(ng/ml) 
Mean dialysate 
adiponectin 
concentrations 
(ng/ml) 
Ratio of 
Plasma/Dialysate 
Concentrations 
1 4075.6 2.5 1630 
2 4299.8 2.4 1791 
3 5120.3 Below detection limit --- 
4 5900.6 23.0 256 
5 7434.9 11.1 669 
6 8358.9 14.7 568 
Time (hour) 
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4.5 Discussion 
The main aim of this study was to compare the adiponectin concentrations 
in the dialysate collected by 100 KD microdialysis catheters and the plasma 
concentration.  
The adiponectin concentrations in dialysate samples were very low, with 
mean concentrations between 2.5 and 23 ng/ml. This range is similar to 
those in Chapter 3 in female volunteers where the means ranged from 3 – 
88.9 ng/ml. They are also similar to values of about 2 – 25 ng/ml reported 
by Dostalova et al.(2009). 
Table 4.2 compares the concentrations of adiponectin in plasma and 
dialysate. The adiponectin concentrations in plasma were between 256 and 
1791 times higher than those in dialysate. Both sets of samples were tested 
using the same Mercodia ELISA kits. Indeed the samples were processed at 
the same time. Thus the difference cannot be due to sensitivity of analysis 
or degradation of samples in storage. The most likely explanation lies in the 
dialysate samples containing only the monomeric form of adiponectin whilst 
the plasma samples contain a range of forms. It was discussed earlier that 
the microdialysis catheter recovers only a very small fraction of the 
hormone. That was discussed earlier in chapter 3 section 3-5  
Some other studies on males using microdialysis catheters with cut offs at 
950 KD demonstrated that the adiponectin concentrations in dialysate 
samples were up to 25 times lower than the adiponectin concentrations in 
plasma. This reflects the better recovery of heavier molecular weight forms 
of adiponectin. The plasma concentrations were similar in this study and in 
the previously published work (Clausen et al., 2009; Hojbjerre et al., 2007; 
Nielsen et al., 2009).  
It is hard to make direct comparisons of body composition in males and in 
females. It is worth noting that even at similar BMIs the females almost 
certainly have a higher percentage body fat (El Ati et al., 2012; Flegal et 
al., 2010; Kelly et al., 2008). In male adults, adipose tissue constitutes 
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about 8 to 18% of body weight, while for females it is about 14% to 28%. This 
percentage greatly increases in case of obesity and could reach 60% to 70% 
of body weight (Cinti, 2007). 
In these experiments, like in chapter 3, the insertion of the catheters was 
successful. They were well tolerated and no infections or problems were 
found. The data collected over two days, by microdialysis and plasma 
samples, allowed the adiponectin concentrations in fasted and non fasted 
states to be compared. Whilst the data sets are small it appears that fasting 
has little effect on the adiponectin concentrations. 
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Chapter 5 
5 The effect of short bouts of exercise on 
HMW adiponectin concentrations in plasma 
5.1 Introduction 
On the basis of the data in chapter 3 and 4 it can be concluded that the CMA 
66 (100 KD) microdialysis catheters only recover a small fraction of the total 
adiponectin and this does not reflect the concentrations of all forms of 
adiponectin. It was very obvious that there was a big difference between 
the total adiponectin concentration in plasma and the concentration of the 
monomer or the homotrimer in the interstitial fluid recovered via the 
microdialysis catheter (Table 4-2). Further, many studies have been done on 
the effect of exercise on adiponectin concentration in plasma, but very few 
studies on the effect of the acute exercise on the active form of the 
hormone (HMWA). In addition almost all of them studied male subjects. 
Adiponectin is a complex hormone which occurs in many forms. The active 
form of the hormone is the heavy molecular weight adiponectin (HMWA) 
(Hada et al., 2007). HMWA exhibits the greatest binding activity to 
membrane fractions and the most effective part of the hormone in the 
activation of adenosine monophosphate (AMP)- activated protein kinase 
(Hada et al., 2007). Many studies have reported that the HMWA 
concentration is a better predictor than total adiponectin concentration of 
many conditions such as insulin resistance, metabolic syndrome and 
coronary artery disease (Hara et al., 2006; Lara-Castro et al., 2006; Von et 
al., 2008). In addition, it has very important role in the metabolism of lipid 
and glucose in skeletal muscle (Hada et al., 2007). It is well known that 
exercise reduces the risk of T2D and CVD (Helmrich et al., 1991). Physical 
exercise makes a substantial improvement in lipid metabolism and insulin 
resistance in individuals with existing metabolic syndrome (Byberg et al., 
2001). Recently Numao et al. demonstrated the effect of 60 minutes of 
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moderate intensity exercise on HMWA in young healthy males with high 
fitness level (Numao et al., 2008).  
Accordingly; the aims of this study were to investigate the effects of a short 
bout of exercise on: 
1- the plasma concentrations of HMWA and total adiponectin  
2- the plasma concentrations of IL-6 and TNF-α.  
3- the plasma concentrations of insulin and glucose. 
These experiments were done in a group of normal healthy young women.  
5.2 Materials and Methods 
Volunteers were screened and enrolled for this study as described in chapter 
2 section 2.2, following the inclusion and exclusion criteria in chapter 2 
section 2.3.   
5.2.1 Subjects 
The College of Medical, Veterinary and Life Sciences Ethics Committee for 
Non-Clinical Research Projects, University of Glasgow approved this study. 
The information sheet about the study was given Appendix 2. 
The volunteers gave written informed consent for taking part. Sixteen young 
healthy female volunteers were recruited for this study via posters assigned 
around the University campus. Thirteen subjects finished the whole 
experiment. The other three stopped for different reasons. One did not 
meet the inclusion criteria because she was significantly overweight. One 
stopped after the initial anthropometry and fitness tests, without giving any 
reason. One said she had a family problem. 
The thirteen sedentary females were aged 20 to 30 years old. All of them 
were students at University of Glasgow, mostly European in origin. None of 
Chapter 5   
M. Alzwayi  119  
these volunteers had participated in the earlier experiments. They 
confirmed that they did not do any vigorous exercise. Table 5-1 shows the 
general characteristics of volunteers. The volunteers were all in the 
follicular phase of their menstrual cycle. 
 
Age 
(years) 
Weight 
(kg) 
Height 
(cm) 
BMI 
(kg/m2 ) 
Fat 
(%) 
2
.
OV max 
(ml/kg/min) 
1 21 55.3 174.0 18.3 21.6 34.0 
2 24 56.7 168.0 20.1 27.0 35.0 
3 24 65.3 173.0 21.8 25.7 42.0 
4 25 56.7 172.0 19.2 25.6 35.0 
5 22 77.8 177.5 24.7 37.1 32.0 
6 28 59.2 161.0 22.8 35.9 45.0 
7 25 61.9 162.0 23.6 31.5 42.0 
8 25 56.0 161.0 21.6 30.0 41.0 
9 21 71.8 172.2 24.2 32.6 40.0 
10 23 61.9 164.4 22.9 29.4 42.0 
11 22 68.5 167.0 24.6 31.9 36.0 
12 26 66.4 171.0 22.7 27.6 47.0 
13 30 47.5 159.0 18.8 19.0 32.0 
Mean 
± 
SD 
24.3 
± 
2.7 
61.9 
± 
8.0 
167.9 
± 
5.9 
21.9 
± 
2.2 
28.8 
± 
5.2 
38.7 
± 
5.0 
Table  5-1  
Characteristics of the volunteers.  
 
5.2.2 Design of the experiment 
The general design was similar to that followed in chapter 3. Healthy female 
volunteers attended the lab on two days, rest on one and exercise on the 
other. The sequence was randomly allocated and the days were separated 
by at least two weeks. 
Each day the volunteers arrived to the lab at 8 am having fasted overnight. 
A cannula was inserted in an antecubital vein to allow blood collection. A 
series of three 8 ml of blood samples were collected at intervals of one 
hour. The cannula was flushed with 8 ml non-heparinised saline solution 
after each collection to prevent clotting obstructing the cannula. Details of 
the technique are given in chapter 2 section 2.7.  
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On one day the volunteers exercised by walking on a treadmill at a preset 
speed. This ensured they exercised at 50% of their 2
.
OV max. That speed was 
determined at least one week before the actual experiment. Blood samples 
were collected directly before the exercise, at the end of the walk and one 
hour later. A fourth blood sample was taken two days later. The time line is 
shown in figure 5-1 
On the other day the volunteers rested in the investigation room, seated on 
a chair or sleeping on a bed for the same duration. Four blood samples were 
collected at the same intervals.  
 
Figure  5-1  
This diagram shows the experimental protocol. Maximum oxygen consumption was estimated 
for the all subjects at least one week before the main trials. Body fat percentage was 
estimated on the first day of the experiment. Blood sample collected at 0, 1, 2 hours. On 
exercise day, volunteers exercised for one hour at 50% of their 
2
.
OV max after the 0 blood 
sample was collected. Volunteers came back 48 hour after the rest or exercise and one blood 
sample was collected. 
 
 
Measurement of 
the 2
.
OV max 
-7 days  
Main trials 
0 1 2 
Exercise 
48 (hours) 
◊ 
Blood samples 
◊ Fat percentage 
measurement 
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5.2.3 Blood sample collection 
The blood samples were collected using cannulae in EDTA tubes for 
subsequent measurement of adiponectin, HMW adiponectin, insulin, IL-6 and 
TNF-α. Additional samples for glucose measurement were collected in tubes 
with Fluoride Oxalate as the anti coagulant. All samples were centrifuged 
within 30 minutes of collection. Those to be used for measurements of 
HMWA, IL-6 and TNF-α were spun at 1000 g for 15 minutes at 4oC (Sorvall, 
legend RT plus centrifuge, Germany). Those for measurements of the 
adiponectin, insulin and glucose were spun at 1400 g for 10 minutes 
(Universal 320R centrifuge, Germany). Plasma samples were transferred into 
two Eppendorf tubes using 1ml plastic Pasteur pipettes (Wilford Industrial 
Estate, Nottingham). 
Plasma samples were stored at −80oC for maximum 1 month. An exception to 
this was the storage of glucose samples which had to be kept frozen for 
about six months because of technical problem. 
5.2.4 Statistical analysis 
All data were analysed using statistical software (Minitab 16). Descriptive 
statistics were calculated for all parameters. Data were presented as mean 
± SD. A normality test was applied to all parameters using the Ryan Joiner 
normality test. Paired t-tests were applied to compare the first samples on 
rest and exercise day. Two way repeated measures ANOVA (trial x time) 
were used to compare changes over time and across the two trials for 
normally distributed data. Non parametric Kruskal-Wallis test was applied 
for not normally distributed data. 
5.3 Results 
5.3.1 Adiponectin concentrations in plasma 
The concentrations of total adiponectin and the HMW adiponectin were 
measured. The values for the first samples on the two days are plotted 
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below in figure 5-2. The values lie in the same range as in previous published 
works (Arita et al., 1999; Hada et al., 2007). The mean total adiponectin 
concentration was 10.2 ± 2.5 µg/ml and the mean HMW adiponectin 
concentration was 4.1 ± 1.7 µg/ml (Mean ± SD).  
A paired t-test for normally distributed data showed no significant 
difference between the mean concentrations in the first samples on the two 
days (P value >0.05). The mean values for total adiponectin were 10.1 ± 2.4 
µg/ml and 10.4 ± 2.7 µg/ml. The mean values for the HMW adiponectin 
concentrations were 4.2 ± 1.8 µg/ml and 3.9 ± 1.7 µg/ml for rest and 
exercise day respectively. These data are illustrated in Figure 5-2 A & B. 
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Figure  5-2  
The interaction plots show total adiponectin concentrations (A) and HMW adiponectin 
concentrations (B) in the first samples for all volunteers on their rest and exercise 
days. ● The first day was resting day.  □ The first day was exercise day 
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The plasma samples for each volunteer on both days were analysed at the 
same time. The interaction plots below illustrate the concentrations of total 
adiponectin figure 5-3 A, and HMW adiponectin concentrations figure 5-3 B. 
The overall impression is that neither concentration changes over the four 
samples. 
Four series of samples had HMWA concentrations which were clearly higher 
than the others, figure 5-3 B. Those samples came from two volunteers on 
their rest and exercise days. They also had the highest total adiponectin 
concentrations. Similarly, the volunteers with the lowest total adiponectin 
concentrations also had the lowest HMWA concentrations.  
The plots in figure 5-3 suggest that the data distribution might not be 
normal. This was tested using Ryan Joiner tests; figure 5-4 A and B show the 
results. The total adiponectin concentrations were normally distributed p 
values = 0.086 and the HMW adiponectin concentrations were not normally 
distributed p values <0.010. It is strange that no samples had concentrations 
between 5 and 6.5 µg/ml. This will have a big effect on the normality of 
these data. There is no obvious explanation for this. It is possibly just a 
chance observation that no samples had concentrations in that range.  
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Figure  5-3  
Panel A shows the total adiponectin concentrations for all volunteers at all sample 
time on both days. Panel B shows the HMWA concentrations in same blood samples. 
The values are stable over time.  
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Figure  5-4 Normality test for total adiponectin concentrations (A), HMW 
adiponectin concentrations (B). 
 
A two way ANOVA with repeated measures showed no time x trial 
interaction for total adiponectin concentrations figure 5-5 A (p value = 0.9). 
Nonparametric Kruskal Wallis test was applied for HMW adiponectin 
concentrations. No significant change was found between trails (p value = 
0.5) figure 5-5 B. There was no change in total adiponectin concentrations 
and HMW adiponectin concentrations in plasma immediately, one, two, and 
48 hours after rest and exercise. The statistical analysis confirms the early 
visual impression.  
The percentage of the HMW adiponectin found in this study was 38.5% of the 
total adiponectin concentrations. There was no effect of the exercise on the 
ratio of HMW to the total adiponectin concentration. 
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Figure  5-5  
Box plot for plasma total (A) and HMW (B) adiponectin concentrations at rest and 
exercise. It is clear from the graphs that there is no effect of the exercise on both 
of the parameters p values > 0.05. 
 
5.3.2 Plasma IL-6 concentrations 
The samples from the thirteen volunteers was also analysed for IL-6 using 
the methods described in section 2-8-4. Two volunteers showed very high 
concentrations: one on their rest day and other on their exercise day. These 
values show as the outliers in the box plots of the data in figure 5-6A. Both 
Exercise 
Time (hours) 
Exercise 
Time (hours) 
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volunteers were unwell on these two days and reported that they had a 
cold. Consequently, those samples were omitted and were not included in 
the statistical analysis. Data for eleven volunteers were analysed. 
The mean IL-6 concentrations in the first samples were 1.4 ± 0.6 pg/ml on 
the rest day and 1.3 ± 0.4 pg/ml on the exercise day. A paired t-test showed 
no significant difference between the mean concentrations first samples on 
both days (P value = 0.6). The data are plotted in Figure 5-7.  
The scatter plot in figure 5-8 shows the IL-6 concentrations on rest and 
exercise days and 48 hours later. Almost all samples showed higher IL-6 
concentrations one hour after the exercise.   
The normality test was applied for the IL-6 data. Data were not normally 
distributed. Nonparametric test was applied, Kruskal Wallis test showed a 
significant change between trial for plasma IL-6 (p value = 0.036). This is 
clearly illustrated in the box plots in Figure 5-9. 
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Figure  5-6  
The figures show box plots to show the means of the raw data medians, quartile 
ranges and ranges of the IL-6 concentrations in plasma samples. The upper panel 
shows all data including the two volunteers with high samples. The starred values 
clearly lie outside the expected ranges. The lower panel shows the data re-plotted 
after removal of the six high samples. 
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Figure  5-7  
Interaction plot shows the concentration of IL-6 of the first samples on rest and exercise days. 
Most samples were stable. Two samples were higher on rest day than on exercise day. One 
sample was lower on rest than the exercise day. ● Volunteers were rested on first day.  □ 
Volunteers were exercised on first day 
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Figure  5-8   
Scatter plot shows the IL-6 concentrations on rest and exercise days. Almost all samples 
show increased IL-6 concentrations one hour after the exercise. Two volunteers (1 & 4) have 
data for one day, as the missing data were plotted as outlier in figure 5-6 
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Figure  5-9  
Figure shows the IL-6 concentrations on rest and exercise day. There is a significant increase 
of IL-6 concentrations one hour after the exercise (P value = 0.036). 
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5.3.3 Plasma TNF-α concentrations 
The plasma samples were also analysed for TNF–α using the methods 
describe in chapter 2 section 2-8-4. The concentrations of the first samples 
on two days are plotted in figure 5-10. The mean values were 2.6 ± 1.5 
pg/ml on rest days and 2.1 ± 0.9 pg/ml on exercise days. The result of a 
paired t-test showed no significant difference p value = 0.113.  
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Figure  5-10  
Interaction plot for the TNF–α concentrations show the first samples for the volunteers on rest 
and exercise days. Some samples showed no difference. Other samples showed lower values 
on exercise day. Only one sample showed higher value on exercise day. The data for ten 
volunteers, three volunteers had concentrations below the detection limit of the kit.                 
● Volunteers were rested on first day.  □ Volunteers were exercised on first day 
 
 
The scatter plot was plotted for the TNF–α for all the data. Big variations 
between the volunteers were illustrated. Some show no change, some show 
decreases in TNF–α concentration one hour after the exercise and the others 
show slight increases in TNF–α concentrations one hour after the exercise as 
illustrated in figure 5-11. 
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Figure  5-11 Scatter plot for TNF–α concentration on both days. 
 
The normality test was applied for the TNF–α concentrations data. Data 
were not normally distributed (p value = 0.015). Nonparametric test was 
applied, Kruskal-Wallis test showed no significant change between trials (p 
value = 0.9) for TNF–α concentrations in plasma, Figure 5-12. 
 
48210
7
6
5
4
3
2
1
0
T
N
F
-a
 c
o
n
ce
n
tr
a
ti
o
n
s 
(p
g
/m
l)
Exercise
Rest
 
Figure  5-12  
Box plot shows TNF-α concentration on rest and exercise days.  
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5.3.4 Plasma insulin concentrations 
A normality test was applied to the insulin concentrations. It confirmed that 
the data were normally distributed. 
The mean insulin concentrations for the first samples on rest and exercise 
day were 6.3 ± 2.3 mU/l. A paired t-test showed no significant difference 
between the first samples on rest and exercise day. The mean values were 
5.8 ± 2.6 mU/l on rest and 6.7 ± 2.2 mU/l on exercise day (p value = 0.12). 
These values are plotted in figure 5-13.  
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Figure  5-13  
Interaction plot for the insulin concentrations in plasma shows the first samples for all 
volunteers on rest and exercise days.  No significant difference between the first samples on 
rest and exercise day. 
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The scatter plot for insulin concentrations in plasma at all time points were 
plotted; this is shown at figure 5-14. Most samples showed sharp decrease 
one hour after the exercise.  
 
3210 3210
12
9
6
3
0
12
9
6
3
0
3210
12
9
6
3
0
3210
12
9
6
3
0
1
Time (hour)
In
su
lin
 c
o
n
ce
n
tr
a
ti
o
n
s 
(m
U
/l
)
2 3 4
5 6 7 8
9 10 11 12
13
Exercise
Rest
Panel variable: Subjects
 
Figure  5-14  
The scatter plot for the insulin concentrations at all time points. Almost all samples show 
decrease one hour after the exercise (time 2) 
 
Two way ANOVA with repeated measures for insulin concentrations in 
plasma showed no time x trial interactions (p value = 0.3). These data are 
plotted in figure 5-15 A. However; one way ANOVA showed a significant 
difference with time in plasma insulin concentrations on the exercise day. 
Post hoc analysis using the Tukey method showed a significant difference in 
insulin concentrations one hour after exercise (p value = 0.003). This is clear 
in figure 5-15 B.  
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Figure  5-15 
Box plot shows the insulin concentrations on rest and exercise days (A). It is clear from the 
graph that there is no significant difference in insulin concentration between rest and exercise 
days (p value = 0.3). The lower panel (B) showing the box plot for insulin concentrations on 
exercise day. A significant decrease of insulin concentrations occurs one hour after the 
exercise (p value = 0.003) 
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The lack of significant differences in the data plotted in 5-15A was surprising. 
Dr Tom Aitchison, formerly of the Statistic Department of Glasgow University 
was consulted. He suggested a further analysis to the differences in insulin 
concentrations between rest and exercise days (Exercise – rest). This method  
generates confidence intervals based on all differences (Newell et al., 2010). 
The differences in insulin concentrations between exercise and rest days at 
each time point for each person were calculated. The result for this analysis 
is plotted in figure 5-16. Figure 5-16B shows the difference of the time points 
after the exercise from the basal point or the time zero (before the 
exercise). The 98.3% CI of the differences were calculated and are plotted. 
The use of 98.3% CI is the result of a Bonferroni correction due to use of 
multiple comparisons  
This analysis shows that there is a difference in mean insulin concentrations 
on two days. For example the mean concentration at start of sample 
collection is different on the two days by 1.4 mU/l, but the confidence 
interval of the difference includes zero (-0.9, 3.7) figure 5-16A. There is a 
drop in insulin concentrations at the 2 hour point. The insulin concentrations 
resting value are higher but the CI includes zero. The difference against 
resting time (time zero) is shown in figure 5-16B. The difference in insulin 
concentration is now clear, but it is CI still includes zero. The result suggests 
that a difference would have to be greater than 1.7 mU/l to be detected with 
this sample size. 
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Figure  5-16  
Interval plots show the difference in insulin concentration at different time points. A- Each point 
Shows the mean difference in insulin concentration (exercise – rest) at a series of time points: 
EX0-RE0 is the difference before exercise, EX1-RE1 is the difference one hour latter 
(immediately after the exercise), EX2-RE2 is the difference at 2 hours (one hour after the end 
of the exercise) and EX48-RE48 is the difference 48 hours latter. B- Shows the difference in 
insulin concentration at different time points after the exercise from the basal point (time before 
exercise): 1-0 is the difference at 1hour from the basal point, 2-0 is the difference at 2 hours 
from the basal point and 48-0 is the difference at 48 hours from the basal point. The mean 
difference is shown and the associated 98.3% CI. If the CI crosses the no effect line at zero, 
then there is no significant change. 
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5.3.5 Plasma Glucose concentrations 
The mean glucose concentrations for the first samples on rest and exercise 
days were 4.3 ± 0.25 mmol/l. Paired t-tests showed no significant 
differences between the mean values on rest and exercise day. The mean 
values were 4.4 ± 0.2 mmol/l on rest and 4.3 ± 0.3 mmol/l on exercise day, 
p value = 0.4. These data are illustrated in figures 5-17 and 5-18. 
The glucose concentrations in plasma were normally distributed. A two way 
ANOVA with repeated measures showed no significant time x trial 
interactions (p value = 0.6). The plasma glucose concentrations were similar 
on both days and did not change significantly with time. Box plots of these 
data are shown in figure 5-19 
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Figure  5-17  
Interaction plot for the glucose concentrations in plasma samples shows the first samples for 
all volunteers on rest and exercise days.   
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Figure  5-18  
The graph shows the glucose concentrations for all volunteers at all time points. No 
differences in the concentrations were found.  
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Figure  5-19  
Box plot shows glucose concentrations on rest and exercise days. The (*) are outlier 
concentrations. 
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5.4 Discussion 
This study was designed to investigate the effect of a short bout of exercise 
at 50% 2
.
OV max on adipocytokines in healthy young females. The 
adipocytokines of particular interest were: adiponectin, both the total 
adiponectin and the HMW form, IL-6 and TNF α. In addition, the effects of 
exercise on insulin and glucose concentrations were investigated. These 
experiments follow on a similar approach described in chapter 3 where 
adiponectin was partially recovered by tissue microdialysis. The hope was 
that by moving to larger volume plasma samples it would be possible to 
investigate the full range of adiponectin and IL-6 and TNF-α which 
antagonise the actions of adiponectin.  
This experiment gave more conclusive results than the first experiment using 
CMA microdialysis catheters. The volume of plasma samples was much larger, 
about 4 ml rather than 30-45 microlitres of dialysate. This made the handling 
of samples and the simultaneous analysis of several adipocytokines possible. 
The adiponectin concentrations were easier to analyse because they were 
much higher. The range of concentrations was similar to those found by other 
investigators. (Bobbert et al., 2007; Hoffstedt et al., 2004; Hojbjerre et al., 
2007; Hulver et al., 2002; Jurimae et al., 2009; Magkos et al., 2010; Numao 
et al., 2008). Also the concentrations for the other cytokines measured (IL-6 
and TNF-α) were in the normal range and similar to others (Hojbjerre et al., 
2007; Kaminäski et al., 2009; Lyngs et al., 2002; Mohamed-Ali et al., 1997; 
Nybo et al., 2002).  
It was easier to recruit new volunteers. The new group of volunteers were 
recruited in a much shorter period than that for the first experiment. It is 
possible that volunteers were more familiar with the idea of blood sampling 
than they were with the newer microdialysis technique. However, the 
duration of this experiment was longer and this did not seem to cause 
problems. The volunteers were invited to come during their follicular phase 
and that could be one to two weeks after the first visit. 
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The results in this chapter showed no significant effect of one hour of 
exercise on the total and HMW adiponectin concentrations in plasma, either 
directly after exercise or 48 hours later figure 5-5 A & B. These findings 
were in agreement with several previous studies on healthy young men, 
where moderate intensity exercise lasting 60-90 minutes, had no effect on 
the concentrations of HMWA or total adiponectin concentration (Numao et 
al., 2008; Bobbert et al., 2007; Hojbjerre et al., 2007; Magkos et al., 2010). 
Other studies in young healthy men found no effect of higher intensity 
exercise (Kraemer et al., 2003) or longer duration moderate intensity 
exercise (Punyadeera et al., 2005). Furthermore, several studies concluded 
that adiponectin concentrations were not changed under the effect of 
chronic exercise lasting several weeks (Boudou et al., 2003; Hulver et al., 
2002; Yatagai et al., 2003) However, Kriketos et al showed that adiponectin 
concentrations more than doubled after 10 weeks of training of overweight 
males volunteers (Kriketos et al., 2004).  
One previous study has directly compared the effect of cycling at 65% 2
.
OV max 
on adiponectin concentrations in both sexes and they too found no 
difference in concentrations after exercise in men or women (Ferguson et 
al., 2004). 
In summary, one hour of walking at 50% 2
.
OV max has no effect on total or 
HMW adiponectin concentrations in plasma. This was similar to the finding of 
several previous studies.  
IL-6 is a cytokine synthesised in many tissues including skeletal muscle. 
Muscle secretes the majority of the Il-6 in plasma during exercise (Steensberg 
et al., 2000). However; other tissues such as, ligament and tendon related 
connective tissue and endothelial tissue in the vasculature are important 
sources of IL-6 during exercise (Langberg et al., 2002). This secretion 
depends mostly on the duration and intensity of the exercise and is less 
affected by the mode of exercise (Fischer, 2006). In addition, it has been 
suggested that the increase in IL-6 concentrations is related to sympatho-
adrenal response (Rhind et al., 2001). 
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This study shows a significant increase of IL-6 concentrations after one hour 
of exercise figure 5-9. The concentration increased to almost double that of 
the basal level (1.3 ± 0.4 pg/ml to 2.9 ± 0.8 pg/ml). This finding was similar 
to others on male volunteers (Brenner et al., 1999; Hojbjerre et al., 2007; 
Kaminäski et al., 2009; Lundby & Steensberg, 2004).The effect of the 
exercise on IL-6 has recently been reviewed by many researchers (Febbraio 
& Pedersen, 2002; Gokbel et al., 2012; Lyngs et al., 2002; Nybo et al., 
2002). One consistent finding of all these studies was a marked increase in 
circulating IL-6 concentrations after exercise. The data reported here are in 
line with this pattern. Interestingly, these observations on plasma Il-6 
concentration changes are similar to those in microdialysis samples from 
subcutaneous abdominal adipose tissue (SCAAT) (Hojbjerre et al., 2007). 
This suggests that Il-6, with a MW of 21 - 30 KD can be recovered 
successfully using their specialised microdialysis techniques with the large 
pore diameter membranes.  
The data shown in figure 5-12 shows no change in the concentration of TNF-
α after moderate exercise. The published literature suggests little effect of 
moderate exercise on TNF-α concentrations in plasma (Hojbjerre et al., 
2007; Numao et al., 2011) in young men. The data in this thesis suggest that 
a similar lack of effect also exists in young women.  
The effect of exercise on TNF-α concentration is relatively small in 
comparison with that on IL-6. These two cytokines are known as an 
inhibitors of the actions adiponectin (Fasshauer et al., 2003). However the 
increased level of IL-6 concentrations in this study had no effect either on 
the total or HMW adiponectin. Thus, even if the concentration of 
adiponectin is stable after exercise, as shown in figure 5-5 A & B, its action 
may decrease as a result of raised IL-6 concentrations. 
It is possible that the intensity or duration of exercise was too mild to 
provoke a response in adiponectin or TNF-α concentration. Helge et al. 
found an increase in IL-6  that was directly related to the intensity of the 
exercise (Helge et al., 2003). The kinetics of hormones and metabolites, 
especially catecholamine, are increased by the intensity of the exercise and 
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that may have an inhibitory effect on adiponectin secretion in adipose tissue 
or even the gene expression of adiponectin (Cong et al., 2007).  
In short, in this study one hour of exercise increased the concentration of IL-
6 significantly, but has no effect on the concentration of TNF-α. The role of 
IL-6 in insulin resistance is highly controversial (Petersen & Pedersen, 2005). 
In males, circulating IL-6 concentrations may or may not be associated with 
insulin resistance (Bastard et al., 2002; Carey et al., 2004). The 
concentration of insulin decreased in diabetic patients when they were given 
recombinant human IL-6. This indicated that the IL-6 improved insulin 
sensitivity (Petersen et al., 2005). 
The last part of this experiment examined the effect of exercise on insulin 
and glucose concentrations. However, the statistical analysis showed no 
difference between rest and exercise days on the insulin concentrations. The 
effect of the exercise on the insulin was very clear, as illustrated in figure 5-
15. The initial ANOVA test showed no significant difference in insulin 
concentrations between rest and exercise day. This was unexpected, many 
papers have shown a clear effect of exercise on the insulin concentrations. 
This prompted the further analysis of the differences shown in figure 5-16. 
The most likely explanation is that a fall in mean insulin of less than 1.7 mU/l 
did not show up as a significant, because the 98.3% CI included zero. The 
interval was raised from 95% to 98.3% to compensate for repeated tests. This 
is similar to Bonferroni correction. The author suspects that a larger sample 
size would have given a more robust estimate of the CI, and thus might allow 
the change to be identical as statistically significant. Thus the study was 
probably under powered. The number of volunteers could not be increased 
because of the difficulty in the recruitment of volunteers and the time and 
financial limits of the study. Interestingly Hojbjerre et al. also found no 
effect of the exercise on insulin concentration (Hojbjerre et al., 2007). These 
experiments used similar number of volunteers and may have encountered 
the same statistical problem.  At the same time there was no effect of one 
hour of the exercise on the glucose concentrations. 
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During moderate duration of exercise, plasma glucose concentrations remain 
quite stable due to the increase in hepatic glucose output (Romijn et al., 
1993). Kjaer states that ‘hepatic glucose output is stimulated by afferent 
neural feedback from contracting muscle and by unidentified substances 
released from the muscle into the blood’. Consequently, a decline in insulin 
concentrations in plasma is the most important factor stimulating the 
production of glucose from the liver (Kjaer, 1998). 
The data in this chapter are in agreement with several studies of the effects 
of acute exercise on plasma insulin and glucose concentrations where the 
general effect is an increase in insulin sensitivity after exercise. (Bobbert et 
al., 2007; Ferguson et al., 2004; Hulver et al., 2002; Magkos et al., 2010; 
Numao et al., 2008; Yatagai et al., 2003).  
Most of the studies on the effect of acute exercise on total and HMW 
adiponectin concentrations in plasma were on young healthy males (Bobbert 
et al., 2007; Hojbjerre et al., 2007; Kriketos et al., 2004; Numao et al., 
2008; Punyadeera et al., 2005; Yatagai et al., 2003). This experiment was 
on young healthy females. However; the finding was similar to that of the 
previous studies. The exercise has no effect on total and HMW adiponectin 
concentrations. IL-6 concentrations increased to double concentration of the 
basal level and insulin sensitivity was slightly improved.  
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Chapter 6 
6 General discussion 
6.1 Summary 
The prevalence of obesity is a rapidly increasing problem all over the world. 
It is a matter of concern due to the associated serious risks to health. It is a 
natural consequence of over nutrition and sedentary lifestyle. However, the 
main causes are not well understood. Obesity is commonly related to insulin 
resistance, abnormalities in the metabolism of glucose and T2D (Iacobellis & 
Leonetti, 2005). Adipocytokines are thought to play a vital role in the link 
between obesity and pathophysiology of diabetes (Snijder et al., 2006). 
These adipocytokines include leptin, TNF-α, IL-6, adipsin, resistin, visfatin 
and adiponectin (Ronti et al., 2006). 
There is a significant difference in the occurrence of obesity between sexes 
all over the world (Chalfant et al., 2012). It is more common among women. 
Further , it is recognised that “ the prevalence of overweight and obesity was 
higher in economically developed countries compared with economically 
developing countries in 2005” (Kelly et al., 2008). Adiponectin is an adipokine 
secreted mainly from adipose tissue. It has inverse relation with obesity and 
insulin resistance, as the obese people tend to have lower adiponectin 
concentrations than lean. 
It is well known that exercise increases insulin sensitivity and insulin is one of 
regulators of adiponectin concentration. This thesis aimed to investigate the 
effect of acute exercise on the adiponectin concentration in young healthy 
lean and overweight females.  
The samples used in the experiments in this thesis were obtained in two main 
ways. Dialysate samples (chapter 3 &4), and plasma samples (chapter 4 & 5). 
Dialysate samples were collected from abdominal subcutaneous tissue using 
CMA 66 microdialysis catheters. There is a long history of analysis of plasma 
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samples. In contrast, microdialysis is a relatively new technique first used in 
1985 (Ungerstedt, 1991). It is a validated sampling technique that allows 
direct measurements of exogenous and endogenous substances in the 
interstitial fluid in vivo (Clough, 2005). One of the advantages of this 
technique is the possibility of follow the regional variations of the molecules 
of the interest at the site of attention. Recently, it is possible to recover the 
large molecular weight molecules using microdialysis catheters with high cut 
off membranes (Clough, 2005). 
The advantages of the dialysate samples over the plasma samples were the 
clean samples. Dialysate samples need no preparations, it is ready to store or 
analyse without any extra work. In contrast, the plasma samples may include 
proteins and enzymes. One possibility is that enzymes may affect the 
concentrations of the molecules being studied. Some authors have added 
protease inhibitors such as Trasylol to prevent this (Hojbjerre et al., 2007; 
Nielsen et al., 2009). In addition, blood samples require processing such as 
centrifugation to separate the plasma from the cells. Despite this, there were 
advantages in using plasma samples rather than dialysate. Firstly, the plasma 
contains all the forms of adiponectin. In addition it is easy to collect larger 
volumes and so several assays could be run from one sample.  
The initial experiments reported in chapter 3 examined adiponectin 
concentrations in subcutaneous adipose tissue. It was suspected that this was 
the major site for adiponectin secretion (Scherer et al., 1995). The 
experiments used the commercially available CMA 66 microdialysis catheters 
with cut off 100 KD. In general these catheters worked well and were well 
tolerated by the volunteers. However, two problems were experienced: the 
volumes of recovered fluid were very small and very low adiponectin 
concentrations were found.  This made the interpretation of the results 
difficult. The analytical procedure was good. This is shown by the inter assay 
coefficients of variation. These were 1.7% and 1.8% respectively for low and 
high controls. While the intra assay coefficient of variation for low and high 
controls were 3.1% and 2.2% respectively. The sensitivity of the ELISA kits was 
high. In conclusion, after review of the balance of benefits and problems 
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associated with the microdialysis approach it was decided to move to 
recovering plasma samples.  
The second study was aimed to compare the dialysate and plasma 
adiponectin concentrations in samples taken at the same time. The second 
study found substantial differences between the plasma and the interstitial 
adiponectin concentrations. The plasma concentrations were up to 1791 
times greater (Table 4-2). Thus, a third series of experiments was designed 
with the aims of studying the effect of acute exercise on the concentrations 
of total and HMW adiponectin in plasma. In addition, the effect of exercise 
on other cytokines such as IL-6 and TNF–α and the effect on insulin and 
glucose concentrations were examined.  
6.2 The main findings 
 Successful recovery of the fluid over two successive days. CMA 
microdialysis catheters were great technique to work with. 
 No difference in adiponectin concentration in dialysate samples 
between lean and overweight females.  
 The concentration of adiponectin was very low due to the 
polymerization of adiponectin to bigger forms that have molecular 
weights bigger than the cut off of the microdialysis membranes. 
 No clear effect of the exercise on the concentration of adiponectin in 
dialysate samples (chapter 3). 
 The second study showed a substantial difference between plasma and 
dialysate adiponectin concentrations (chapter 4). That confirms the 
low recovery of the 100 KD CMA microdialysis catheters. 
 A single bout of exercise at 50% 2
.
OV max had no effect on total and 
HMW adiponectin, TNF–α and glucose concentrations in plasma in 
young healthy females (chapter 5). 
Chapter 6   
M. Alzwayi  148  
 IL-6 concentration increases to double of the basal values after one 
hour of the exercise at 50% 2
.
OV max in young healthy females (chapter 5) 
The effects of exercise on insulin concentrations were not clear; the 
insulin concentration showed a significant decrease one hour after the 
exercise when tested with one way ANOVA.  The effect was not 
significant when tested with the two way ANOVA with repeated 
measures and differences. Subsequent analysis suggests that the 
change seen was at the limits of what might be detected with this 
sample size. 
On the bases of the findings of the three studies in this thesis it was 
interesting to work with the microdialysis system, despite of some problems 
such as the small sample volumes. As mentioned before the volume of the 
samples collected was 30 – 45 microlitres. To overcome this problem more 
than one catheter could be used per volunteer, or the time of the collection 
of single sample could be increased to more than one hour. The previous 
studies used more than one catheter at the same time (Hojbjerre et al., 
2007; Nielsen et al., 2009). The advantages of plasma samples overcome this 
problem in this thesis.  
The concentrations of adiponectin in dialysate samples were very low 
(chapter 3 & 4) and very variable, Figure 3-5B. However, Hojbjerre et al. 
demonstrated that the concentrations of adiponectin in SCAAT of lean and 
overweight subjects, obtained using a microdialysis catheter with 950 KD cut-
off, is about 20% of the plasma adiponectin concentrations (Hojbjerre et al., 
2007). “Adiponectin circulates in plasma as complexes of which some are 
larger than 400 KD” (Pajvani et al., 2003b). Therefore, the adiponectin 
complexes could be too large to pass the microdialysis membrane, and the 
actual interstitial adiponectin concentration could be higher than that 
measured by the microdialysis probe.  
One possible reason for the low concentrations of adiponectin found in 
SCAAT, even when the most permeable 950 KD membrane has been used, 
could be the formation of larger complexes of adiponectin in the interstitial 
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fluid. Secondly, adiponectin is secreted from other adipose tissue stores like 
visceral adipose tissue. Then, adiponectin is passed in vesicles into the 
interstitial space (Hojbjerre et al., 2007). Next, adiponectin is strongly bound 
to transport proteins in plasma that lead to a low free plasma concentrations 
of adiponectin in balance with the interstitial adiponectin concentration. 
Another possible reason is that the transport of adiponectin from adipocyte 
to plasma is an active regulated transport process working against the 
concentration gradients. Or adiponectin is transported from the interstitial 
fluid by lymph (Hojbjerre et al., 2007).  
These findings led to the second study which confirmed that the problem was 
with the cut off of the CMA microdialysis catheters. Consequently it was 
decided in the last study to work on plasma samples (chapter 5). The first 
idea in this chapter was to investigate the effect of acute exercise on the 
high molecular weight adiponectin instead of the total adiponectin. Several 
studies had been done on the effect of the exercise on the total adiponectin 
concentration. However the results were controversial but the majority 
demonstrated no effect of the acute and chronic exercise on the total 
adiponectin concentrations. In addition very few studies were on the effect 
of the HMW adiponectin concentrations as the biologically active form of 
adiponectin (chapter 5). 
There were no effects of acute exercise on total or HMW adiponectin 
concentrations in plasma, either directly or after the two days follow up. The 
exercise was moderate (50% 2
.
OV max) and for a short time (60 minutes) 
without any specific diet control. The high concentration of adiponectin in 
plasma (3 -30 µg/ml) has been mentioned in many studies. This concentration 
is relatively stable over the day (Gavrila et al., 2003). This elevated 
adiponectin concentration and stability might need a big alteration in the 
rate of secretion (Hojbjerre et al., 2007). Previous studies demonstrated that 
weight loss or reduction in body fat is necessary to increase adiponectin 
concentrations in plasma (Hotta et al., 2000). That might be achieved by a 
longer exercise program with a controlled diet. Also there was no effect on 
the ratio of HMW to the total adiponectin concentration. The percentage of 
the HMW adiponectin found in this study was 38.5% of the total adiponectin 
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concentrations. This was similar to the previous study (Beltowski et al., 
2008).  
In comparison between the adiponectin concentrations in plasma for males 
(chapter 4) and females (chapter 5), females have higher adiponectin 
concentration than males. However the two groups were not different in the 
concentration of adiponectin in dialysate samples.  The higher plasma 
adiponectin levels in women were in agreement with many other studies 
(Arita et al., 1999; Cnop et al., 2003; Pajvani et al., 2003a; Steffes et al., 
2004). This finding might be related to androgen levels since androgens can 
have an inhibitory effect on adiponectin secretion. Testosterone suppressed 
adiponectin secretion in mice and in cells in culture media (Nishizawa et al., 
2002). In contrast, the effect of oestrogens on adiponectin secretion is not 
fully understood (Sieminska et al., 2005).  
No correlations were found between total and HMW adiponectin 
concentrations in plasma and BMI or fat percentage that might be because 
the volunteers had similar BMI and fat percentage. A strong negative 
correlation was illustrated between the BMI and adiponectin concentrations 
by others (Arita et al., 1999; Weyer et al., 2001). Although this correlation 
was not found in Hojbjerre’s study. Also the group were from same age group 
so no correlation between age and total or HMW adiponectin concentrations 
was seen. It might be the sample size is small to detect a significant 
correlation, although, the sample size is comparable to most published 
studies. Again despite the positive effect of the acute exercise on IL—6 
(chapter 5), there was no detectable inhibitory effect of that increase on 
total or HMW adiponectin concentration.  
Insulin concentrations showed a significant decrease using a one way ANOVA 
but no significance using a two way ANOVA with repeated measures and 
differences. This may indicate that the result is close to significance but the 
small sample size makes it difficult to be certain. Glucose concentrations 
show no change. This finding was similar to that which has been described by 
Hojbjerre et al (Hojbjerre et al., 2007) 
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6.3 Conclusion 
The results in this thesis found that the CMA 66 microdialysis catheters with a 
cut-off of 100 KD were not enough or appropriate to recover the total 
adiponectin or its active form. The positive effect of acute moderate exercise 
on IL-6 and insulin had no effect on total and HMW adiponectin 
concentrations in healthy young females. Whether this effect is applicable to 
overweight and obese volunteers is not clear.  
6.4 Difficulties  
It was difficult to recruit volunteers for these studies. That might be 
understandable especially for the application for the microdialysis catheters. 
A previous study on the dialysate adiponectin concentrations demonstrated 
increased interstitial adiponectin concentration despite no change in 
adiponectin concentrations in plasma for the same group of volunteers 
(Hojbjerre et al., 2007). That was interesting but the limitation of the 
present study was that catheters with higher cut-offs could not be bought or 
manufactured locally. 
6.5 Future studies 
This study shows the effect of acute moderate intensity exercise on total 
adiponectin concentration, HMW adiponectin concentration, IL-6, TNF- α, 
insulin and glucose in young healthy females. However little is known about 
the effect of the same activity on these hormones on over weight and obese 
females. It would be good for the future studies to be on this group of 
volunteers. Further, some studies reported ethnicity difference in 
adiponectin concentration, and most of the published studies were on limited 
ethnic groups. So it would be interesting to investigate other ethnic groups. 
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Appendix 1 
Application Form for Ethical Approval 
Ethics Committee for Non Clinical Research  
Involving Human Subjects, Material or Data 
 
Application Form for Ethical Approval 
 
 
NOTES: 
 
A submission to this Committee does not automatically result in approval. 
Investigators must wait for written approval before commencing data collection. 
Disciplinary measures will be taken if work commences without ethical approval 
being in place. The matter will be referred to the Dean for appropriate action.  
 
THIS APPLICATION FORM SHOULD BE TYPED, NOT HAND WRITTEN. 
 
ALL QUESTIONS MUST BE ANSWERED. “NOT APPLICABLE” IS A SATISFACTORY ANSWER 
WHERE APPROPRIATE. 
_____________________________________________________________ 
 
Project Title:  An investigation of the effects of short bouts of exercise on 
adiponectin in young healthy females. 
 
Is this project from a commercial source, or funded by a research grant of any kind? 
 
No 
 
If yes,  
 
a) Has it been referred to Research & Enterprise?   
 
    Has it been allocated a project Number?    
 
b) Give details and ensure that this is stated on the Informed Consent form. 
 
Date of submission: 27 January 2010  
 
Name of all person(s) submitting research proposal  
Mrs. Mabroukah Alzwayi, Dr Ronald Baxendale 
 
Position(s) held:  PhD. Student (IBLS), Reader 
  
Division: Integrative and system biology (ISB) 
 
Address for correspondence relating to this submission 
Mrs Mabroukah Alzwayi, room 244a, West Medical Building, Glasgow University 
 
 
Name of Principal Researcher (if different from above e.g., Student’s Supervisor): 
Dr Ronald Baxendale 
 
Position held: Reader___________________________________________ 
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1. Describe the purposes of the research proposed.  
 
Obesity is a major health problem in most countries. A great amount of advice on diet 
and physical activity is available, but the details of the effects of physical activity and 
the hormonal control of adipose tissue remains poorly understood. Adipose tissue is 
not only energy storage organ, but also it plays a major role in the secretion of many 
important metabolic hormones. These are known as adipokines (1). Some of these 
adipokines play an important role in metabolic syndromes such as type 2 diabetes and 
related cardiovascular complications.  Central or visceral obesity (2) is particularly 
important.  
 
The purpose of this project is to investigate the effect of acute exercise on 
adiponectin and resistin concentrations in both plasma and interstitial fluid in young 
healthy women. The effects of exercise on the concentration of adiponectin have 
been examined in recent studies in healthy young males, but conflicting results have 
been reported (Stenken et al., 2010).  
 
Some studies conclude that chronic exercise has no effect on plasma adiponectin 
concentrations (4, 7). However, others found that exercise increased the level of 
plasma adiponectin concentration substantially but only after two to three bouts of 
moderate intensity exercise. This last study was performed in overweight males (5). 
 
Hojbjerre et al (8) used a microdialysis technique to compare interstitial fluid and 
plasma concentrations of adiponectin. They showed that adiponctin concentrations 
increased in interstitial fluid in adipose tissue after acute bout of exercise in both 
overweight and lean male subjects; on the other hand, there was no effect on the 
plasma adiponectin concentration. Perhaps the adipokine concentrations are diluted 
in the larger plasma volume.  
 
This proposal will follow the protocol used by Hojbjerre et al. We plan to repeat their 
study in healthy young women. 
  
1- Bastard J.P, Maachi M, Lagathu C, Kim M.J, Caron M and Vidal H et al., Recent advances in 
the relationship between obesity, inflammation and insulin resistance, Eur Cytokine Netw 
2006 17 4–12.  
2- Antuna-Puente B, Feve B, Fellahi S and Bastard J.P, Adipokines: the missing link between 
insulin resistance and obesity, Diabetes Metab. 2008 34 2–11 
3- Bluher M, Bullen JW Jr, Lee JH, Kralisch S, Fasshauer M, Kloting N, Niebauer J, Schon MR, 
Williams CJ & Mantzoros CS. Circulating adiponectin and expression of adiponectin 
receptors in human skeletal muscle: associations with metabolic parameters and insulin 
resistance and regulation by physical training. Journal of Clinical Endocrinology and 
Metabolism 2006 91 2310–2316. 
4- Hulver MW, Zheng D, Tanner CJ, Houmard JA, Kraus WE, Slentz CA, Sinha MK, Pories WJ, 
MacDonald KG & Dohm GL. Adiponectin is not altered with exercise training despite 
enhanced insulin action. American Journal of Physiology. Endocrinology and Metabolism 
2002 283 E861–E865. 
5- Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ & Campbell LV. Exercise increases 
adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004 27 629–630. 
6- Punyadeera C, Zorenc AH, Koopman R, McAinch AJ, Smit E, Manders R, Keizer HA, Cameron-
Smith D & van Loon LJ. The effects of exercise and adipose tissue lipolysis on plasma 
adiponectin concentration and adiponectin receptor expression in human skeletal muscle. 
European Journal of Endocrinology 2005 152 427–436. 
7- Yatagai T, Nishida Y, Nagasaka S, Nakamura T, Tokuyama K, Shindo M, Tanaka H & Ishibashi 
S. Relationship between exercise training-induced increase in insulin sensitivity and 
adiponectinemia in healthy men. Endocrine Journal 2003 50 233–238. 
8- Højbjerre L, Rosenzweig M, Dela F, Bruun JM, Stallknecht B.  Acute exercise increase 
adipose tissue interstitial adiponectin concentration in healthy overweight and lean 
subjects. Eur J Endocrinol 2007 157 613–623 
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2. Please give a summary of the design and methodology of the project.  Please also 
include in this section details of the proposed sample size, giving indications of the 
calculations used to determine the required sample size, including any assumptions 
you may have made. (If in doubt, please obtain statistical advice). 
 
The design of the experiment follows the establish protocol published by Højbjerre et 
al (2007) except that healthy female volunteers will be used rather than the healthy 
males in their study. 
 
We seek permission to invite up to 16 healthy adult females (8 lean and 8 overweight) 
in the age range 20-35 years. Volunteers will be invited to the lab three times. 
 
First day, the visit will take about 1 hours. The experiment will be explained, 
questions will be answered and consent will be sought. They will know they are free 
to stop the experiment at any time. If they agree to participate, they will familiarize 
with the lab. Their age, weight, height, VO2 max, total body fat percentage and 
abdominal skin fold thickness will be measured.  
Lastly, the volunteer will be randomly assigned to the following two days. These will 
be either exercise day followed by rest day or rest day followed by exercise day. For 
simplicity only the first option is described. 
 
Second day: they will be invited for exercise day. They will visit the lab for 6 to 8 
hours. They will arrive in the morning fasted. A microdialysis catheter will be inserted 
into their subcutaneous fat about 4 cm lateral to the umbilicus on the left side for 
interstitial fluid collection and another catheter will be inserted into the antecubital 
vein for blood collection. Standard aseptic precautions will be followed. The 
volunteer rests for 3 hours, exercises for 1 hour at about 50% of their maximal 
capacity by walking on a treadmill and then rests again for 2.5 hours.  
 
Third day is the rest day. This day lasts for 6 hours. During this day the volunteer 
follows the same protocol as the exercise day except that exercise is omitted.  
 
These blood and interstitial fluid samples will collected every 30 minutes and 
subsequently the adiponectin, interlukin-6, insulin and glucose will be measured. The 
concentrations before, during and after exercise will be compared using two way 
repeated measures ANOVA. 
 
 
3. Please give a detailed account of the method of recruitment of volunteers. 
 
In the first instance, will attempt to recruit women volunteers from students and 
staff of Glasgow University.  They will be in the age range 20 – 35 years. Initial 
contact will be via posters, websites and personal contact. If this fails, the search will 
be extended to other universities in the west of Scotland.   
 
We aim to include healthy young women who are non smokers. We aim to exclude any 
pregnant volunteers or any volunteers who likely to become pregnant. We also aim to 
exclude any woman who has a first degree relative with type 2 diabetes. 
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4. Describe the research procedures as they affect the research subject and any other 
parties involved. 
 
The volunteers will be invited for three visits, the first one lasts up to 4 hours to 
familiarize volunteers with the experiment, to distribute information sheet, to give 
an oral explanation of the nature of the experiment and answer any questions. After 
that the volunteers will be asked to sign the consent form if they are agreeing to 
participate in the experiment. Volunteers will complete a PARQ to confirm they are in 
good health before testing begins.  
 
Then base line measurements will be made. Age, weight and height will be measured. 
Abdominal skin fold thickness will be measured with callipers. Total body fat will be 
measured by bio impedance. This requires the attachment of adhesive pads to the 
hands and feet. The volunteer must lie flat for 15 minutes. Their VO2 max will 
measured by a standard treadmill test during which their heart rate will be measured.  
 
The maximum oxygen up take (VO2MAX) is the utilization of oxygen at maximum rate is 
a commonly used measure of aerobic fitness. We propose to establish this by 
extrapolation from sub-maximal values taken during low and moderate intensity 
exercise. 
 
The volunteer’s heart rate will be recorded continuously using a Polar Heart Rate 
monitor. The heart rate will be recorded as a running average over 10 second periods. 
The volunteer will inspire room air via a Hans Rudolph valve. They will wear a nose 
clip, and will be allowed to rest for about five minutes to become familiar with the 
equipment.  The volunteer’s expired gas will be collected in a 150L Douglas Bag via 
the expired gas port of the Hans Rudolf valve via flexible tubing and a T piece valve. 
Gas will be collected for periods of 2 minutes. Their oxygen consumption in each 2 
minute period will be calculated using standard formulae using the volume and 
composition of the expired gas sample. Appropriate corrections will be made for gas 
temperature and barometric pressure. 
 
The oxygen consumption will be measured at rest, and a low intensity exercise with a 
mean heart rate of about 110 beats/minute, at a higher intensity with a mean heart 
rate of about 130 beats/ minute and finally at a mean heart rate of about 150 
beats/minute. Thus, even at the highest intensity of exercise the heart rate will not 
exceed 80% of their predicted maximum. If the volunteer is unhappy with the exercise 
intensity, the test will be terminated. The exercise intensity will be controlled by 
adjusting the speed and gradient of the treadmill. The resting value will be taken 
with the volunteer standing stationary on the treadmill.  
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This oxygen consumption is plotted against heart rate. The line is extrapolated to the 
volunteer’s predicted maximum heart rate, based on their age. The predicted VO2MAX 
is the used to calculate their half maximum value for the tests on subsequent days.  
 
No warm is thought necessary. The test increases in intensity progressively. The 
intensity of the test is moderate at best and the volunteer is slowly returned to rest 
as the belt is slowed over the next two minutes. 
 
The volunteer is then invited for two more days: a rest and an exercise day. These are 
in random order. Each visit will last for 6 to 8 hours. 
 
For the rest day, the subject visit the lab for period of about 6 hours and catheter  
will be inserted into subcutaneous fat and another one into the antecubital vein for 
collection of interstitial and blood samples respectively every 30 minutes. The 
microdialysis sample volume is tiny, less than 1 ml in total. The total blood sample 
will be less than 100 ml, comprising 10 samples of 10 ml each.  
The volunteer arrives fasted. They rest for the whole period.   
 
After about two weeks the subject will be invited again to the lab for exercise day. 
This lasts for a similar period. The same protocol is followed for the first 3 hours. The 
volunteer then exercises for 1 hour at about 50% of their maximum capacity by 
walking on a treadmill. During the exercise the volunteer’s heart rate is measured 
and expired gas samples are taken at intervals. They then rest for a further 2.5 hours.  
 
The volunteer is able to stop at any time. 
 
5. What in your opinion are the ethical considerations involved in this proposal?  (You 
may wish for example to comment on issues to do with consent, confidentiality, risk 
to subjects, etc.) 
anonymity 
 
In our opinion the ethical considerations are minor. We think that each volunteer is 
familiarised with the procedures. They are all adults and able to make their views 
clear. They are able to stop the experiment at any time.  
 
There are very minor risks of local infection at the site of catheter insertion. All 
standard aseptic precautions will be taken to avoid any infections.  These will include 
cleaning the insertion site using  alcohol Wipes - 70% isopropyl alcohol, disposable 
single use needles, catheters gloves etc. 
 
No significant additional risks are associated with the sub-maximal exercise 
intensities. The volunteers are screened with a questionnaire to confirm they are 
healthy before test begins. The walk up at moderate to brisk speeds. It is possible 
that they could stumble during this walk. Analysis of the accident records in the 
building reveals that slips and falls are far more common on the external steps than 
they are inside the building. It is concluded that the test poses no measureable 
increase in risk. 
 
A first aid box available for any minor injuries might happen.  
 
All data files will be anonymised. 
 
The procedures may be uncomfortable at times but present no special risks.  
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6. Outline the reasons which lead you to be satisfied that the possible benefits to be 
gained from the project justify any risks or discomforts involved. 
 
The risk of minor infection at the catheter entry sites is small and standard 
precautions are in place to keep this at a minimum. The risks associated with sub 
maximal exercise test in a young healthy population are also very small. The 
discomfort at the site of catheter insertion is minor and short lasting. The diameters 
of the catheters are small. The microdialysis catheter is 0.6 millimetres in diameter 
and it is introduced through a sterile tube a little more than 1 millimetre in 
diameter. In clinical use, these catheters are left in place for up to 7 days. One 
applicant (RHB) has had these catheters inserted and after the initial ‘sting’ of 
insertion did not notice any uncomfortable sensation for the following 5 days 
The experimenters believe these risks and discomforts to be very small. The 
potential benefits are large. The experiment will give information on the effects of 
exercise on body fat in young women. Ultimately, this may help reduce the risks of 
chronic diseases such as diabetes. 
 
7. Who are the investigators (including assistants) who will conduct the research and 
what are their qualifications and experience? Is it necessary for the investigators to 
have clearance from Disclosure (Scotland) and if so, has this been completed?  
Mabroukah Alzwayi is a lecturer at Sebha University, Libya. She is presently a PhD 
student at Glasgow University. She has worked for about ten years in clinical 
laboratories. She has more than ten years experience in collecting blood samples, 
different age groups, (children, adult and old people) and both genders. These blood 
samples were collected from antecubital vein. During the project she will be trained 
on microdialysis collection. 
Dr Ronald Baxendale has extensive experience in exercise testing normal and clinical 
populations. He has used the micodialysis technique in experiments performed in 
University of Brighton, Brunel University and Oxford Brookes University. 
 
The volunteers are all adults and Disclosure clearance is not necessary 
 
8. Are arrangements for the provision of clinical facilities to handle emergencies 
necessary?  If so, briefly describe the arrangements made. 
 
All exercise testing will be sub-maximal. Only healthy young volunteers will be 
tested. 
No special arrangements are required. We believe that standard laboratory practice 
is sufficient to test a group of healthy young volunteers. Standard first aid facilities 
are available and there is a telephone to call for help if necessary.  
 
9. In cases where subjects will be identified from information held by another party 
(for example, a doctor or hospital) describe the arrangements you intend to make to 
gain access to this information including, where appropriate, which  Multi Centre 
Research Ethics Committee or Local Research Ethics Committee will be applied to. 
 
N/A 
 
10. Specify whether subjects will include students or others in a dependent 
relationship and where possible avoid recruiting students who might feel to be or be 
construed to be under an obligation to volunteer for a project. This is most likely to 
be where a student is enrolled on a course where the investigator is a teacher. In 
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these circumstances the recruitment could be carried out by one of the other 
investigators or a suitably qualified third party. 
 
Students are not in a dependent relation ship with the researchers. 
Students will be recruited, if they are agreeing to participate. Such student could 
come from any part of the University. Glasgow University has more than 15,000 
undergraduate students, 4,900 postgraduate students and 5,000 adult learners. Dr 
Baxendale does teach a number of courses in FBLS and Medical Schools. These 
courses do not make up more than 5% of the student population and so it is unlikely, 
but not impossible, that the volunteers will come form those courses. In these cases 
Mabroukah will recruit the volunteers following the standard procedures. 
 
11. Specify whether the research will include children or people with mental illness, 
disability or handicap.  If so, please explain the necessity of involving these 
individuals as research subjects. 
 
The experiment will not include children or people with mental illness, disability or 
handicap. 
 
12. Will payment or any other incentive, such as a gift or free services, be made to 
any research subject?  If so, please specify and state the level of payment to be 
made and/or the source of the funds/gift/free service to be used. Please explain the 
justification for offering payment or other incentive. 
 
Yes. We propose to repay travel expenses to volunteers. They will be asked to 
provide receipts and repayment will be calculated following the Glasgow University 
guidelines up to a maximum of £20. Given the time commitment required, it may be 
necessary to offer some financial reward to help with recruitment. A maximum 
payment of £100 to each volunteer is proposed. This will come from the bench fees 
associated with the project. 
 
13. Please give details of how consent is to be obtained. A copy of the proposed 
consent form, along with a separate information sheet, written in simple, non-
technical language MUST ACCOMPANY THIS PROPOSAL FORM. 
 
The subjects will be invited to discuss the experiment and any questions will be 
answered, also written information sheet will be given to them, and they are free to 
stop the test at any time they want.  
They will be invited to sign a consent form. 
 
14. Comment on any cultural, social or gender-based characteristics of the subject 
which have affected the design of the project or which may affect its conduct. 
 
The study aims to investigate the metabolic responses of healthy young women. No 
unhealthy people will be recruited. No men will be recruited. This is not bias, it is 
simply a question of experimental design.  
We think there are no cultural or social based characteristics of the volunteer 
population that may affect the design of the project. 
 
15.  Please state who will have access to the data and what measures which will be 
adopted to maintain the confidentiality of the research subject and to comply with 
data protection requirements e.g. will the data be anonymised? 
Only the experimenters will have access to the data. 
These data will be recorded using anonymised serial numbers to prevent 
identification of the volunteers.  
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16. Will the intended group of research subjects, to your knowledge, be involved in 
other research?  If so, please justify. 
 
It is the aim of the experimenters to avoid recruiting volunteers who are 
participating on other concurrent experiments.   
Given that, Glasgow University has more than 15,000 undergraduate students, 4,900 
postgraduate students and 5,000 adult learners and many of these will be in courses 
with experimental components, it is impossible to estimate how many students 
might be involved in one or more experiments. The applicants do not have any 
means of listing all the current projects in the University. The University has 6,000 
staff. If the staff only runs one project each the possible combination must be 
astronomically high! 
 
Those who are participating in exercise or diet restricted studies will be excluded. 
 
17. Date on which the project will begin 1st March 2010.and end..1st March 2011.. 
 
18. Please state location(s) where the project will be carried out. 
 
Exercise science laboratories on level 2 of the West Medical Building 
 
19. Please state briefly any precautions being taken to protect the health and safety 
of researchers and others associated with the project (as distinct from the research 
subjects) e.g. where blood samples are being taken 
 
Standard aseptic techniques will be used to handle fluid samples.  
No other additional health or safety risk has been specially identified. 
The researchers will be chaperoned appropriately during the anthropometry stages 
of the experiment. 
 
Signed ___________________________________    Date  ________________ 
(Proposer of research) 
 
Where the proposal is from a student, the Supervisor is asked to certify the accuracy 
of the above account. 
 
Signed ___________________________________________   Date  ________________ 
(Supervisor of student) 
 
Email the completed form to: S.Morrison@bio.gla.ac.uk 
 
And send the signed hard copy to: 
 
Stuart Morrison 
Faculty Research Office 
Faculty of Biomedical & Life Sciences 
West Medical Building 
University of Glasgow 
Gilmorehill 
Glasgow 
G12 8QQ 
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Appendix 2 
A- Information sheet for the first study 
An investigation of the effects of short bouts of exercise on the interstitial 
adiponectin concentrations in young healthy females. 
 
You are invited to take part in a research study to investigate the effects of 
short bouts of exercise on adiponectin hormone secreted by body fat cells. 
The information on this sheet will help you understand what will happen.  
Please read it carefully and I will be happy to answer any questions you have. 
It is very important that understand what you are going to do before you 
consider giving consent. 
 
What is the aim of the study? 
The aim of this study is to investigate how exercise affects adiponectin and 
ultimately what effect this may have on health. This may help reduce the 
risks of chronic diseases like diabetes. 
 
Do I have to take part? 
No, it is up to you. You are a volunteer, and you can stop when you want. 
 
Why I have been chosen? 
Because you are healthy young women within the age range under 
investigation. 
 
What will happen to me? 
You will be invited for three visits.  
 
First visit:  
This will last for about one hour. During this any questions will be answered. 
Your weight, height and body fat will be measured. Your fitness will be 
measured as you exercise at mild and moderate intensities by walking on a 
treadmill. This will involve breathing through a mouthpiece for a few 
minutes. You will wear a device on a belt round your chest to record your 
heart rate. You will walk on a treadmill for a total of 10-15 minutes at slow, 
moderate and brisk speeds. 
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Second visit:  
Your second visit will last for 6 hours. This day will be either a rest day or an 
exercise day. For the last two days you have to come to the lab in a fasting 
state 
On the first day, A needle, of about 1 mm diameter will be inserted through 
the skin of your abdomen about 40 mm left of your navel. This will be 
removed after a few minutes when a very fine sample tube has been 
introduced into the fat below the skin. Tiny volumes of fluid round the fat 
cells will be sampled during the experiment. You will rest for the whole 
period.  
 
Third Visit: 
The third day is similar to the second day, except you are invited to exercise 
by walking at a moderate speed on a treadmill for 1 hour. The fluid samples 
will be repeated. 
 
What are the risks or side effects of taking part? 
There are no special side effects or risks to taking part in this study. Similar 
studies have been done before.  
The exercise intensities are delivered by walking at slow moderate of brisk 
speeds. This is extremely unlikely to cause any problems in a healthy young 
population.   
The staffs are trained in taking the samples under sterile conditions. 
There is risk of minor skin reddening at the site where the needles are 
inserted. This will be temporary. Some people may feel faint when they see a 
needle. Volunteer sit or lie flat whilst the needles are inserted and so this is 
unlikely to be a problem. 
First aid and emergency procedures are in place for any accident. 
 
What are the possible advantages of taking part? 
There are no major advantages for volunteers. They will learn a little about 
their body composition and fitness. On the other hand, this type of research 
might improve understanding of common chronic diseases such as diabetes. 
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Will my taking part in this research be kept confidential? 
Yes.  
 
What will happen to the results of the research study? 
The results of the study will be published in PhD thesis. They might also 
appear in scientific papers in a form which protects your identity. We can 
give you your results if you want. 
 
Contact Details 
If you have any questions please contact  
Dr Ronald Baxendale, West Medical Building, the University, Glasgow. G12 
8QQ 
Telephone 0141 330 5344 
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B- Information Sheet for the second study 
Plasma and interstitial adiponectin concentration on two days 
microdialysis catheter insertion. 
 
You are invited to take part in a research study to examine the effects of two 
days microdialysis catheter insertion on adiponectin concentration in blood 
and subcutaneous tissue. The information on this sheet will help you 
understand what will happen.  
Please read it carefully and I will be happy to answer any questions you have. 
It is very important that understand what you are going to do before you 
consider giving consent. 
 
What is the aim of the study? 
The aim of this study is to follow the response of adiponectin concentration 
in your adipose tissue to microdialysis catheter inserted for two days, and 
compare these concentrations with adiponectin concentration in your blood. 
 
Do I have to take part? 
No, it is up to you. You are a volunteer, and you can stop when you want. 
 
Why I have been chosen? 
Because you are healthy young person within the age range under 
investigation. 
 
What will happen to me? 
You will be invited for two visits (one of them should be fasting and for all 
period of collection). Each visit will last for about five hours. A needle, of 
about 1 mm diameter will be inserted through the skin of your abdomen 
about 40mm left of your navel. This will be removed after a few minutes 
when a very fine sample tube has been introduced into the fat below the skin 
and will left for two days unless it is not functioning. Tiny volumes of fluid 
round the fat cells will be sampled during the experiment. In addition, blood 
catheter will insert into cubital vein for blood collection. Dialysat and 2 ml 
blood will collect every hour for total five samples every day. 
These catheters are very fine and you could do your usual work as usual. 
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What are the risks or side effects of taking part? 
There are no special side effects or risks to taking part in this study. Similar 
studies have been done before.  
The staffs are trained in taking the samples under sterile conditions. 
There is a minor skin reddening at the site where the needles are inserted. 
This will be temporary. Some people may feel faint when they see a needle. 
Volunteer sit or lie flat whilst the needles are inserted and so this is unlikely 
to be a problem. 
First aid and emergency procedures are in place for any accident. 
 
What are the possible advantages of taking part? 
There are no major advantages for volunteers. They will learn a little about 
their body composition.  
 
Will my taking part in this research be kept confidential? 
Yes.  
What will happen to the results of the research study? 
The results of the study will be published in PhD thesis. They might also 
appear in scientific papers in a form which protects your identity. We can 
give you your results if you want. 
 
Contact Details 
If you have any questions please contact  
Dr Ronald Baxendale, West Medical Building,  
The University, Glasgow. G12 8QQ 
Telephone 0141 330 5344 
Mabroukah M. Alzwayi 
West Medical Building, Faculty of Life Sciences, Glasgow University 
Mobile 07786694228, Email, m.alzwayi.1@research.gla.ac.uk 
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C- Information Sheet for the third study 
Concentration of plasma high molecular weight adiponectin following 
acute aerobic exercise in normal women. 
 
You are invited to take part in a research study to investigate the effects of 
short bouts of exercise on some hormones in plasma. These are high 
molecular weight  adiponectin, insulin, tumour necrosis factor alpha (TNF-α) 
and interleukin- 6 (IL-6). The information on this sheet will help you 
understand what will happen.  
Please read it carefully and I will be happy to answer any questions you have. 
It is very important that understand what you are going to do before you 
consider giving consent. 
 
What is the aim of the study? 
The aim of this study is to investigate how exercise affects these hormones 
and ultimately what effect these may have on health. This may help reduce 
the risks of chronic diseases like diabetes. 
 
Inclusion criteria,  
You are healthy young women. You will between 20 and 30 years old. You will 
have no special history of athletic training and you will not be overweight. 
 
Do I have to take part? 
No, it is up to you. You are a volunteer, and you can stop when you want. 
 
What will happen to me? 
You will be invited for four visits.  
 
First visit.  
This will last for about 30 minutes. During this any questions will be 
answered. Your weight, height and body fat will be measured. Your fitness 
will be measured as you exercise at mild and moderate intensities by walking 
on a treadmill. This will involve breathing through a mouthpiece for a few 
minutes. You will wear a device on a belt round your chest to record your 
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heart rate. You will walk on a treadmill for a total of 10-15 minutes at slow, 
moderate and brisk speeds. 
 
Second visit  
Your second visit will last for 2 hours. This day will be either a rest day or an 
exercise day. For these two days you have to come to the lab in a fasting 
state 
On the rest day, blood cannula will be inserted into your vein (the needle will 
be removed after a few minutes when a very fine sample tube has been 
introduced into the vein) to collect 8 ml of blood every hour, 3 samples (0, 1, 
2). (24 ml of blood totally will be collected on that day). You will rest for the 
whole period.  
 
Third Visit 
The third day is similar to the second day, except you are invited to exercise 
by walking at a moderate speed on a treadmill for 1 hour. The blood samples 
will be repeated. 
 
Fourth visit 
This visit will last only for 10 minutes and you will come for this visit twice 
one after resting day and one after exercise day, by 2 days (about 48 hours) 
just to collect a sample of blood (8 ml) using small fine needle. 
 
What are the risks or side effects of taking part? 
There are no special side effects or risks to taking part in this study. Similar 
studies have been done before.  
The exercise intensities are delivered by walking at slow moderate of brisk 
speeds. This is extremely unlikely to cause any problems in a healthy young 
population.   
The staffs are trained in taking the samples under sterile conditions. 
There is risk of minor skin reddening at the site where the needles are 
inserted. This will be temporary. Some people may feel faint when they see a 
needle. Volunteer sit or lie flat whilst the needles are inserted and so this is 
unlikely to be a problem. 
First aid and emergency procedures are in place for any accident. 
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What are the possible advantages of taking part? 
There are no major advantages for volunteers. They will learn a little about 
their body composition and fitness. On the other hand, this type of research 
might improve understanding of common chronic diseases such as diabetes. 
£100 will be paid for each subject at the end of the experiment.  
 
Will my taking part in this research be kept confidential? 
Yes.  
 
What will happen to the results of the research study? 
The results of the study will be published in PhD thesis. They might also 
appear in scientific papers in a form which protects your identity. We can 
give you your results if you want. 
 
Contact Details 
If you have any questions please contact  
Dr Ronald Baxendale, West Medical Building, The University, Glasgow. G12 
8QQ 
Telephone 0141 330 5344 
 
Mabroukah M. Alzwayi 
West Medical Building, School of Life Sciences, Glasgow University 
Mobile 07786694228 
Email, m.alzwayi.1@research.gla.ac.uk 
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Appendix 3  
A- Consent form 
 
Ethics Committee for Non Clinical Research 
Involving Human Subjects, Material or Data 
 
Consent Form 
 
Title of Project: An investigation of the effects of short bouts of exercise on 
adiponectin in young healthy females. 
 
Name of Researcher: Mabroukah M.A. Alzwayi. 
 
Please initial boxes 
 
I confirm that I have read and understand the information sheet for the 
above study and have had the opportunity to ask questions 
 
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and with no 
consequences 
 
I agree for my samples to be used for future research       YES/NO 
       (delete as appropriate) 
 
 
I AGREE TO TAKE PART IN THE ABOVE STUDY. 
Name of Volunteer:   
Signature:  Date:  
Name of person taking consent 
(if different from researcher):   
Signature:   Date:  
 
Name of Researcher:    
 
Signature:   Date:  
 
Witness:  Date:  
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B- Volunteer questionnaire for short bouts exercise 
 
Name _________________________________ age:__________________years  
Height _____________metre.    Weight____________ Kg    VO2max   __________ 
Total body fat percentage: ____________ Total skin fold:________________ 
 
You are excluded from the study if you feel unwell on the day of exercise or 
if you are pregnant or likely to be pregnant. Furthermore if you are diabetic 
or one of your first relatives is diabetic. 
 
1- Do you have high or low blood pressure?                                     Yes/No 
2- Do you have a heart condition?                                                  Yes /No 
3- Have you ever felt pain in your chest when you do physical exercise?  
                                                                                                    Yes / No 
4- Is your doctor currently prescribing you drugs or medications?     Yes/No 
5- Have you ever suffered from shortness of breath at rest or with mild 
exercise?                                                                                      Yes /No 
6- Is there a history of sudden death in people under 40 in your family?  
                                                                                                    Yes /No 
7- Do you currently smoke?                                                           Yes / No 
8- Can you think of any other reason why you should not take part in our   
experiment?                                                                              Yes /No 
Please 
specify_________________________________________________________ 
 
I have read, understand and completed this questionnaire. 
Name: - _____________________. Signature: _____________ Date: _______ 
 
 
 M. Alzwayi  197  
Appendix 4 
Servomex 1440 gas analyser operating procedure: 
Machine is left switched on all the times. 
Approximately 30 minutes before machine is calibrated switch on both pumps 
using silver toggle switches on front panel. 
Machine will be measuring atmospheric air and should be reading 20.9% 
oxygen and 0.003% carbon dioxide. 
Open both cylinders, Oxygen Free Nitrogen and mixed O2 & CO2. 
Gently open the flow meter on the OFN cylinder so that the float just moves. 
It is important not to increase the flow above this level. 
Leave until the machine gives a stable reading of zero and adjust the ZERO 
control with screwdriver if required. 
Turn off flow meter and check that the reading returns to atmospheric 
values. 
Repeat using the mixed calibration gas and the machine should show 16% O2 
and 6% CO2. Adjust SPAN with screwdriver if required.  
Turn off valve and check the values return to atmospheric levels. 
 
Ensure both gas cylinders are closed. 
 
Once test is finished turn off pumps but do not switch off machine 
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Appendix 5 
Oxygen consumption calculation 
Oxygen uptake and carbon dioxide production at rest 
1. Evacuate a Douglas bag and fit connecting tubing, a valve box and a 
mouthpiece. 
2. Ensure that your subject is sitting quietly for 5-10 minutes before any 
measurements are made. 
3. Place the mouthpiece in the subject’s mouth and fit the nose-clip. 
Allow the subject to breathe quietly through the mouthpiece out to 
the room for 2-3 minutes before collecting air into the Douglas bag 
4. Take a six-minute expired air sample.   
5. Withdraw a sample of air from the Douglas bag to measure the 
percentage of oxygen and carbon dioxide in the gas using the 
paramagnetic oxygen analyser and infra-red carbon dioxide analyser. 
6. Measure the volume of air in the bag using the dry gas meter.  Record 
the temperature of the gas during evacuation.  Take a note of the 
barometric pressure. 
7. Divide the volume by six to calculate the volume of air expired per 
minute. 
8. Convert the gas volume to standard temperature and pressure for a dry 
gas (STPD). See below. 
 
Standardising Gas Volumes 
Gas volumes vary with temperature and pressure. Thus, to compare 
respiratory gas volumes on different days and with different ambient 
conditions, it is necessary to correct volumes to standard conditions.  
Standard pressure is defined as 760 mm Hg and standard temperature as 273 
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K (0°C). Gas volumes are measured under ambient conditions, i.e. the 
conditions at the time of the experiment, and subsequently converted to 
STPD using the gas laws. 
The universal gas equation: 
  PV/T = constant  OR  P1V1/T1 = P2V2/T2 
Where P is pressure, T is temperature and V is volume. 
As expired air is saturated with water vapour, an additional correction factor 
is required to correct volumes to standard conditions. Water vapour exerts a 
pressure which reduces the gas pressure by an amount related to 
temperature. 
 
So,  V
.
ESTPD = V
.
EATPS x (BP – SWVP)/760 x 273/ (273 + t) 
 
Where:  BP is barometric pressure in mm Hg 
SWVP# is saturated water vapour pressure in mm Hg at ambient* 
temperature  
t is ambient temperature in degrees Celsius 
ATPS is ambient temperature and pressure, saturated with 
water vapour. 
 
*Ambient temperature and pressure describe the conditions as the 
volume of expired air sample is measured (not necessarily the same as 
room temperature). 
 
#SWVP = (1.1001 x t) – 4.19 
Where t is temperature in degrees Celsius and SWVP is in mm Hg 
9. Calculate oxygen uptake (V
.
O2) and carbon dioxide production (V
.
CO2) 
rates at rest.  See box over the page. 
 M. Alzwayi  200  
Calculation of oxygen uptake and carbon dioxide production  
Oxygen uptake (V
.
O2) = volume O2 inspired – volume O2 expired 
Volume O2 inspired = V
.
I x FIO2%/100  
Where:  V
.
I is the inspired air volume (per minute)  
FIO2% is the percentage of oxygen in atmospheric air, assumed to be 
20.93% (this is very stable) 
Volume O2 expired = V
.
E x FEO2%/100 
Where:  V
.
E is the measured expired air volume (per minute)  
FEO2% is the measured percentage of oxygen in expired air 
 [Remember to use STPD gas volumes for these calculations]  
Similarly, 
Carbon dioxide production (V
.
CO2) = volume of CO2 expired – volume CO2 
inspired 
 Volume CO2 expired = V
.
E x FECO2%/100 
Where:  V
.
E is the measured expired air volume (per minute)  
FECO2% is the measured percentage of carbon dioxide in expired 
air 
Volume CO2 inspired = V
.
I x FICO2%/100  
Where:  V
.
I is the inspired air volume (per minute)  
FICO2% is the percentage of carbon dioxide in atmospheric air, assumed 
to be 0.03% (this is stable, unless there are a large number of people in 
a confined place). 
FIO2%, FICO2%, FEO2%, FECO2% and V
.
E are known (either assumed or measured) 
but V
.
I is not known.  While it may seem intuitively obvious that V
.
I should 
equal V
.
E, this is not always true and we cannot assume it to be the case.  
This explained below: 
The inequality between inspired and expired gas volumes 
If carbohydrate is the only energy source then V
.
I does equal V
.
E, as illustrated 
by the equation for glucose oxidation: 
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   C6H12O6 + 6O2 → 6CO2 + 6H2O + 38 ATP 
One mole of any gas occupies the same volume at STPD (22.4 l) so, for every 
volume of oxygen used, an equal volume of carbon dioxide is produced.  It 
therefore follows that V
.
I equals V
.
E, in this circumstance. The ratio of carbon 
dioxide production (V
.
CO2) to oxygen uptake (V
.
O2) is called the respiratory 
exchange ratio (R or RER), and when 100% carbohydrate is oxidised this 
equals 6/6 = 1. However, carbohydrate is not the only energy substrate.  In 
fact, at rest and during light exercise, fat is likely to be a quantitatively more 
important fuel.  The equation for the oxidation of palmitic acid, a typical fat, 
is: 
  C16H32O2 + 23O2 → 16CO2 + 16H2O + 130 ATP  
For every 23 moles of oxygen utilised, 16 moles of carbon dioxide are 
produced, thus it is clear that V
.
I is greater than V
.
E. The RER is 16/23 = 0.7. 
Thus, from the ratio of V
.
CO2 to V
.
O2 it is possible to calculate the relative 
contribution of carbohydrate and fat to energy provision (protein oxidation is 
negligible under normal circumstances). An RER of 0.7 denotes 100% of 
energy provision is from fat oxidation, an RER of 1.0 denotes 100% 
carbohydrate oxidation, an RER of 0.85 denotes 50% carbohydrate oxidation 
and 50% fat oxidation. 
 
On the other hand, during high intensity exercise, V
.
E is often greater than V
.
I 
because carbon dioxide production exceeds oxygen uptake.  This is because 
lactic acid accumulates in the circulation at high exercise intensities.  To 
prevent blood pH from falling this is buffered by bicarbonate, which is one of 
the most important buffers in blood, as follows: 
  HCO3
- + H+ → H2CO3 → H2O + CO2 
Thus, carbon dioxide is produced as a result on buffering by bicarbonate is 
excreted at the lung, together with carbon dioxide produced by oxidative 
metabolism. This results in an excess of carbon dioxide production over 
oxygen uptake and V
.
E is greater than V
.
I. (Under these circumstances it is not 
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possible to calculate the relative energy provision from fat and carbohydrate 
from the RER). 
 
The assumption that V
.
I equals V
.
E is therefore invalid and it is necessary to 
calculate V
.
I. This can be done using the Haldane Transformation. 
 
The Haldane Transformation relies on the fact that there is not net uptake or 
production of nitrogen at the lung. The mass of nitrogen inspired therefore 
equals the mass of nitrogen expired. Concentration is mass/volume, thus if 
the concentration of nitrogen differs in inspired and expired air, there must 
be a difference between V
.
I and V
.
E. If V
.
E and the concentration of nitrogen in 
inspired and expired air are known, V
.
I can be deduced. The nitrogen 
concentration is not measured, but determined by subtracting oxygen and 
carbon dioxide concentrations from 100%. The calculation is described below: 
Mass inspired nitrogen = mass expired nitrogen 
Mass = concentration x volume   
 
So, FIN2% x V
.
I = FEN2% x V
.
E 
Therefore:   V
.
I = V
.
E x FEN2%/FIN2%   
 
Where:  FIN2% = 100 - FIO2% - FICO2% 
FEN2% = 100 - FEO2% - FECO2% 
Thus, FIO2%, FICO2%, FEO2%, FECO2%, V
.
E and V
.
I are all known and V
.
O2 and V
.
CO2 
can be calculated: 
V
.
O2 = V
.
I x FIO2%/100 - V
.
E x FEO2%/100 
V
.
CO2 = V
.
E x FECO2%/100 - V
.
I x FICO2%/100 
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Appendix 6  
A- CMA 66 Microdialysis Catheter 
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B- CMA107 Microdialysis Pump 
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C- Micro vials 
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D- Perfusion fluid  
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Appendix 7  
A- Mercodia adiponectin ELISA:  
REAGENTS 
Each Mercodia Adiponectin ELISA kit (10-1193-01) contains reagents for 96 wells, sufficient for 
42 samples and one calibrator curve in duplicate. For larger series of assays, use pooled 
reagents from packages bearing identical lot numbers. The expiry date for the complete kit is 
stated on the outer label. The recommended storage temperature is 2-8°C. 
 
Coated Plate 1 plate 96 wells Ready for use 
(Mouse monoclonal anti-human adiponectin) 8-well strips 
For unused microtitration strips, reseal the bag using adhesive tape and store at 2-8°C for two 
months. 
 
Calibrators 1, 2, 3, 4, 5 5 vials 1000 µl Ready for Use 
(Recombinant human adiponectin) 
Concentration stated on vial label. Color coded yellow 
 
Calibrator 0 1 vial 5 ml Ready for use 
Color coded yellow 
 
Assay Buffer 1 vial 12 ml Ready for use 
Color coded red 
 
Sample Buffer 2X 1 bottle 50 ml 
Dilute with 50 ml redistilled water to make sample buffer. 
Color coded yellow 
Storage after dilution: 2-8°C for two months 
 
Enzyme Conjugate 11X 1 vial 1.3 ml Preparation, see below 
(Peroxidase conjugated mouse monoclonal anti-human adiponectin) 
 
Enzyme Conjugate Buffer 1 vial 13 ml Ready for use 
Color coded blue 
 
Wash Buffer 21X 1 bottle 40 ml 
Dilute with 800 ml redistilled water to make wash buffer. 
Storage after dilution: 2-8°C for two months 
 
Substrate TMB 1 bottle 22 ml Ready for use 
(TMB) Colorless solution Note! Light sensitive! 
Stop Solution 1 vial 7 ml Ready for use 0.5 M H2SO4 
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Preparation of enzyme conjugate solution 
Prepare the needed volume of enzyme conjugate solution by dilution of Enzyme Conjugate 
11X, 
(1+10) in Enzyme Conjugate Buffer according to the table below. Mix gently. 
When preparing enzyme conjugate solution for the whole plate or if the reagents are to be used 
within two months, pour all of the Enzyme Conjugate Buffer into the Enzyme Conjugate 11X 
vial. 
Storage after dilution: 2-8°C for two months. 
 
SPECIMEN COLLECTION AND HANDLING 
Serum 
Collect blood by venipuncture, allow to clot. Separate the serum by centrifugation at 4 300 g for 
15 minutes at 2-8°C. Specimen can be stored at 2-8° C up to 14 days. For longer periods, store 
samples at –20°C. Avoid repeated freezing and thawi ng. 
 
Plasma 
Collect blood by venipuncture into tubes containing heparin, citrate or EDTA as anticoagulant, 
and separate the plasma fraction. Samples can be stored at 2-8°C up to 14 days. For longer 
periods store samples at –20°C. Avoid repeated free zing and thawing. 
 
PREPARATION OF SAMPLES 
Samples should be diluted 1/101 v/v with sample buffer (20 µl sample + 2,0 ml sample buffer). 
Diluted samples can be stored at 2-8°C up to 14 day s. Note! Buffers containing sodium azide 
(NaN3) can not be used for sample dilution. 
TEST PROCEDURE 
All reagents and samples must be brought to room temperature before use. Prepare a 
calibrator curve for each assay run. 
1. Prepare enzyme conjugate solution (according to the table on previous page), sample 
    buffer, wash buffer and samples. 
2. Prepare sufficient microplate wells to accommodate Calibrators and samples in duplicate. 
3. Pipette 25 µl each of Calibrators and samples into appropriate wells. 
4. Add 100 µl of Assay Buffer into each well. 
5. Incubate on a plate shaker (700-900 rpm) for 1 hour at room temperature (18-25°C). 
6. Wash plate 6 times with automatic plate washer 
   Or aspirate the reaction volume completely and fill each well with 350 µl wash buffer. 
   Aspirate liquid completely. Repeat 5 times. After final wash, invert and tap the plate firmly 
   against absorbent paper. 
7. Add 100 µl of enzyme conjugate solution into each well. 
8. Incubate on a plate shaker for 1 hour at room temperature (18-25°C). 
9. Wash plate 6 times with automatic plate washer 
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   Or aspirate the reaction volume completely and fill each well with 350 µl wash buffer. 
   Aspirate liquid completely. Repeat 5 times. After final wash, invert and tap the plate firmly 
   against absorbent paper. 
10. Add 200 µl Substrate TMB into each well. 
11. Incubate for 15 minutes at room temperature (18-25°C). 
12. Add 50 µl Stop Solution to each well. 
     Place the plate on the shaker for approximately 5 seconds to ensure mixing. 
13. Read optical density at 450 nm and calculate results. 
     Read within 30 minutes. 
Note! To prevent contamination between the conjugate and substrate, separate pipettes are 
recommended. 
 
INTERNAL QUALITY CONTROL 
Commercial controls such as Mercodia Obesity Control kit (10-1241-01) and/or internal serum 
pools with low, intermediate and high adiponectin concentrations should routinely be assayed 
as unknowns, and results charted from day to day. It is good laboratory practice to record the 
following data for each assay: kit lot number; reconstitution dates of kit components; OD values 
for the blank (sample buffer), Calibrators and controls. 
 
CALCULATION OF RESULTS 
Computerized calculation 
The concentration of adiponectin is obtained by computerized data reduction of the absorbance 
for the Calibrators 1-5 versus the concentration using cubic spline regression. 
Manual calculation 
1. Plot the absorbance values obtained for the Calibrators 1-5 against the adiponectin     
concentration on a log log paper and construct a calibrator curve. 
2. Read the concentration of the unknown samples from the calibrator curve. 
3. Multiply the concentration with the dilution factor. 
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B- Mercodia Insulin ELISA 
REAGENTS 1 X 96 
Each Mercodia Insulin ELISA kit (10-1113-01) contains reagents for 96 wells, sufficient for 42 
samples and one calibrator curve in duplicate. For larger series of assays, use pooled reagents 
from packages bearing identical lot numbers. The expiry date for the complete kit is stated 
onthe outer label. The recommended storage temperature is 2–8°C. 
Coated Plate 1 plate 96 wells Ready for Use 
Mouse monoclonal anti-insulin 8-well strips 
For unused microplate wells completely reseal the bag using adhesive tape and use within two 
months. 
Calibrators 1, 2, 3, 4, 5  vials 1000 µL Ready for Use 
Concentration indicated on vial label. 
(recombinant human insulin) Color coded yellow 
Calibrator 0 1 vial 5 mL Ready for Use 
Color coded yellow 
Enzyme Conjugate 11X 1 vial 1.2 mL Preparation, 
Peroxidase conjugated mouse monoclonal anti-insulin see below 
Enzyme Conjugate Buffer 1 vial 12 mL Ready for use 
Color coded blue 
Wash Buffer 21X 1 bottle 50 mL Dilute with 1000 mL 
Storage after dilution: redistilled water to 
2-8°C for 4 weeks. make wash buffer 1X solution 
Substrate TMB 1 bottle 22 mL Ready for Use 
Colorless solution 
Note! Light sensitive! 
Stop Solution 1 vial 7 mL Ready for Use 
0.5 M H2SO4 
Preparation of enzyme conjugate 1X solution 
Prepare the needed volume of enzyme conjugate 1X solution by dilution of Enzyme Conjugate 
11X, (1+10) in Enzyme Conjugate Buffer according to the table below. When preparing enzyme 
conjugate 1X solution for the whole plate, pour all of the Enzyme Conjugate Buffer into the 
Enzyme Conjugate 11X vial. Mix gently. Use within one day. 
SPECIMEN COLLECTION AND HANDLING 
Serum 
Collect blood by venipuncture, allow to clot, and separate the serum by centrifugation. Samples 
can be stored at 2–8°C up to 24 hours. For longer p eriods, store samples at –20°C. Avoid 
repeated freezing and thawing. 
Plasma 
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Collect blood by venipuncture into tubes containing heparin or EDTA as anticoagulant, and 
separate the plasma fraction. Samples can be stored at 2–8°C up to 24 hours. For longer 
periods store samples at –20°C. Avoid repeated free zing and thawing. 
Preparation of samples 
No dilution is normally required, however, samples containing >200 mU/L should be diluted 1+9 
v/v with Calibrator 0. 
TEST PROCEDURE 
All reagents and samples must be brought to room temperature before use. 
Prepare a calibrator curve for each assay run. 
1. Prepare enzyme conjugate 1X solution and wash buffer 1X solution. 
2. Prepare sufficient microplate wells to accomodate Calibrators and samples in   duplicate. 
3. Pipette 25 µL each of Calibrators and samples into appropriate wells. 
4. Add 100 µL of enzyme conjugate 1X solution to each well. 
5. Incubate on a plate shaker (700-900 rpm) for 1 hour at room temperature (18–25°C). 
6. Wash 6 times with 700 µL wash buffer 1X solution per well using an automatic plate washer 
with overflow-wash function. Do not include soak step in washing procedure. Or manually, 
discard the reaction volume by inverting the microplate over a sink. Add 350 µL wash buffer 1X 
solution to each well. Discard the wash solution, tap firmly several times against absorbent 
paper to remove excess liquid. Repeat 5 times. Avoid prolonged soaking during washing. 
7. Add 200 µL Substrate TMB into each well 
8. Incubate for 15 minutes at room temperature (18–25°C). 
9. Add 50 µL Stop Solution to each well. Place plate on a shaker for approximately 5 seconds 
to ensure mixing. 
10. Read optical density at 450 nm and calculate results. Read within 30 minutes. 
Note! To prevent contamination between the conjugate and substrate, separate pipettes are 
recommended. 
INTERNAL QUALITY CONTROL 
Commersial controls such as Mercodia Diabetes Antigen Control (Cat. No. 10-1134-01/10- 
1164-01) and/or internal serum pools with low, intermediate and high insulin concentration 
should routinely be assayed as samples, and results charted from day to day. It is good 
laboratory practice to record the following data for each assay: kit lot number, dilution and/or 
reconstitution date of components, OD values for the blank, Calibrators and Controls. 
CALCULATION OF RESULTS 
Computerized calculation 
The concentration of insulin is obtained by computerized data reduction of the absorbance for 
the Calibrators, except for Calibrator 0, versus the concentration. 
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Appendix 8 
R&D systems, Quantikine ELISA 
A- Human IL-6 
REAGENT PREPARATION 
Bring all reagents to room temperature before use. 
Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix 
gently until the crystals have completely dissolved. Dilute 20 mL of Wash Buffer Concentrate 
into deionized or distilled water to prepare 500 mL of Wash Buffer. 
Substrate Solution - Color Reagents A and B should be mixed together in equal volumes 
within 15 minutes of use. Protect from light. 200 µL of the resultant mixture is required per well. 
IL-6 Standard - Reconstitute the IL-6 Standard with 5.0 mL of Calibrator Diluent RD5T (for cell 
culture supernate samples) or Calibrator Diluent RD6F (for serum/plasma samples). This 
reconstitution produces a stock solution of 300 pg/mL. Allow the standard to sit for a minimum 
of 15 minutes with gentle agitation prior to making dilutions.  
Pipette 667 µL of the appropriate Calibrator Diluent into the 100 pg/mL tube and 500 µL 
of diluent into each remaining tube. Use the stock solution to produce a dilution series 
(below). Mix each tube thoroughly before the next transfer. The undiluted standard serves as 
the high standard (300 pg/mL). The appropriate Calibrator Diluent serves as the zero standard 
(0 pg/mL). 
 
ASSAY PROCEDURE  
Bring all reagents and samples to room temperature before use. It is recommended that 
all standards, samples, and controls be assayed in duplicate. 
1. Prepare all reagents and working standards as directed in the previous sections. 
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing  the desiccant pack, and reseal. 
3. Add 100 µL of Assay Diluent RD1W to each well. 
4. Add 100 µL of Standard, sample, or control per well. Cover with the adhesive strip provided. 
Incubate for 2 hours at room temperature. A plate layout is provided to record standards and 
samples assayed. 
5. Aspirate each well and wash, repeating the process three times for a total of four washes. 
Wash by filling each well with Wash Buffer (Schnabele, 2009 400 /id) using a squirt bottle, 
manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to 
good performance. After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against clean paper towels. 
6. Add 200 µL of IL-6 Conjugate to each well. Cover with a new adhesive strip. Incubate for 2 
hours at room temperature. 
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7. Repeat the aspiration/wash as in step 5. 
8. Add 200 µL of Substrate Solution to each well. Incubate for 20 minutes at room temperature. 
Protect from light. 
9. Add 50 µL of Stop Solution to each well. The color in the wells should change from blue to 
yellow. If the color in the wells is green or the color change does not appear uniform, gently 
tap the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a 
microplate reader set to 450 nm. If wavelength correction is available, set to 
540 nm or 570 nm. If wavelength correction is not available, subtract 
readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction 
will correct for optical imperfections in the plate. Readings made directly at 
450 nm without correction may be higher and less accurate. 
 
 CALCULATION OF RESULTS 
Average the duplicate readings for each standard, control, and sample and subtract the 
average zero standard optical density. 
Create a standard curve by reducing the data using computer software capable of generating a 
four parameter logistic (4-PL) curve fit. As an alternative, construct a standard curve by plotting 
the mean absorbance for each standard on the y-axis against the concentration on the x-axis 
and draw a best fit curve through the points on the graph. The data may be linearized by 
plotting the log of the IL-6 concentrations versus the log of the O.D. and the best fit line can be 
determined by regression analysis. This procedure will produce an adequate but less precise fit 
of the data. 
If samples have been diluted, the concentration read from the standard curve must be 
multiplied by the dilution factor.  
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B- Human TNF-α 
REAGENT PREPARATION 
Bring all reagents to room temperature before use. 
Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix 
gently until the crystals have completely dissolved. Dilute 20 mL of Wash Buffer Concentrate 
into deionized or distilled water to prepare 500 mL of Wash Buffer. 
Calibrator Diluent RD6-35 (1X) (for cell culture supernate samples) - Add 10 mL of Calibrator 
Diluent RD6-35 to 40 mL of deionized or distilled water to yield 50 mL of Diluted Calibrator 
Diluent RD6-35. 
Substrate Solution - Color Reagents A and B should be mixed together in equal volumes 
within 15 minutes of use. Protect from light. 200 µL of the resultant mixture is required per well. 
TNF-α Standard - Refer to vial label for reconstitution volume. Reconstitute the TNF-α 
Standard with deionized or distilled water. This reconstitution produces a stock solution of 
10,000 pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior 
to making dilutions. 
Pipette 900 µL of Calibrator Diluent RD6-35 (for serum/plasma samples) or Calibrator Diluent 
RD6-35 (1X) (for cell culture supernate samples) into the 1000 pg/mL tube. Pipette 500 µL of 
the appropriate Calibrator Diluent into the remaining tubes. Use the stock solution to produce a 
dilution series (below). Mix each tube thoroughly before the next transfer. The 1000 pg/mL 
standard serves as the high standard. The appropriate Calibrator Diluent serves as the zero 
standard (0 pg/mL). 
 
ASSAY PROCEDURE  
Bring all reagents and samples to room temperature before use. It is recommended that 
all standards, samples, and controls be assayed in duplicate. 
1. Prepare all reagents and working standards as directed in the previous sections. 
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal. 
3. Add 50 µL of Assay Diluent RD1F to each well. Assay Diluent RD1F will have a precipitate 
present. Mix well before and during use. 
4. Add 200 µL of Standard, sample, or control per well. Cover with the adhesive strip provided. 
Incubate for 2 hours at room temperature. A plate layout is provided to record standards and 
samples assayed. 
5. Aspirate each well and wash, repeating the process three times for a total of four washes. 
Wash by filling each well with Wash Buffer (Schnabele, 2009 400 /id) using a squirt bottle, 
manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to 
good performance. After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against clean paper towels. 
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6. Add 200 µL of TNF-α Conjugate to each well. Cover with a new adhesive strip.For Cell 
Culture Supernate Samples: Incubate for 1 hour at room temperature.For Serum/Plasma 
Samples: Incubate for 2 hours at room temperature. 
7. Repeat the aspiration/wash as in step 5. 
8. Add 200 µL of Substrate Solution to each well. Incubate for 20 minutes at room temperature. 
Protect from light. 
9. Add 50 µL of Stop Solution to each well. The color in the wells should change from blue to 
yellow. If the color in the wells is green or if the color change does not appear uniform, gently 
tap the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a microplate reader set 
to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength 
correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. 
This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 
nm without correction may be higher and less accurate. 
 
CALCULATION OF RESULTS 
Average the duplicate readings for each standard, control, and sample and subtract the 
average zero standard optical density. 
Create a standard curve by reducing the data using computer software capable of generating a 
four parameter logistic (4-PL) curve fit. As an alternative, construct a standard curve by plotting 
the mean absorbance for each standard on the y-axis against the concentration on the x-axis 
and draw a best fit curve through the points on the graph. The data may be linearized by 
plotting the log of the TNF-α concentrations versus the log of the O.D. and the best fit line can 
be determined by regression analysis. This procedure will produce an adequate but less 
precise fit of the data. 
If samples have been diluted, the concentration read from the standard curve must be 
multiplied by the dilution factor 
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 C- High molecular weight adiponectin (HMWA) 
SAMPLE COLLECTION & STORAGE 
The sample collection and storage conditions listed below are intended as general guidelines. 
Sample stability has not been evaluated. 
Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes before 
centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and 
store samples at ≤ -20° C. Avoid repeated freeze-thaw cycles. 
Plasma - Collect plasma using heparin or EDTA as an anticoagulant. Centrifuge for 15 minutes 
at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ 
-20° C. Avoid repeated freeze-thaw cycles. 
Note: Citrate plasma has not been validated for use in this assay. 
SAMPLE PREPARATION 
Serum and plasma samples require a 100-fold dilution. A suggested 100-fold dilution is 10 µL 
of sample + 990 µL of Calibrator Diluent RD6-61. 
 
REAGENT PREPARATION 
Bring all reagents to room temperature before use. 
Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix 
gently until the crystals have completely dissolved. Dilute 20 mL of Wash Buffer Concentrate 
into deionized or distilled water to prepare 500 mL of Wash Buffer. 
Substrate Solution - Color Reagents A and B should be mixed together in equal volumes 
within 15 minutes of use. Protect from light. 200 mL of the resultant mixture is required per well. 
HMW Adiponectin Standard - Refer to the vial label for reconstitution volume. 
Reconstitute the HMW Adiponectin Standard with deionized or distilled water. This 
reconstitution produces a stock solution of 500 ng/mL. Mix the standard to ensure complete 
reconstitution and allow the standard to sit for a minimum of 15 minutes. Mix well prior to 
making dilutions. 
Pipette 200 µL of Calibrator Diluent RD6-61 into each tube. Use the stock solution to produce a 
dilution series (below). Mix each tube thoroughly before the next transfer. The 250 ng/mL 
standard serves as the high standard. Calibrator Diluent RD6-61 serves as the zero standard 
(0 ng/mL). 
  
ASSAY PROCEDURE  
Bring all reagents and samples to room temperature before use. It is recommended that 
all samples, controls, and standards be assayed in duplicate. 
1. Prepare all reagents, working standards, and samples as directed in the previous sections. 
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal. 
3. Add 100 µL of Assay Diluent RD1W to each well. 
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4. Add 50 µL of Standard, control, or sample* per well. Cover with the adhesive strip provided. 
Incubate for 3 hours at room temperature. A plate layout is provided to record standards and 
samples assayed. 
5. Aspirate each well and wash, repeating the process three times for a total of four washes. 
Wash by filling each well with Wash Buffer (Schnabele, 2009 400 /id) using a squirt bottle, 
manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to 
good performance. After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against clean paper towels. 
6. Add 200 µL of HMW Adiponectin Conjugate to each well. Cover with a new adhesive strip. 
Incubate for 1 hour at room temperature. 
7. Repeat the aspiration/wash as in step 5. 
8. Add 200 µL of Substrate Solution to each well. Incubate for 30 minutes at room temperature. 
Protect from light. 
9. Add 50 µL of Stop Solution to each well. The color in the wells should change from blue to 
yellow. If the color in the wells is green or the color change does not appear uniform, gently 
tap the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a microplate reader set 
to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength 
correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 
nm. This subtraction will correct for optical imperfections in the plate. Readings made 
directly at 450 nm without correction may be higher and less accurate. 
*Samples require dilution. See Sample Preparation section.  
 
CALCULATION OF RESULTS 
Average the duplicate readings for each standard, control, and sample and subtract the 
average zero standard optical density (O.D.). 
Create a standard curve by reducing the data using computer software capable of generating a 
four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting 
the mean absorbance for each standard on the y-axis against the concentration on the x-axis 
and draw a best fit curve through the points on the graph. The data may be linearized by 
plotting the log of the HMW Adiponectin concentrations versus the log of the O.D. and the best 
fit line can be determined by regression analysis. This procedure will produce an adequate but 
less precise fit of the data. 
Since samples have been diluted, the concentration read from the standard curve must be 
multiplied by the dilution factor. 
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Appendix 9 
Plasma glucose measurements 
San Diego, CA 92121 
GLUCOSE OXIDASE REAGENT SET 
(PHENOL FREE) 
Catalog Number: BQ018B-CR 
INTENDED USE 
For the quantitative determination of total glucose in human serum. 
REAGENT COMPOSITION 
When reconstituted as directed, the reagent for Glucose contains the following: 
1. Glucose reagent: (Concentrations refer to the reconstituted reagent) Glucose Oxidase 
15µl/ml, Peroxidase (horseradish) 1.2µl/ml. Mutarotase 4.0 µl/ml. 4-Aminoantipyrine 0.38 
mM p-Hydroxybenzene sulfonate 10 mM, and non-reactive ingredients. 
2. Glucose standard: (100mg/dl b-D-glucose). 
WARNINGS AND PRECAUTIONS 
1. for in vitro diagnostic use.  
CAUTION: In vitro diagnostic reagents may be hazardous. Handle in accordance with good 
laboratory procedures which dictate avoiding ingestion, and eye or skin contact. 
2. Specimens should be considered infectious and handled appropriately. 
3. Use distilled or deionized water where indicated. 
REAGENT STORAGE AND STABILITY 
Both dry reagent and standard should be stored at 2 – 8 °C prior to reconstitution. The 
reagent may be used until the expiration date indicated on the package label. The 
reconstituted reagent should be stored in an AMBER container at 2 – 8 °C and is stable for 
thirty (30) days when stored as directed. The reagent should be clear and colorless. 
REAGENT DETERIORATION 
The reagent should be discarded if: 
1. Turbidity has occurred; turbidity may be a sign of contamination. 
2. Moisture has penetrated the vial and caking has occurred. 
3. The reagent fails to meet linearity claims or fails to recover control values in the stated 
range. 
SPECIMEN COLLECTION 
1. Test specimens should be serum and free from hemolysis. 
2. Plasma containing citrate, EDTA, heparin or oxalate as an anticoagulant may not be used. 
3. Serum must be separated from the clot promptly since the rate of glucose decrease is 
approximately 7% per hour in whole blood. 
4. Glucose in serum or plasma is stable for twenty-four (24) hours when stored 2 – 8 ° C. 
INTERFERING SUBSTANCES 
 M. Alzwayi  221  
Grossly lipemic or icteric sera will cause false glucose values and require the use of a serum 
blank. Add 0.02 ml (20 µl) of patient sera to 3.0 ml distilled water and read against water 
blank. Subtract this absorbance from the patient test absorbance to correct for the lipemia 
or icterus. Young et al. give a comprehensive review of drug interferences.5 
MATERIALS REQUIRED BUT NOT PROVIDED 
1. Pipettes to accurately measure required volumes 
2. Test tubes/rack 
3. Timer 
4. 37° C heating block or water bath 
5. Spectrophotometer capable of accurately measuring absorbance at 500 nm 
GENERAL INSTRUCTIONS 
The reagent for glucose is intended for use either as an automated procedure on chemistry 
instruments or as a manual procedure on a suitable spectrophotometer. 
AUTOMATED PROCEDURE 
Please refer to appropriate application manual available. 
MANUAL PROCEDURE 
1. Prepare reagent according to instructions. 
2. Label test tubes: blank, standard, control, patient, etc. 
3. Pipette 1.5 ml of working reagent to all tubes and place in 37 °C heating bath for at least 
five (5) minutes. 
4. Add 0.01 ml (10 µl) of sample to respective tubes, mix and incubate at 37 °C for exactly 
ten (10) minutes. 
5. After incubation, zero spectrophotometer with the reagent blank. Read and record the 
absorbance of all tubes at 500 nm (Wavelength range: 500 – 520 nm). Final colour is stable 
for at least thirty (30) minutes. 
* TC MULTI-PURPOSE CALIBRATOR MAY BE USED TO 
REPLACE STANDARD. 
NOTE: 
If the spectrophotometer being used requires a final volume greater than 1.5 ml for accurate 
reading, use 0.02 ml (20 µl) of sample to 3.0 ml of reagent. Perform the test as described 
above. 
LIMITATIONS 
The reagent is linear to 500 mg/dl. Samples that have glucose values greater than 500 mg/dl 
should be diluted with water 1:1. 
  
